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Abstract 
 
Inflammatory bowel disease (IBD) involves dysregulated immune responses to intestinal 
microbiota. Intestinal dendritic cells (DC) play a pivotal role in bacterial recognition, 
tolerance induction, T cell homing and differentiation. 
 
We hypothesized that alterations in human colonic DC are central to the inflammatory 
process, lymphocyte homing, and therapeutic responses in patients with IBD.  Colonic 
CD11c+ cells have been shown to be activated in IBD but CD11c- cells have not been 
characterised. We identified, in ulcerative colitis (UC), a CD11c- population that had 
morphological features of DC, expressed MHC class II and Natural Killer cell marker 
CD56, expressed less activation markers and produced less cytokine, and were weakly 
stimulatory. Few were plasmacytoid DC.  Their number increased in UC and Crohn’s 
disease (CD) but decreased after inflammation resolved.  
 
We explored function and homing properties of colonic CD11c+ DC, and their relationship 
with intestinal microbiota in IBD. In acute UC, IL-10+ and IL-12p40+ CD11c+ DC 
increased, and fewer CD11c+ DC expressed the homing molecule α-E (CD103). In active 
CD, IL-12p40+ DC increased and the ratio of pro:anti-inflammatory bacteria, namely 
bacteroides:bifidobacteria,  correlated positively with IL-12p40+ DC; IL-6+  DC also 
increased and correlated with increased C-reactive protein, but negatively with anti-
inflammatory Faecalibacterium praustnitzii. 
 
In IBD probiotics and corticosteroids may work, in part, by modulating DC function. In 
UC patients treated with the probiotic mixture VSL#3, TLR-2+ DC and IL-12p40+ DC 
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decreased while IL-10+ DC increased. In patients on corticosteroids similar changes were 
seen. Such effects were however not seen in patients on placebo.  
 
In conclusion, intestinal inflammation in IBD is associated with novel human colonic cells 
that share features of DC and NK cells. Intestinal DC function is influenced by 
composition of the commensal microbiota. Probiotics and corticosteroids are associated 
with altered “favourable” DC function; these effects may contribute to therapeutic benefit 
in patients with IBD.  
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1.1 Dendritic Cells 
 
Dendritic cells (DC) are a heterogenous population of uniquely equipped cells that 
specialized in antigen presentation, and they are widely distributed in small numbers 
throughout the body. DC act as sentinels, acquiring antigens in peripheral tissues before 
migrating to secondary lymphoid organs where they interact with lymphocytes (Randolph 
et al., 2005). Their migratory capacity distinguishes them from macrophages (Randolph et 
al., 2008). DC are also sensors, responding to a spectrum of environmental cues by 
extensive differentiation or maturation.  They play a critical role in the initiation and 
regulation of immune responses (Banchereau et al., 2000). Unlike other antigen presenting 
cells such as B cells and macrophages, DC have the unique ability to stimulate the 
proliferation and differentiation of both naive and memory T cells. They can determine 
whether non-responsiveness (tolerance) or an active immune response occurs to a 
particular antigen, as well as influence whether a T helper (Th) 1, Th 2, Th17 or a 
regulatory response predominates (Kelsall, 2008; Steinman, 2003). New data have 
suggested that basophils can also function as professional antigen presenting cells, at least, 
for the generation of Th2 responses (Wynn, 2009). DC also control tissue specific homing 
of effector T cells (Mora, 2008). 
 
DC present in all lymphoid organs can be divided into subsets according to their 
phenotype, anatomical location and functions (Dudziak et al., 2007). These subsets may 
display distinct predetermined functions and plasticity depending on their local 
environment. Several intricate and innate properties account for their sentinel and sensor 
roles in the immune system. Firstly they have special mechanisms for antigen capture and 
processing; secondly they are able to migrate to defined sites in lymphoid organs to 
initiate immunity, and lastly, they can rapidly differentiate or mature in response to a 
24 
 
spectrum of stimuli ranging from Toll-like receptor (TLR) ligands to many other non-
microbial factors such as cytokines, innate lymphocytes, and immune complexes 
(Steinman and Banchereau, 2007). 
 
DC were first described in 1868 by a medical student, Paul Langerhans. The “Langerhans 
cell” was initially observed in gold-stained human skin and had DC like projections in 
their cytoplasm (Langerhans, 1868); these cells have now been identified as a unique 
subset of DC that contained Birbeck’s granules in their cytoplasms (Birbeck et al., 1961). 
In 1973, Steinman and Cohn discovered and characterised an unsual population of cells 
that were widely distributed in the lymphoid organs. In the murine spleen these large 
stellate cells had properties distinct from those of phagocytes, lymphocytes and 
granulocytes.  They had large nuclei but lacked features of active endocytosis and their 
cytoplasms bore pseudopods of various forms, sizes and numbers; they were therefore 
named “dendritic cell” (Steinman and Cohn, 1973). Steinman and Cohn showed that DC 
expressed major histocompatibility complex (MHC) class II molecules required for 
antigen presentation and stimulated mixed lymphocyte response (Steinman et al., 1983). 
They later demonstrated that DC exist in human as well as in mice (Banchereau and 
Steinman, 1998; Van Voorhis et al., 1982).  These enriched splenic cells, now known as 
conventional DC, are present in all lymphoid organs (Dudziak et al., 2007). Until the 
1990s, progress in the DC field has been slow due to the small numbers of DC in vivo, the 
lack of markers that distinguish them from macrophages or monocytes, and the technical 
difficulties in purifying DC.  However in the last decade, methods have been developed to 
isolate and generate DC from the blood and bone marrow, and studies have begun to 
establish the role of DC in the maintenance of immune homeostasis and their importance 
in human diseases (Caux et al., 1992; Inaba et al., 1992; Sallusto and Lanzavecchia, 1994; 
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Steinman, 2003; Steinman and Banchereau, 2007). Multiple DC subsets have been 
identified in mice and humans; these subsets differ in cellular origin, half life in peripheral 
tissues, and possibly, the mechanism by which they are renewed (Ardavin, 2003; 
Geissmann, 2007; Shortman and Liu, 2002).  
 
 
1.1.1 Dendritic Cell Origin, Development and Subsets  
 
Human DC originate from haematopoietic stems cells in the bone marrow and occasional 
peripheral blood stem cells (Geissmann, 2007; Inaba et al., 1993; Katz et al., 1979; Reid, 
1997). DC develop in vivo from immature precursors into two major populations:  
“conventional” or myeloid DC, and plasmacytoid DC.  DC development from 
haematopoetic progenitors is associated with Flt3 expression and their ability to respond to 
Flt3-ligand (Flt3L) (D'Amico and Wu, 2003; Karsunky et al., 2003). Flt3L enhances the 
generation of both myeloid DC and plasmacytoid DC in vitro (Blom et al., 2000) and in 
vivo (Maraskovsky et al., 2000; Pulendran et al., 2000). In healthy human volunteers 
administration of Flt3L increased the frequencies of blood myeloid and plasmacytoid DC 
(Pulendran et al., 2000). In contrast, Flt3L-deficient mice showed a decrease in numbers 
of DC in both peripheral and lymphoid tissues (McKenna et al., 2000). These data indicate 
that Flt3L is a critical factor for DC development in both humans and mice. Figure 1.1 
illustrates the origin and development of DC in steady state conditions. 
 
Myeloid DC - In vivo, human myeloid DC can be divided into peripheral tissue resident 
DC, secondary lymphoid organ resident DC, and circulating blood myeloid DC (Merad 
and Manz, 2009). In the skin epidermis myeloid precursors differentiate into CD11c+ 
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CD1a+ Langerhan cells whereas in other tissues they differentiate into CD11c+ CD1a- 
interstitial/dermal cells (Caux et al., 1997; Ito et al., 1999; Strunk et al., 1997). Skin DC 
subsets express different sets of molecules. Epidermal Langerhan cells express Langerin, 
CD1a and E-Cadherin, while dermal DC express DC-specific ICAM-3 grabbing non-
integrin (DC-SIGN), CD11b, factor XIIIa, and CD14  (Merad et al., 2008). DC in 
secondary lymphoid tissues are the most studied DC population in mice, but little 
information is available on the human counterparts. In the steady state, peripheral and 
lymphoid tissue DC are maintained by circulating blood precursors from the bone-
marrow, with the exception of Langerhans cells which can repopulate locally through self-
renewal (Merad and Manz, 2009). Myeloid DC maintain self tolerance and induce 
immune response against invading pathogens (Banchereau and Steinman, 1998; Steinman, 
2003). 
 
Most studies with human myeloid DC subsets have been performed with in vitro-
generated DC. Human myeloid DC can be derived from peripheral blood monocytes in 
vitro by stimulation with granulocyte macrophage colony stimulating factor (GM-CSF) 
and interleukin (IL)-4 (Sallusto and Lanzavecchia, 1994), or following transmigration 
through endothelial cells and phagocytosis (Randolph et al., 1998). These cells express 
CD11c and other myeloid markers such as CD11b, CD33, CD13, and they lack expression 
of lymphoid markers. They are CD45RA- and CD45RO+ and express low levels of IL-3 
receptor (CD123), and are immature based on their low stimulatory capacity and low 
expression of co-stimulatory molecules. When these cells are cultured, they upregulate co-
stimulatory molecules and become highly stimulatory (Sallusto and Lanzavecchia, 1994).  
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Plasmacytoid DC - Human plasmacytoid DC express very low or no levels of CD11c. 
Instead, they express CD4 and CD45RA, the c-type lectin receptor, BDCA-2, and the 
neuronal receptor, BDCA-4, as well as high levels of CD123 (Banchereau and Steinman, 
1998; Shortman and Liu, 2002). Plasmacytoid DC express little GM-CSF receptor and 
require activation before displaying characteristic stimulatory activity in vitro, and they 
can express TLR-9 that responds to bacterial deoxyribonucleic acid (DNA) and 
demethylated CpG deoxyoligonucleotides (Bauer et al., 2001; Krug et al., 2001a; Krug et 
al., 2001b). In the steady state, they circulate in the blood and can be found in the bone 
marrow, spleen, thymus, liver and lymph nodes. Human and mouse plasmacytoid DC 
enter the lymph nodes through high endothelial venules (HEV) (Yoneyama et al., 2004) to 
accumulate in the paracortical T cell-rich regions (Colonna et al., 2004). In the spleen and 
lymph nodes, plasmacytoid DC have a short lifespan and continuous replacement from the 
blood is necessary (Merad and Manz, 2009). In vitro, they act as antigen presenting cells 
(APC) but their role in T cell priming in vivo has not been established. They are known for 
their role in secreting large amount of type 1 interferon (IFN) upon viral exposure (Cella et 
al., 2000; Grouard et al., 1997; Liu, 2005). Recently, IFN-producing killer cells (IKDC) 
have been identified as a novel subset of mouse plasmacytoid DC that is capable of killing 
target cells and secreting large quantities of type 1 and 2 IFN (Chan et al., 2006; Taieb et 
al., 2006). 
 
Blood DC have been mostly studied in humans and contains both myeloid and 
plasmacytoid DC. These cells have been characterized as human leucocyte antigen 
(HLA)-DR+ Lineage (lin)- [Lineage = CD3-, CD19-, CD14-, CD16-, CD34-, CD56-) cells 
with the expression of CD11c in myeloid DC, and the expression of IL-3Ra chain and 
CD123 in plasmacytoid DC (Olweus et al., 1997; Siegal et al., 1999). During 
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inflammation, plasmacytoid DC appear to migrate directly into the inflamed secondary 
lymphoid tissues through HEV (Yoneyama et al., 2004), while myeloid DC migrate into 
the secondary lymphoid tissues via afferent lymph at inflammatory sites (Randolph et al., 
2005; Randolph et al., 2008)  
 
The factors regulating DC development and homeostasis, and the nature of DC precursor 
that migrates from bone marrow to peripheral lymphoid organ are incompletely 
understood.  These questions are difficult for several reasons; firstly, monocytes can 
develop phenotypic characteristics of DC in vivo during inflammation or in vitro in the 
presence of cytokines (Geissmann, 2007; Randolph et al., 1998). Secondly, monocytes, 
plasmacytoid DC and myeloid DC in lymphoid tissue share a common progenitor known 
as the macrophage and DC precursor (Fogg et al., 2006; Varol et al., 2007), and lastly DC 
subsets are functionally and phenotypically diverse (Shortman and Liu, 2002). Recent 
murine data suggest that in the steady state, monocytes do not develop into myeloid DC; 
instead they only make a minor contribution to the lymphoid-organ DC network 
(Geissmann, 2007).  
 
Traditionally, many DC subsets have been thought of as non-dividing terminally 
differentiated cells, generated from the bone marrow, that circulate in the blood as 
committed precursors, where they migrate to peripheral tissues to maintain the DC pool 
(Geissmann, 2007). Two studies have now challenged this view (Bogunovic et al., 2006; 
Kabashima et al., 2005); Kabashima et al. showed that in parabiotic mice, only about five 
percent of splenic DC were undergoing cell division at any time, and only a small 
proportion was replenished by circulating precursors over a six week period (Kabashima 
et al., 2005), whereas Bogunovic et al. showed that dermal DC proliferated in situ in mice 
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and normal human dermis (Bogunovic et al., 2006). These results support a new paradigm 
that tissue-resident DC have local proliferation properties in the steady state. In contrast, 
Liu et al. recently showed that spleen and lymph node DC from parabiotic mice were 
indeed continually replaced by blood borne precursors but that these precursors had a short 
half-life and were rapidly cleared from the circulation. They also revealed that regulatory 
T cells control DC development in the peripheral lymphoid organs in a Flt3-dependent 
manner (Liu et al., 2009). Taken together these studies suggest that tissue DC subsets 
probably have different half lives and could be maintained or be renewed through 
replenishment from bone marrow precursors, or through the proliferation of resident or 
local progenitors.  
 
There is no single specific marker in humans that identifies all DC, but they can be 
recognised by excluding other cell types. In human, these cells are characterised by their 
high expression of HLA-DR and they lack the expression of lineage markers; T cells 
(CD3), B cells (CD19), monocytes (CD14), macrophages (CD16), progenitor cells (CD34) 
and natural killer (NK) cells (CD56) (Bell et al., 2001). Throughout this thesis, human DC 
have been defined as HLA-DR+ Lin- cells. 
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Figure 1.1: Dendritic cell (DC) origin and development 
Haematopoietic stem cell produces myeloid and lymphoid DC progenitors in the bone marrow, 
following mobilisation by Fit3L. In the skin, two myeloid DC subsets, Langerhans cells and 
interstitial cells, are present. Blood contains two major DC subsets, myeloid and plasmacytoid DC. 
New data suggest that most conventional or myeloid DC in lymphoid tissue originate, without a 
monocytic intermediate, from bone marrow-derived myeloid precursor (Merad and Manz, 2009). 
Plasmacytoid DC originate from lymphoid progenitors and enter lymphoid tissues via high 
endothelial venules. 
 
 
1.1.2 Dendritic Cell Maturation 
 
A major feature of the life history of DC is maturation. Maturation is used to describe the 
intricate differentiation process whereby DC respond to environmental stimuli, acquire 
potent immunostimulatory functions and subsequently elicit an adaptive immune response. 
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This process involves the loss of their endocytic and phagocytic receptors (Garrett et al., 
2000), the extension of dendrites to expand surface area for T cell interaction, the up-
regulation of surface MHC class II and co-stimulatory molecules (eg. CD40, CD80, 
CD86), and a change in chemokine receptor expression from chemokine receptor CCR6 to 
CCR7, to promote DC migration to lymphoid tissues (Sallusto et al., 1999; Sallusto, 
1999).  In concert with these processes, DC acquire the ability to activate naive T cells. 
For example, during inflammation or infection, DC can be activated directly by interacting 
with pattern recognition receptors (PRR) of pathogens, or indirectly (Iwasaki and 
Medzhitov, 2004), by exposure to inflammatory cytokines such as α, type 1-IFN, or IL-1 
(Honda et al., 2003). Exposure to pathogen components results in fully activated DC that 
promote Th differentiation. In contrast, indirect activation by inflammatory mediators 
generates DC to support T cell clonal expansion (Sporri and Reis e Sousa, 2005).  
 
When DC encounter microbial stimuli, maturation may also occur following their 
interaction with CD40-CD40 ligands, resulting in cytokine release and prolongation of DC 
survival (Banchereau et al., 2000; Kapsenberg, 2003; Reis e Sousa et al., 2003; Rescigno, 
2002). Signalling through receptor activator of nuclear factor kappa-light chain enhancers 
of activated B cells (NFkB) and RANK, by the RANK ligand (RANKL) on T cell surface 
promotes DC survival whereas TNF-related apoptosis-inducing ligand (TRAIL), a TNF 
family member produced by activated T cells induces DC apoptosis via the TRAIL 
receptor. In addition chemokines directly provide maturation signals to DC. For instance 
CCL19, a chemokine receptor CCR7 ligand, induces maturation of activated murine DC, 
but not those in the steady state, as well as rapid endocytosis and dendrite formation 
(Yanagawa and Onoe, 2002; Yanagawa and Onoe, 2003).  
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Innate lymphocytes, NK cells, NKT cells and γδ T cells can also trigger DC maturation 
(Reschner et al., 2008). This cross talk between DC and innate lymphocytes occurs largely 
in secondary lymphoid organs, which leads to innate lymphocyte activation and DC 
maturation. This process is multi-directional, involving not only cell-to-cell contact but 
also the presence of soluble factors (Reschner et al., 2008).  Initially innate cells induce 
DC maturation via cell contact mechanisms, DC then enhance and expand the numbers of 
innate lymphocytes. Lastly, maturing DC process antigens from cells lysed by innate 
lymphocytes to elicit T cell adaptive immunity. The interaction of DC with innate 
lymphocytes appears to represent a major control mechanism for immunity that is 
independent of TLR ligands (Munz et al., 2005). 
 
 
1.1.3 Dendritic Cell Migration and Recruitment 
 
DC migration is dependent upon the coordinate expression of distinct chemokine receptors 
that direct immature precursor cells into the peripheral tissues and translocation of mature 
DC in regional lymphoid follicles (Randolph et al., 2008). In the absence of inflammation 
or infection, immature or “steady state” DC within tissues are continuously on patrol and 
migrate to organised lymphoid tissues via the lymphatic channels as non-activated or 
partially activated cells; these immature cells present self-antigens for the induction and 
maintenance of self-tolerance (Steinman et al., 2000; Steinman et al., 2003). These cells 
process self antigens which silences potentially autoreactive T cells that may have escaped 
thymic deletion (Lutz and Schuler, 2002; Steinman and Nussenzweig, 2002). Non-
responsiveness is not only confined to self antigens but can also be induced to foreign 
antigens (Hawiger et al., 2001). Immature tissue DC are endocytically active but express 
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low levels of MHC class II and co-stimulatory molecules, and are weak stimulators of T 
cell proliferation (Coombes and Maloy, 2007).  
 
In contrast, when exposed to inflammatory signals or microbial products, DC mature and 
migrate at higher rates to secondary organised lymphoid tissue where stimulation of naive 
T cells takes place.  This pathway is mediated by the interaction between PRR, such as 
TLR on DC, and pathogen-associated molecular patterns (PAMPs) present on the surface 
of microrganisms (Kaisho and Akira, 2003). When migrating from peripheral tissues to 
lymph nodes DC mature by which they downregulate their antigen acquisition machinery 
and enhance ability to stimulate T cells (Banchereau and Steinman, 1998). Inflammatory 
cues also tigger maturation of DC and concomittant upregulation of CCR7, the chemokine 
receptor centrally require for DC migration to lymph nodes (Forster et al., 1999; Sallusto 
et al., 1999). 
 
Historically, all lymph node DC were thought to migrate from upstream tisues via afferent 
lymphatic channels, based on several observations: DC were abundant in cannulated 
afferent lymph and were involved in transporting antigens, whereas commited DC 
precursors were sparse in the circulation of humans (Steinman, 1991). When afferent 
lymphatics were severed, lymph nodes were voided of DC and antigen presentation was 
inhibited (Mebius et al., 1991). Some DC populations have now been shown to enter 
lymph nodes directly from the circulation, via specialised high endothelial venules (HEV), 
notably plasmacytoid DC (Cella et al., 1999; Villadangos and Schnorrer, 2007) and mouse 
CD8α+ DC (Kamath et al., 2002; Randolph et al., 2008). However, their true trafficking 
patterns remain to be determined. In the steady state, DC in lymph nodes do not orginate 
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from upstream tissue DC, but it appears that during inflammation tissue-derived DC 
comprise a major fraction of lymph node DC (Jakubzick et al., 2008). 
 
Different chemokines receptors are important for the process of DC migration; CCR2 is 
involved in splenic DC translocation into T cell rich areas of lymphoid tissues during 
infection with Leishmania Major (Sato et al., 2000). In the intestine, CCR2 may be 
responsible for recruitment of circulating blood DC to the epithelium and lamina propria 
(Vanbervliet et al., 2002). CCR5 is important in DC recruitment to inflammatory sites 
(Aliberti et al., 2000; Sallusto et al., 1998). CCR6 is essential for DC positioning at 
epithelial surfaces (Cook et al., 2000; Vanbervliet et al., 2002) and CCR7 drives the 
migration of lamina propria DC to mesenteric lymph nodes (MLN) (Dieu et al., 1998; 
Forster et al., 1999; Jang et al., 2006; Sallusto et al., 1999). In the mouse, mucosal DC 
drive intestinal immune compartmentalisation by imprinting α4 Beta7 (β7) integrin and 
CCR9 on T cells that they activate resulting in homing to the small intestine (Mora et al., 
2003; Stagg et al., 2002).  
 
In summary, the trafficking patterns of DC are highly regulated and differ among different 
types of DC and these processes are influenced by distinct signalling cascade. Many DC 
from peripheral tissue enter lymph nodes through the afferent lymph, whilst mouse CD8α+ 
DC and plasmacytoid DC enter lymph nodes through HEV. Only a few DC enter blood 
either through reentry into venules present within peripheral tissues or via escape into 
efferent lymph (Randolph et al., 2008). 
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1.1.4 Stimulation of Adaptive Immunity 
 
DC can contribute to the expansion and differentiation of most classes of lymphocytes 
(Ueno et al., 2007). Apart from T cells, they play a role in the differentiation of B cells, 
innate NK, (Gerosa et al., 2002) and NKT cells (Vincent et al., 2002) although little is 
known about the mechanism for stimulating these other lymphocytes. Both the type of DC 
and its maturational status influence the subsequent T cell responses and their effects on 
adaptive immunity. In addition to driving the clonal expansion of proliferative T cells, DC 
can shape the functional differentiation of dividing T cells.  
 
Over 20 years ago, Mossman and Coffman showed that effector CD4+ T cells 
differentiated into two subsets, T helper (Th) 1 and Th2 cells based on distinct patterns of 
cytokine production (Mosmann et al., 1986). Most recently the identification of an 
additional subset, known as Th17 cells, has further illustrated the complexity and diversity 
of effector CD4+ T cells (Maloy and Kullberg, 2008).  
 
Th1 cells secrete high levels of IL-2, GM-CSF, TNF-α and   IFN-γ which are instrumental 
cytokines in cell-mediated immunity against intracellular virus, bacteria or protozoa and/or 
promotion of cytoxocity in NK cells and CD8+ T cells (Mosmann et al., 1986). Signal 
transducer and activator transcription (STAT) proteins are pivotal in the signalling of Th 
subset differentiation. STAT-1 and STAT-4 maintain and amplify the Th1 responses 
(Kaplan et al., 1996; Meraz et al., 1996).  The production of IL-12 by DC has been shown 
to drive a Th1 response (Macatonia et al., 1995). IL-12, a heterodimeric cytokine, 
composed of two subunits known as IL-12p35 and IL-12p40, induces and maintains Th1 
cells (Oppmann et al., 2000). IL-12 is closely related to IL-23, a relatively recent 
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discovery, which is composed of IL-23p40 and the unique IL-23p19 subunit (Kastelein et 
al., 2007; Oppmann et al., 2000). Studies in murine models of autoimmune diseases and 
inflammatory bowel disease (IBD) demonstrated that IL-23 played a key role in driving 
autoimmune tissue pathology (Cua et al., 2003; Murphy et al., 2003), and intestinal 
inflammation (Hue et al., 2006). The autoimmune and inflammatory processes were 
associated with the production of a novel subset of CD4+ T cell secreting IL-17A, 
subsequently termed Th17 cells (Bettelli et al., 2008; Langrish et al., 2004; Weaver et al., 
2007).  
 
IL-23 is secreted by DC in response to microbial stimulation but the factors that determine 
whether an activated DC produce IL-12 or IL-23 remain unclear. These responses may be 
dependent on distinct expression of PRR and associated signal transduction pathways 
(Maloy and Kullberg, 2008). For instance, commensal gram-negative bacteria or 
peptidoglycan activation of TLR2 or nucleotide binding oligomerisation domain (NOD) 
pathways resulted in IL-23 production (Smits et al., 2004; van Beelen et al., 2007). 
Another IL-12 related cytokine member includes IL-27 which consists of p28 and EBI3 
subunits. IL-27 is produced by DC and it induces the proliferation of naive T cells (Pflanz 
et al., 2002; Smits et al., 2004).  
 
Th2 cells predominantly secrete IL-4, IL-5 and IL-13 and drive humoral immunity 
directed towards clearing extracellular pathogens (Mosmann and Coffman, 1989). They 
stimulate B cells to produce immunoglobulin (IgG)-E and enhance the maturation of 
eosinophils and the degranulation of mast cells and basophils. STAT-6 activation is 
necessary for Th2 development (Kaplan et al., 1996). The production of IL-4 and IL-10 by 
DC contributes to a Th2 response; these cytokines are important against multicellular 
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parasites, such as helminths. However, three recent papers showed that DC were not 
required for the generation of CD4+ Th2 responses to protease allergens (Sokol et al., 
2009a), helminths (Perrigoue et al., 2009), or antigen IgG-E complexes in vivo 
(Yoshimoto et al., 2009). Instead, basophils that expressed MHC-II and produced IL-4 
were required and sufficient for the generation of Th2 immunity by functioning as APC in 
draining lymph nodes (Wynn, 2009). 
 
Th17 cells represent a new heterogenous population, with effector functions distinct from 
those of Th1 and Th2 cells, which is capable of secreting a diverse range of cytokines 
including IL-6, IL-17A, IL-17F, IL-21, IL-22, IFN-γ and TNF-α (Bettelli et al., 2008; 
McGeachy and Cua, 2008; Weaver et al., 2007). It is primarily characterised by the 
secretion of the cytokine IL-17. Human Th17 cells may produce IL-26 and CCL20 
(Wilson et al., 2007). IL-23 is no longer necessary to induce differentiation of Th17 cells. 
TGF-β together with IL-6 or IL-21 initiates the differentiation of Th17 cells, while IL-23 
may act as an expansion or maintenance factor for Th17 cells (Awasthi and Kuchroo, 
2009; Langrish et al., 2005; McGeachy and Cua, 2008). TGF-β is essential for the 
production of both Th17 and regulatory T cells (Treg) from naive T cells (Maloy and 
Kullberg, 2008). In vitro Treg cells can promote the development of Th17 cells in a TGF- 
β dependent manner (Awasthi et al., 2008; Xu et al., 2007). The generation of Th17 cells 
also involves STAT-3 and retinoic-acid receptor related orphan receptor γt (RORγt). In the 
intestine, the precise relationship between Treg and Th17 cell lineages, and the functions 
of Th-17 associated cytokines remains unclear. The local cytokine microenvironment is 
likely to determine the tissue protective and pro-inflammatory roles of Th17 cells (Maloy, 
2008; Maloy and Kullberg, 2008). 
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DC can also promote negative selection in the thymus, (Brocker et al., 1997) and influence 
peripheral tolerance and the generation of regulatory T cells (Treg) (Dhodapkar and 
Steinman, 2002). Treg is characterised by the expression of forkhead box transcription 
factor (Fox) p3 the and high expression of CD25. Treg can downregulate several types of 
immune responses (Curotto de Lafaille and Lafaille, 2009). Naturally occurring CD4+ 
CD25+ Treg cells that express Foxp3 differentiate in the thymus and migrate to peripheral 
tissues with their regulatory function already intact (Hori et al., 2003), whereas adaptive or 
induced Foxp3+ Treg cells differentiate in secondary lymphoid organs and tissues from 
naïve CD4+ T cells following the oral administration of antigens (Coombes and Powrie, 
2008; Curotto de Lafaille and Lafaille, 2009). Cytokines that induce the differentiation of 
Th1, Th2 or Th17 cells antagonise Foxp3+ Treg cell differentiation (Zhou et al., 2009). In 
the mouse, lamina propria and MLN CD103+ DC produce both TGF-β and retinoic acid 
(RA)  and mediate the differentiation of naïve T cells into Foxp3+ Treg cells in the 
absence of any exogenous factors (Coombes et al., 2007; Sun et al., 2007). However this 
feature was not common to CD103- DC in the MLN.  
 
Distinction between various Th cell subsets, however, is not absolute and T cell subsets 
that produce intermediate patterns of cytokine exist (Gor et al., 2003; Lyakh et al., 2008). 
In summary, DC play an integral role in shaping the nature of immune response in the gut. 
DC conditioning in the intestine are influenced by local environmental factors.  In the 
steady state, commensal bacteria signaling via PRR activates NFκB expression on 
intestinal epithelial cells, which act on DC to downregulate IL-12/23p40 production in 
response to microbial stimuli. IL-10 and TGF-β can limit the responsiveness of intestinal 
DC to bacteria signals. Defective conditioning of DC in the intestine may result in 
intestinal inflammation. 
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1.2 Intestinal Dendritic Cells and Immune Regulation 
 
The gastrointestinal (GI) tract is in constant contact with a dynamic and diverse luminal 
environment that contains an enormous number of commensal bacteria and potentially a 
variety of pathogens (Guarner and Malagelada, 2003). In this highly antigenic 
environment, the ability to maintain immune tolerance to commensal bacteria or self 
antigens as well as to mount effector responses to invading pathogens is a key feature of 
the gut immune system (Macpherson et al., 2005).  Mucosal DC located at the intersection 
between the innate and adaptive immune systems are likely to be central to this process.  
They survey the microbial environment, coordinate immune responses to danger signals 
(Niess and Reinecker, 2005), and prime naive T cells to control overwhelming infections 
or tissue inflammation (Nagler-Anderson, 2001; Steinman et al., 2003). The decision 
between the induction of tolerance and active immunity depends on the subpopulation of 
DC and the surface receptors involved, and the tissue environment during DC activation 
and T cell priming. During the steady state, DC traffic through intestinal tissues with the 
turnover time of a few days (Pugh et al., 1983).  
 
Within the GI tract DC are found in organised lymphoid tissue; this includes the Peyer’s 
patches and MLN where the induction of T and B cell response occur, and within 
generalised tissues interspersed with effector cells which include the lamina propria and 
intestinal epithelium (Iwasaki and Kelsall, 2001; Maric et al., 1996). DC in intestinal 
tissues include conventional CD11c+ DC and plasmacytoid DC (Iwasaki, 2007). A 
previously unrecognised network of DC that respond to microbial stimuli and upregulate 
CD80 and CD86 in vivo has been identified within the muscular layer of the mouse 
intestine (Flores-Langarica et al., 2005).  
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As in other tissues, intestinal DC comprise a heterogenous population. Although diverse 
DC lineages with distinct morphology have been recognised in the lamina propria and 
organised lymphoid tissues, their specific role in antigen sampling and presentation 
remains largely unknown.  
 
In the murine intestine, three subsets of CD11c+ DC have been described in the MLN and 
Peyer’s patches: CD11b+ CD8α- DC in the subepithelial dome, CD11b- CD8α+ in the 
interfollicular regions and CD11b- CD8α- (double negative) subsets in both areas (Iwasaki 
and Kelsall, 2000; Iwasaki and Kelsall, 2001). DC from Peyer’s patches can also be 
described in terms of their expression of the chemokine receptors CX3C-chemokine 
receptor 1 (CX3CR1) and CCR-6 (Niess et al., 2005; Salazar-Gonzalez et al., 2006).  
Myeloid-derived mucosal DC in mice expressed the chemokine receptor CX3CR1 to form 
transepithelial dendrites for direct sampling of luminal antigens (Niess et al., 2005).   
CX3CR1 controlled the clearance of entero-invasive pathogens by DC, suggesting that 
specialised mucosal DC control host bacteria interaction via a CX3CR1-dependent process 
(Niess et al., 2005). The murine small intestinal lamina propria also contains similar DC 
subsets to Peyer’s patches DC apart from CD8α+ DC (Niess et al., 2005). Lamina propria 
DC that express the integrin CD103 or αE have been identified in the mouse intestine 
(Annacker et al., 2005; Johansson-Lindbom et al., 2005) and their functions will be 
discussed in the next section 1.2.4. 
 
In the human colon, lamina propria DC are characterised by their expression of CD83 and 
DC-SIGN and they have the phenotype of CD11c+ Lin- with an immature state and low 
TLR-2 and -4 expression compared with their blood counterparts (Bell et al., 2001). In the 
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human intestinal lamina propria, DC are largely HLA-DR+ CD11c+ lin- myeloid cells with 
few identifiable plasmacytoid DC (CD11c- CD123+) (Bell et al., 2001; Hart et al., 2005). 
 
During inflammation, DC are recruited to the intestine but whether these cells represent a 
separate lineage to those already present in the steady state, and whether the ability of 
these “inflammatory DC” to drive pro-inflammatory responses relate to their exposure to 
microbial signals and pro-inflammatory cytokines on arrival in the intestine remains 
unclear (Coombes and Powrie, 2008). The tissue microenvironment, among other factors, 
influences DC responses to stimulation. In addition, the subsets, phenotype and functions 
of DC are likely to be influenced by tissue specific factors produced by intraepithelial 
lymphocytes and epithelial cells in response to signals from commensal or pathogenic 
microorganism (Rescigno et al., 2008; Rescigno, 2008; Rimoldi et al., 2005). DC display 
regional specialisation that enables them to function appropriately in diverse settings.  
 
Macrophages are present in high numbers in the intestinal tract of mice and humans. Both 
DC and macrophages are members of the mononuclear phagocyte systems. Intestinal DC 
can be distinguished from macrophages based on their dendritic morphology, their ability 
to capture, process and present antigens to naïve T cells (Kelsall, 2008). Macrophages, on 
the other hand, capture and kill microbes, scavenge apoptotic cells and secrete regulatory 
cytokines. However, the phenotype and functions of DC and macrophages can vary in the 
presence of inflammation or exposure to microbial stimuli (Kelsall, 2008). 
 
In summary, intestinal DC are flexible. They have unique functions compared with DC 
from other sites. These properties include the shaping of intestinal immune responses 
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mediated by environmental cues, the imprinting of mucosal homing receptors on T and B 
cells, and the induction of regulatory cells to soluble antigens. 
 
 
1.2.1 Sampling of Luminal Antigen by Intestinal Dendritic Cells 
 
DC are present as immature cells with high phagocytic activity within peripheral tissues 
and discrete regions of organised secondary lymphoid organs. Immature DC act as 
sentinels of the immune system where they constantly sample foreign and self antigens 
from the intestinal lumen (Liu and MacPherson, 1993).  
 
Within the GI tract, several pathways have been described by which DC can sample and 
process specific antigens or pathogens. Traditionally the main route for microorganisms or 
macromolecules to gain access to the mucosal immune system is via specialised epithelial 
cells, known as M (microfold) cells (Kraehenbuhl and Neutra, 2000). These cells are 
scattered among conventional epithelial cells overlying the dome of the Peyer’s patches 
follicle and they shuttle luminal antigens to DC in the subepithelial dome regions. In this 
regard, DC have been shown to phagocytose orally administered Salmonella typhimurium 
into the tissue via the M cells (Hopkins et al., 2000; Hopkins and Kraehenbuhl, 1997). DC 
are early cellular targets for Listeria monocytogenes infections in rats, and are responsible 
for bacterial spread to the host (Pron et al., 2001). A population of CD11c+ CD11b- CD8-  
DC residing in the subepithelial dome take up fluorescent polystyrene microparticles given 
orally and subsequently migrate to B cell follicles or T cell parafollicular zones following 
the ingestion of cholera toxin or live salmonella bacteria (Shreedhar et al., 2003). 
Macrophages in close proximity were however not involved in this process. These data 
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suggest that DC can migrate in response to enterotoxin adjuvants and live bacteria that 
enter the mucosa via M cells (Shreedhar et al., 2003). Antigen uptake by M cells can be 
enhanced by IgA (Neutra and Kraehenbuhl, 1993; Weltzin et al., 1989). The observation 
that DC express IgA receptors suggests that this interaction may help to increase antigen 
uptake (Geissmann et al., 2001; Heystek et al., 2002). M cells covering the Peyer’s 
patches express chemokines such as CCL20 and CXCL16 which may facilitate DC 
migration (Hase et al., 2006; Iwasaki and Kelsall, 2000). 
 
Secondly DC may acquire antigen indirectly via the internalisation of apoptotic epithelial 
cells (Huang et al., 2000). Alternatively they may take up antigen exosomes shed from 
epithelial cells (Karlsson et al., 2001; Van et al., 2001). In addition DC in the subepithelial 
follicles can sample antigens directly from apoptotic epithelial cells. For instance, in mice 
infected with type 1 Reovirus, CD11c+ CD11b- CD8-  CD4-  DC in the Peyer’s patches 
capture viral antigens from infected apoptotic epithelial cells (Fleeton et al., 2004). 
 
DC within the lamina propria can sample luminal contents directly by opening tight 
junctions between enterocytes and extending dendrites into the gut lumen, an observation 
that was first made in the 1970s through electron-microscopic (EM) studies of rat ileum    
(Collan, 1972; Rescigno et al., 2001a). This process of sampling by DC has now been 
demonstrated in the terminal ileum of mice both in the steady state (Niess et al., 2005), as 
well as in studies of bacterial uptake in vivo by Salmonella typhimurium and non 
pathogenic Escherichia coli (E. Coli) (Rescigno et al., 2001a). The formation of 
transepithelial dendrites is thought to require myeloid differentiation primary response 
gene 88 (MyD88)-dependent signalling through TLR and the expression of CX3CR1 
(Chieppa et al., 2006; Niess et al., 2005). These lamina propria DC may include subsets 
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that express IL-12p40 and IL-23p19, suggesting that they may be producers of IL-23 
(Becker et al., 2003). It is likely that antigen sampling is induced by signals from 
epithelial cells that have been in contact with luminal bacteria. Figure 1.2 shows an 
electron microscopy picture of a human lamina propria colonic DC projecting dendrites 
across epithelium into the intestinal lumen. 
 
Finally, the identification of a population of DC within the epithelial layers supports the 
notion  that bacteria may gain access to lamina propria DC directly following the 
breakdown of epithelial barrier by infection and/or inflammation, as seen IBD (Maric et 
al., 1996). Here DC penetrate the epithelium and are in direct competition with epithelial 
cells in the processing and presentation of antigens to intraepithelial lymphocytes 
(Rescigno et al., 2001b). Intestinal epithelial cells may also be involved directly with 
antigen uptake pathways by delivering antigens or exosomes to lamina propria DC 
(Morelli, 2006). Intestinal epithelial cells express lectins, NOD 1 and 2, which helps with 
the recognition of bacterial products (Cario et al., 2000; Hisamatsu et al., 2003; Inohara et 
al., 2001).  
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
Figure 1.2: Electron Microscopy (EM) of a human lamina propria DC   
This EM picture shows a human colonic lamina propria DC from a control subject,  
projecting dendrites into the intestinal lumen. 
 
 
1.2.2 Induction of Tolerance and Active Immunity by Intestinal Dendritic Cells 
 
Oral tolerance induction is a key feature of intestinal DC in generating systemic non- 
responsiveness to particular antigens. During the “steady state” such as in the absence of 
inflammation, infection or vaccination with mucosal adjuvants, intestinal DC migrate 
constitutively from the lamina propria and /or Peyer’s patches to the MLN. When DC are 
activated, this process of migration occurs at a faster rate. However the nature of DC 
migrating in the “steady state” versus the “stimulated” state remains unclear. It is likely 
that “steady state” mucosal DC are involved in tolerance induction via the induction of 
regulatory T cells that produce TGF-β or IL-10, or via functional T cell anergy/deletion. In 
contrast, upon exposure to pathogens or cytokines such as IL-1 or TNF-α, activated DC 
that migrate to secondary lymphoid tissues become inducers of effector cells (Cerovic et 
al., 2009). One recent study, however, has shown that DC which migrate from the 
intestine in the steady state, are paradoxically able to induce strong inflammatory 
Dendritic
cell
Lumen
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responses from naive T cells, despite their role in the maintenance of oral tolerance 
(Milling et al., 2009). Intestinal lymphatic DC from the thoracic ducts of rats stimulated 
strong proliferative responses, induced secretion of IFN-γ and  proliferation of FoxP3-
positive lymphocytes (Milling et al., 2009).  
 
Enhanced tolerance to intestinal antigens is observed after expansion of DC following 
stimulation with Fit3-ligand (Viney et al., 1998). Various pathways have been described 
by which DC achieved tolerance which involves the interaction between commensal 
bacteria and distinct DC populations, both in the periphery and local mucosal tissue.  The 
induction of tolerance by DC can be achieved by the downregulation of CD80 and CD86 
(Steinman et al., 2003), the interaction between DC and novel co-stimulatory molecules 
such as CD200 and CD200R (Gorczynski et al., 2005), and the signalling through novel 
receptor ligand interactions (Hoyne et al., 2000). In addition induction of tolerance can be 
achieved by the control of T cell proliferation through the release of immunosuppressive 
cytokines, IL-10, TGF-β and IFN-γ (Levings et al., 2001; Levings et al., 2002; Yamagiwa 
et al., 2001), and the production of metabolites such as indoleamine 2,3 deoxygenase 
(IDO) (Grohmann et al., 2000). 
 
Worbs et al. showed that in mice after the administration of oral soluble antigens, antigens 
were transported via afferent lymphatics by DC into the draining MLN, this process was 
obligatory for the induction of oral tolerance (Worbs et al., 2006). The majority of DC 
entering the MLN originated from the lamina propria suggesting that these were the cells 
likely to contribute to antigen presentation for oral tolerance induction (Bimczok et al., 
2005; Turnbull et al., 2005).  
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The same DC population derived from different tissues can exhibit different responses to 
the same stimuli. For example, in the mouse, mucosally-derived plasmacytoid DC induces 
differentiation of “T reg” like cells that release IL-10 and IL-4 after DC maturation with 
CpG (Bilsborough et al., 2003), whereas bone marrow and spleen-derived plasmacytoid 
DC induce a Th1 T cell phenotype when stimulated by CpG (Boonstra et al., 2003). 
Moreover within the same mucosal tissue, different DC populations display distinct 
functional phenotypes under the same stimulation conditions. In the Peyer’s patches 
CD11c+  CD11b+  DC produced IL-10 whereas CD11c+  CD8α+  DC and CD11c+  CD11b- 
CD8α-  DC produced IL-12p70 following stimulation with CD40L (Iwasaki and Kelsall, 
2001; Kellermann and McEvoy, 2001). All together, these data suggest that the induction 
of tolerance versus active immunity may be complex and is dependent on the tissue 
microenvironment, the types of DC the signalling events and response to microbial 
stimuli. 
 
Figure 1.3 illustrates a model where intestinal DC migrate to secondary lymphoid tissue 
following the sampling of luminal antigen, and subsequently determine the type of T cell 
responses: tolerance (non responsiveness), Th1, Th2, Th17 or a regulatory response. 
 
It remains unclear whether the immune environment in the human gut is the same as that 
in animal models. Ways in which DC interact with microbes may be different in humans 
and mice. Furthermore, it remains to be determined whether functional distinct properties 
of intestinal DC have been predetermined by local microenvironment or whether they are 
functionally committed precursors that have been directed to migrate to the intestine. 
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Figure 1.3: Proposed mechanisms of control of T cell responses by intestinal dendritic cells 
This figure illustrates the development of Th1, Th2, Th17 and Treg cells from naïve CD4+ T cells 
following activation by intestinal DC. The location and precise phenotype that distinguish these 
different subsets remain to be understood. Excessive Th1 response in the absence of adequate 
regulatory response lead to inflammatory pathology. It remains  unclear whether resident DC lose 
their non-inflammatory properties, or whether fresh non-conditioned DC are recruited from blood 
as differentiated cells or monocytic precursor during inflammation. DC promote the development 
of Foxp3+ Treg cells in the GALT in the presence of TGF-β. They can also dictate the homing 
potential of recently activated T cells by imprinting α4β7 on these cells. 
 
 
 
 
 
 
 
 
 
49 
 
1.2.3 Intestinal Dendritic Cells and Microbial Interaction 
 
DC display significant plasticity in their ability to respond to microbial stimuli. The 
outcome of stimulation is dependent on the local interaction between DC populations and 
lymphocytes (Pulendran, 2004). The ability of DC to sample luminal bacteria suggest that 
they play a critical role in the surveillance of pathogens in the gut environment.  
 
Microbial products including lipopolysaccharide (LPS) stimulate DC maturation. In mice, 
LPS from E coli stimulated IL-12 DC production whereas LPS from Porphyromonas 
gingivalis did not, suggesting that LPS from different bacteria activate DC subsets to 
produce different cytokines, and induce distinct types of adaptive immunity in vivo 
(Pulendran et al., 2001). Apart from distinguishing between microorganisms, DC can also 
differentiate between closely related microbial structures of the same organism. Murine 
DC lines produced IL-12 to prime a Th1 response when Candida albicans was ingested, 
whereas IL-4 was produced and IL-12 inhibited when the hyphae form of the yeast was 
ingested (d'Ostiani et al., 2000). Enteric pathogens can also alter intestinal DC function 
(Kapsenberg, 2003). For example, Heligmosomoides polygyrus infection induced DC 
activation and IL-10 expression, which impaired host protection against Citrobacter 
rodentium infection, resulting in an enhanced bacterial infection and more severe colonic 
inflammation (Chen et al., 2006). It is likely that exposure to microbial products alone is 
insufficient to activate intestinal DC and there may be a need for inflammatory signals 
from cytokines to indicate local tissue damage. 
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Studies using oligonucleotide microarrays to compare gene expression of DC exposed to 
candida, influenza virus or E. coli have demonstrated that DC are able to elicit tailored 
immune response to certain organism (Huang et al., 2001). For instance when human 
monocyte-derived DC were exposed to different pathogens, organism-specific responses 
occurred in addition to a temporal cascade of common core response to all tested antigens 
(Huang et al., 2001). 
 
In healthy individuals, CD4+ T cells from the lamina propria exhibit reactivity to 
commensal bacteria including Enterobacter, E. coli and Enterococcus species, as well as 
to the pathogen, Salmonella typhimurium.  Depletion studies showed that bacteria-specific 
CD4+ T cell activation and proliferation in vitro were dependent on intestinal DC, which 
themselves exhibited a pro-inflammatory cytokine profile upon bacterial stimulation 
(Howe et al., 2009).  
 
DC sense their microbial environment by expressing a series of surface PRR that 
recognise a limited set of conserved molecular patterns, referred to as PAMPs, on the 
surface of bacteria (Akira et al., 2006; Akira, 2006). PAMPs are recognised through at 
least three PRR families of molecules: TLR, cell surface c-type lectin receptors and 
intracytoplasmic NOD-like receptors. It is unclear how PRR monitoring and response 
distinguish between the abundant normal microbiota and the rare pathogen. Microbes can 
directly activate DC through PRR, or indirectly, by the capture of apoptotic or necrotic 
cells dying in response to microbial stimuli (Neish, 2008).   
 
Toll-like Receptors (TLR)- The best characterised of all PRR are the TLR. Ten TLR have 
been identified in humans and 13 TLR have been detected in mouse (Akira et al., 2006; 
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Akira, 2009). TLR can be divided based on their cellular localisation and differential 
expression by distinct DC subsets.  TLR-1, TLR-2, TLR-4, TLR-5 and TLR-6 are 
expressed on the cell surface, whereas TLR-3, TLR-7, TLR-8 and TLR- 9 are expressed in 
intracellular compartments (Akira et al., 2001). TLR-2 expressed by CD11c+ DC and its 
ligands are required for recognition of gram-positive cell wall components, including 
lipoproteins and peptidoglycans (Kadowaki et al., 2001). TLR-4 recognises LPS from E. 
coli (Takeuchi et al., 1999); TLR-5 recognises flagellin from gram-negative bacteria, and 
TLR-9 recognises GpG motifs bacterial DNA and is expressed by plasmacytoid DC and B 
cells. Different DC recognise different PAMPs to induce a distinct immune response. E. 
coli LPS stimulates DC via TLR-4 to induce IL-12 secretion and a Th1 response, whereas 
Porphyromonas gingivalis LPS activates DC via TLR-2 to secrete IL-10, and the 
development on Th2 response (Pulendran et al., 2001). 
 
C-type lectin receptors – C-type lectins act as anchors for bacteria, viruses, parasites and 
fungi, and allow internalisation of these microorganisms.  They also act as adhesion 
molecules between DC and other cell types. Distinct DC subsets express different c-type 
lectins:  BDCA-2 is specific to plasmacytoid DC (Dzionek et al., 2001), langerin/CD207 
is specific to langerhans cells (Valladeau et al., 2000), and DC-SIGN is specific to 
interstitial DC (Geijtenbeek et al., 2000). Bacteria (Lactobacillus reuteri and 
Lactobacillus casei) and its cell surface compounds can bind to DC-SIGN, and lead to the 
induction of regulatory T cells (den et al., 2009). DC-SIGN is implicated to play a role in 
the induction of various responses mediated by DC.  Konstantinov et al. have shown that 
the major S layer protein, SlpA, of L. acidophilus NCFM binds to DC-SIGN and induced 
a concentration-dependent production of IL-10 and low IL-12p70. A knockout mutant of 
L. acidophilus NCFM which lacked SlpA was significantly reduced in binding to DC-
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SIGN (Konstantinov et al., 2008). These data suggest that the interaction of probiotic 
bacteria with DC-SIGN ligand is functionally involved in the modulation of DC and T cell 
functions. 
 
In ileal tissues from patients with CD, enhanced infiltrates of DC-SIGN+ and CD83+ DC 
have been found in the subepithelial dome overlying the Peyer’s patches (Salim et al., 
2009). CD83+ cells in Crohn's tissues showed reduced expression of the lymph node 
migratory receptor, CCR7, possibly contributing to their retention within the epithelium. 
These cells expressed TLR-4 and produced TNF-α. When exposed to E coli, CD83+ DC 
co-localized with translocated bacteria (Salim et al., 2009). Thus non-migrating DC in the 
subepithelial dome can internalize non-pathogenic bacteria which may be important for 
the onset and perpetuation of intestinal inflammation in CD (Salim et al., 2009). 
 
NOD-like receptors – NOD-like receptors recognise intracellular microbial components 
and signal pathways that produce pro-inflammatory cytokines (Delbridge and O'Riordan, 
2007; Mariathasan and Monack, 2007). DC express NOD 1, which recognises muramyl-
tripeptides from gram-negative bacteria, and NOD 2, a key cytoplasmic sensor of 
intracellular bacterial peptidoglycan and a mediator of innate immunity. Mutation in 
NOD2 has been associated with ileal Crohn’s disease (CD) (Hugot et al., 2001; Ogura et 
al., 2001) suggesting that the dysregulated recognition of intestinal microbiota bacteria 
results in inflammatory disease in genetically predisposed subjects.  
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1.2.4 Regulation of Lymphocyte Homing by Intestinal Dendritic Cells 
 
Lymphocytes continuously migrate around the body to meet antigens. T cells trafficking to 
lymphoid and extralymphoid tissues involves a multistep process and multiple signals that 
is regulated by the coordinated interaction between cell surface molecules on T cells with 
their respective ligands on the surface of vascular endothelial cells (Butcher, 1992; 
Butcher et al., 1999). In the intestine, lymphocytes primed in MLN draining intestinal 
sites have the propensity to home back to the intestine (Stagg et al., 2002). Two homing 
molecules promote specific homing to the gut: α4β7 which is attracted to its ligand, 
mucosal addressin cell adhesion molecule-1, MadCAM-1, expressed on HEV, Peyer’s 
patches and MLN in the intestine (Butcher et al., 1999), and the chemokine receptor 
CCR9, attracted to its ligand CCL-25 (TECK). The latter plays an important role in the 
recruitment of effector T cells to the small intestine (Zabel et al., 1999). Specific homing 
pathways also exist for other organs. For instance, cutaneous leukocyte antigen (CLA, a 
carbohydrate selectin ligand), CCR4, CCR8 and CCR10 have been implicated in homing 
to the skin (Campbell et al., 1999; Campbell et al., 2007; Ohmori et al., 2006; Schaerli et 
al., 2004). RA is required for the induction of α4β7 and CCR9 by mucosal lymphocytes.  
RA binds to intracellular retinoic receptors, which activates the transcription of genes 
encoding α4β7 and CCR9 (Iwata et al., 2003; Iwata et al., 2004).  Gut DC play an 
important role in the homing process (Dudda et al., 2005; Sigmundsdottir and Butcher, 
2008). Figure 1.4 illustrates proposed mechanisms of control of lymphocyte homing by 
DC. 
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Figure 1.4: Control of lymphocyte homing by dendritic cells 
DC in gut-related lymphoid organs imprint T cells with gut-homing specificity by providing RA 
during antigen presentation. MLN-DC and Peyer’s patches DC produce RA from retinol (vitamin 
A), and imprint gut-homing specificity on T cells upon activation. The imprinted T cells express 
both α4β7 and CCR9, which bind to MAdCAM-1 and CCL25, respectively, and migrate into the 
small intestinal tissues (left panel). Conversely, DC in skin-draining LN imprint CLA, CCR4 or 
CCR10 on T cells, which subsequently migrate to the skin (right panel). 
 
DC not only activate and imprint antigen specificity by presenting antigen to lymphocytes, 
but they also direct lymphocytes to the site where the antigen is most likely to be 
encountered by imprinting tissue specificity (Johansson-Lindbom et al., 2003; Mora et al., 
2003; Stagg et al., 2002). Work from our laboratory has demonstrated that in mice DC 
from MLN, but not from peripheral lymph nodes, induce  4β7 on T cells, thus targeting 
T cells back to intestinal tissue in vivo (Stagg et al., 2002). Others have shown that murine 
intestinal DC from Peyer’s patches, MLN and the lamina propria induce 4β7 and CCR9 
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expression on T cells (Johansson-Lindbom et al., 2003; Johansson-Lindbom et al., 2005). 
In contrast, T cells activated by DC from skin-draining nodes express ligands for skin 
homing molecules, P- and E-selectins and lack expression of gut homing markers (Mora et 
al., 2003). In the mouse, the ability to generate CCR9+ α4B7+ gut homing T cells appears 
to be confined to a functionally distinct subset of MLN DC that express the integrin α 
chain CD103, which make up about 40 percent of DC in the MLN; these specialised cells 
most likely originate from the small intestinal lamina propria (Johansson-Lindbom et al., 
2005). Most small intestinal lamina propria DC express CD103, and DC derived from 
these sites are more potent at generating gut trophic effector T cells than MLN DC, 
implying that DC are imprinted with the ability to generate gut trophic T cells before 
entering MLN (Jaensson et al., 2008). In contrast, CD103- MLN DC did not generate gut 
trophic T cells. The heterodimer αE(CD103) β7 is expressed on the majority of of human 
and mouse intestinal lymphocytes and CD103 mediates adhesion of lymphocytes to 
intestinal epithelial cells via interactions with E-cadherin (Cepek et al., 1994).  
 
The mechanisms and specific signals involved in DC imprinting appear to be dependent 
on vitamin A (Iwata, 2009). The vitamin A metabolite, RA, is converted from retinal by 
retinal dehydrogenase (RALDHs). RA induces gut homing markers on mouse T cells 
together with concomitant suppression of the skin-homing molecules E- and P-selectin 
(Iwata et al., 2004).    
 
T cells with regulatory properties (Treg) play a central role in maintenance of 
immunological homeostasis and tolerance in the gut. Most studied of these cells include 
the naturally occurring population of CD4+ CD25+ Foxp3+ Treg cells that develops in the 
thymus.  Similar to conventional T cells, Treg have homing receptors allowing migration 
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into specific tissues and DC are thought to play an important role in the generation of Treg 
cell responses (Coombes et al., 2007; Siddiqui and Powrie, 2008).   
 
Foxp3+ Treg cells can also be induced from naive FoxP3- CD4+ T cells; this process 
appears to be dependent on RA (Kang et al., 2007). In the mouse, the induction of 
retinoid-induced FoxP3+ Treg cells involved T cell activation driven by mucosal DC and 
costimulation through CD28 (Kang et al., 2007). RA can promote TGF-β1-dependent 
generation of FoxP3+ Treg cells but decrease the TGF-β1- and IL-6-dependent generation 
of inflammatory Th17 cells. RA-induced FoxP3+ Treg cells express gut-homing receptors 
important for migration to the small intestine. Altogether, these results identify RA as 
positive regulatory factors for generation of gut-homing FoxP3+ T cells (Kang et al., 
2007). 
 
In particular, 4β7 is induced on Treg when exposed to DC from MLN but not from 
peripheral lymph nodes, and RA appears to be central to this induction of α4β7 and 
homing to the intestine (Annacker et al., 2005). As with conventional T cells, the DC 
subset, CD103+ DC, is equipped for converting antigen-specific T cells into Treg cells 
(Coombes et al., 2007; Sun et al., 2007). The CD103+ DC population displays an 
enhanced ability to generate Treg compared with their CD103− counterparts in vitro, and 
this ability is inhibited by RA receptor (RAR) antagonist (Benson et al., 2007).  
 
In summary, intestinal DC play a pivotal role in lymphocyte homing; this process is 
dependent on RA and TGF-β. The role of lymphocyte trafficking in the pathogenesis of 
IBD has been discussed separately in section 1.4.3. 
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1.3 Intestinal Microbiota 
 
The term “microbiota” refers to the community of living micro-organisms present in the 
ecological niche of a host individual. The human GI tract is home to an inconceivable 
number of micro-organisms (Backhed et al., 2005; Neish, 2008; Sonnenburg et al., 2004). 
It represents the largest surface area of the body which is colonized by a diverse and 
dynamic microbial community, including the resident microbiota as well as foreign 
bacteria. Bacterial diversity in the gut consists of eight phyla; members of the gram 
negative Bacteroidetes and gram-positive Firmicutes consist between 60 to 80 percent of 
the total faecal microbial community (Eckburg et al., 2005). The composition of bacteria 
within different regions of the GI tract varies (Eckburg et al., 2005).  
 
Although we are all born germ free, as adults our microbiota census exceeds the total 
number of our own human cells by 10-fold and the microbes contribute to many 
physiological and metabolic activities (Gill et al., 2006).  They endow us with functional 
features that we have not had to evolve ourselves (Backhed et al., 2005). There are 
approximately 1014 microbes that reside in each of our bodies. The aggregate genomes of 
these gut species may contain >100 fold more genes than our own genome. Our 
relationship with components of this microbiota is often described as commensal (one 
partner benefits and the other is apparently unaffected) as opposed to mutualistic (both 
partners experience increased fitness) (Gill et al., 2006). 
 
Apart from environmental factors, there is growing evidence that genetic factors may 
contribute to the composition of the gut microbiota. Molecular studies on the faecal 
microbiota have shown that three bacterial divisions dominate: bacteroidetes, firmicutes, 
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and actinobacteria. However, microbial diversity between individuals is remarkably 
different and each individual has a unique suite of bacteria (Guarner, 2005). 
 
The benefits of our microflora are well known which include important metabolic, trophic 
and protective functions. Our microbiota assist the host in the fermentation of non-
digestible residue and the production of short chain fatty acids, which serves as a major 
energy source for colonic enterocytes. They also control epithelial cell proliferation and 
differentiation; as well as provide protection against pathogens (Guarner and Malagelada, 
2003). 
 
The vast majority of microbial communities in the human gut are represented by 
organisms that are unculturable using standard methods in the laboratory (Rehman and 
Jasmer, 1998). Culture-independent methods include metagenomics and molecular 
inventories of 16S rRNA genes. Recently, metagenomics have allowed us to study the 
genes contained in this vast uncultured majority via the isolation and sequencing of DNA 
directly from the community in order to assess diversity and profile (Marchesi and 
Shanahan, 2007). This method helps to indicate the presence or absence of specific 
lineages and allows for community comparisons. Gloux et al. screened a metagenomic 
library of DNA extracted from the distal gut and identified genes that modulate the growth 
of epithelial cells (Gloux et al., 2007). Other culture independent technique includes 
fluorescent in-situ hybridisation (FISH). This technique includes group specific 
fluorescent probes, used to detect and localize the presence or absence of specific DNA 
sequences on chromosomes. The probes bind to only those parts of the chromosome with 
which they show a high degree of sequence similarity (Tannock, 2007).  Metagenomic 
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profiling is important to identify specific functional categories of genes (Kurokawa et al., 
2007; Tringe et al., 2005). 
 
The above discussion emphasizes the importance of the host dialogue with our gut 
microbiota and their interaction with mucosal homeostasis (Marchesi and Shanahan, 
2007). Methods are now available to identify the stability and variation in the microbial 
community in health. A breakdown in the interaction between immune homoestasis and 
intestinal microbiota results in chronic inflammatory bowel disorders such as IBD.  In the 
next section, the role of intestinal microbiota in IBD will be discussed. 
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1.4 Inflammatory Bowel Disease 
 
Ulcerative colitis (UC) and Crohn’s disease (CD), collectively termed IBD, results from a 
dysregulated response of the mucosal immune system to components of the luminal 
microbiota in individuals who are genetically predisposed to the disease (Bamias and 
Cominelli, 2007; Baumgart and Carding, 2007; Sartor, 2006).  
 
 
1.4.1 Role of Intestinal Microbiota in Inflammatory Bowel Disease 
 
In human IBD, several studies have shown that the composition of faecal microbiota 
differs between patients with IBD and healthy controls (Seksik et al., 2003). It remains 
unclear whether changes of the microbial community in IBD are linked to disease 
aetiology, or a result of changes in gut environment due to disease (Macfarlane et al., 
2009). In CD, analysis of faecal bacteria showed an increase in enterobacteria but more 
than 30 percent of the dominant flora belonged to a yet undefined phylogenetic groups. 
Using a metagenomic approach, Manichanch et al. have shown that there was a marked 
reduction in the Firmicutes in CD patients in remission, but no difference in numbers of 
bacteroides and C. coccoides, when compared with controls (Manichanh et al., 2006).  
 
In patients with UC, there is reduced diversity of faecal microbiota (Andoh et al., 2007). 
In UC, higher serum antibody titres to the outer membrane protein of Bacteroides vulgates 
have been reported (Matsuda et al., 2000), and higher numbers of E. coli have been found 
in the mucus layer but not adherent to the surface layer of epithelium (Burke and Axon, 
1988; Schultsz et al., 1997) whilst other E. coli subtypes have shown no difference in 
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adherence properties (Macfarlane et al., 2004). Swidsinski et al. recently demonstrated 
that lower faecal levels of Faecalibacterium (F.) prausnitzii along with faecal leucocyte 
counts differentiated active CD from UC. There was a depletion of F. prausnitzii with a 
normal leukocyte count in CD and a high F.  prausnitzii in patients with UC (Swidsinski 
et al., 2008). 
 
Apart from intestinal bacteria in the gut lumen, mucosal microbial communities may play 
a role in IBD. Distinct microbial communities have been established in biofilms on 
mucosal surfaces of the large bowel (Campieri and Gionchetti, 2001; Matsuda et al., 
2000). Human studies have shown that mucosal bacterial populations in UC may be 
altered towards a more pro-inflammatory phenotype (Sartor, 2001; Sartor, 2008). In 
patients with active UC, baseline reduction, temporal instability, and decrease of bacterial 
richness were observed in the mucosal flora towards disease relapse whereas the colonic 
mucosal-associated flora for controls appeared stable over time (Ott et al., 2008). In 
tissues from IBD patients, species richness increased from control to non-inflamed tissue, 
but declined in fully inflamed tissue (Sepehri et al., 2007). An increased prevalence of 
mucosa E. coli and Bacteroides has been observed in CD patients (Barnich and rfeuille-
Michaud, 2007; Kotlowski et al., 2007; Swidsinski et al., 2005). Invasive E. coli was 
associated with ileal CD, and the number of E. coli in situ correlated with severity of 
disease (Baumgart et al., 2007). 
 
CD has been thought to relate to defective bacterial killing (Packey and Sartor, 2009b). 
Mutation of NOD2 in a subset of patients with CD results in decreased α-defensin 
production and impaired clearance of intracellular bacteria. CD is also associated with 
genetic polymorphisms of at least two components of the autophagy pathway, autophagy-
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related 16-like-1 (ATG16L1) and immunity-related GTPase family M (IRGM) (Prescott et 
al., 2007; Rioux et al., 2007), which lead to decreased antimicrobial peptide secretion, 
inefficient killing of phagocytosed bacteria, persistent intracellular bacteria antigens and 
increased mucosa permeability (Packey and Sartor, 2009a). Although several studies have 
suggested a link between Mycobacterium avium subspecies paratuberculosis (MAP) and 
IBD (Clancy et al., 2007; Juste et al., 2009; Ren et al., 2008), there is no evidence that 
MAP is a causative agent in patients with CD (Packey and Sartor, 2009c). 
 
The search for a causative disease pathogen in IBD has been complicated by the marked 
individuality of the gut microbiota with minimal overlap between individuals (Dicksved et 
al., 2007; Eckburg et al., 2005). Host genotype may partly determine the microbial 
composition in the gut supported by a study showing high similarity in the fecal microbial 
communities in monozygotic twins (Stewart et al., 2005). However, in discordant 
monozygotic twins, analysis of the mucosa-associated microbiota in twin wih  
predominantly ileal CD revealed lower abundance of F. prausnitzii and increased levels of 
E. Coli compared to healthy co-twins. Overall these twin data suggest that dysbiosis is 
likely to be associated with disease phenotype instead of genotype, and that reduced F. 
prausnitzii and increased E .coli are indicative of ileal CD phenotype  (Willing et al., 
2009). 
 
To summarise, IBD is characterised by altered microbial composition, defective clearance 
of bacteria in a subgroup of patients, and enhanced mucosa bacteria uptake; the dysbiosis 
is associated with host genetic alterations in immunoregulation and innate bacterial killing 
(Sartor, 2008). 
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1.4.2 Role of Dendritic Cells in Inflammatory Bowel Disease  
 
Tolerance is developed towards resident intestinal flora but this tolerance is broken in 
intestinal inflammation (Duchmann et al., 1995; Duchmann et al., 1997). In IBD in which 
there is a dysregulated immune response to microbial flora, DC are likely to be of 
fundamental importance. Animal models of colitis have provided strong evidence that the 
interaction between the intestinal microbiota and mucosal immune system plays an 
important role in the pathogenesis of IBD (Karlis et al., 2004).  In murine models of 
colitis, DC accumulate throughout the entire lamina propria and MLN (Leach et al., 1996; 
Strober et al., 2002).  
 
One of the best characterised animal models involves the transfer of CD45RB high CD4+ T 
cells into severe combined immunodeficiency (SCID) mice which results in chronic 
intestinal lesions similar to those seen in human IBD (Malmstrom et al., 2001).  In such a 
model, colitis was associated with increased CD11c+ DC in the MLN and up to one third 
of the DC expressed high levels of activation marker OX40L (CD134L). Co-transfer of 
CD45RBlow CD4+ T cells inhibited the accumulation of CD134L+ DC suggesting that 
regulatory T cells may function, in part, to prevent DC activation. Moreover, blocking 
CD134-CD134L interactions ameliorated the colitis, reduced T cell proliferation and the 
numbers of α4β7+ T cells in the MLN (Malmstrom et al., 2001).   
 
DC are likely to be crucial for the activation and expansion of CD25+ CD4+ T cells in both 
draining lymph nodes and at sites of inflammation to suppress functions of effector T 
cells. Using the CD45RBhigh CD4+ T cell transfer model of colitis, Mottet et al. showed 
that the transfer of CD25+ CD4+ T cells into mice with colitis resulted in resolution of the 
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lamina propria infiltrate and CD25+ CD4+ T cells proliferated between clusters of CD11c+ 
DC in the MLN and inflamed colon (Mottet et al., 2003).    
 
 DC are also involved in the early events of intestinal inflammation demonstrated in a 
slightly different model in which total CD4+ T cells were transferred to RAG1-/- mice 
resulting in colitis. Transplanted T cells formed aggregates with CD11c+ DC in the lamina 
propria, and subsequently underwent proliferation, approximately 8 to 11 days post 
transfer before the manifestation of colitis. The degree of expansion within the DC clusters 
was proportional to the severity of intestinal inflammation supporting the role of DC in the 
initiation, and possibly the maintenance of inflammation (Leithauser et al., 2001).  
  
Other investigators have shown the up-regulation of co-stimulatory molecules CD40, 
CD80 and CD86 together with the expansion of colonic lamina propria DC in murine 
models of colitis. In addition lamina propria DC from inflamed tissue produced higher 
levels of IL-12p40, IL-23p19 and IL-10 (Becker et al., 2003).  
 
IL-23 is a heterodimer which shares the p40 subunit with IL-12. IL-23 consists of IL-
23p19 and IL23p40 whereas IL-12 comprises IL-12p35 and IL-12p40.  Both cytokines, 
produced by activated macrophages and DC, are potent regulators of the adaptive immune 
responses (Lyakh et al., 2008).  IL-12 is required for antimicrobial responses to 
intracellular pathogens, whereas IL-23 is likely to be important for the recruitment and 
activation of a range of inflammatory cells required for the induction of chronic 
inflammation and granuloma formation (Iwakura and Ishigame, 2006). In studies of 
transgenic mice expressing firefly luciferase under the influence of the IL-12p40 
promoter, CD8α and CD11b double-negative CD11c+ lamina propria DC  represented the 
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major source of IL-12p40 production in the small intestine whereas additional IL-23 was 
produced in response to bacterial flora (Langrish et al., 2004). One other possibility is that 
CD11b+  DC in the inflamed mouse colon produced IL-23 and not IL-12, which helped to 
expand pathogenic T cells in situ (Oshitani et al., 1997; Oshitani et al., 1998; Seldenrijk et 
al., 1989; Waraich et al., 1997). B7-H1, a ligand for programmed death-1 receptor (PD-1) 
has also been described to be involved in the development of colitis. Inhibition of B7-H1 
suppressed chronic intestinal inflammation in mice (Kanai et al., 2003). 
 
Furthermore, when DC were selectively depleted in mice before the initiation of DSS-
induced colitis, the disease was more severe, compared with that of DC-intact mice 
(Qualls et al., 2009). Increased IL-6 expression in colon tissues correlated positively with 
increased colitis severity in DC-depleted mice. Thus resident DC can suppress the severity 
of acute DSS colitis and regulation of IL-6 production may contribute to DC-mediated 
control of intestinal inflammation (Qualls et al., 2009). 
 
Similar to findings in murine models of colitis, studies of DC in human IBD have shown 
a role of activated DC at sites of intestinal inflammation (Bell et al., 2001; Kaser et al., 
2004), suggesting that they are likely to contribute to the generation of IBD in humans. 
Early studies have focussed on the comparison of cells in inflamed and normal colonic 
lamina propria.  
 
Several investigators have shown an increased in the number and maturation of DC within 
inflamed IBD tissue (Kaser et al., 2004), whilst others have suggested enhanced 
recruitment of immature DC into inflamed tissue (te Velde et al., 2003). In CD, there was 
an increase in CD83+ and DC-SIGN+ lamina propria DC, which may produce IL-12 and 
66 
 
IL-18 during intestinal inflammation (de et al., 2003). Infiltration of CD83+ CCR7- DC 
have been reported in the subepithelial dome; these cells internalized translocated E. coli 
HB101 in the Peyer’s patches of ileal CD, and may be important in the onset and 
perpetuation of mucosal inflammation (Salim et al., 2009).  In addition, MDC8+ 
monocytes, which were possible precursors of DC, have been identified as a potential 
source of TNF-α. There were increased TNF-α producing cells in the ileal and colonic 
lamina propria of patients with CD than controls. Furthermore, abundant numbers of 
Langerin+ immature DC have been found in the subepithelial space of IBD tissue and were 
associated with enhanced expression of CCL20 in the intestinal epithelium. Thus CCL20 
might regulate the attraction of T lymphocytes and DC in IBD (Kaser et al., 2004).  
 
Vuckovic et al. have reported increased number of CD40+ CD86+ lin- DC in the peripheral 
blood and lamina propria of patients with UC and CD implying the presence of activated 
DC in the blood and tissues (Vuckovic et al., 2001), whereas Baumgart et al. have 
demonstrated that patients with active IBD lacked immature blood plasmacytoid and 
myeloid DC, suggesting recruitment of these cells to the tissue (Baumgart et al., 2005). 
 
The expression of TLR-2 and -4, and the activation of CD40, was enhanced on lamina 
propria DC of patients with CD and UC (Hart et al., 2005). In CD, more colonic DC 
produce pro-inflammatory cytokines, IL-6 and IL-12p40, than controls. In addition, 
treatment of patients with CD patients with anti-TNF therapy resulted in a reduced 
expression of CD40 by lamina propria DC (Hart et al., 2005). 
 
One study in UC has identified an increased number of CD83+ and CD86+ lamina propria 
cells, most likely DC, which produced macrophage inhibitory factor (MIF). MIF can then 
67 
 
induce the production of IL-1 and IL-8 by DC and monocytes, which may enhance 
neutrophil recruitment and activation (Murakami et al., 2002). In addition colonic lamina 
propria in UC contained numerous basal aggregates consisting of lymphocytes and CD80+ 
dendritiform cells that most likely represented activated DC (Yeung et al., 2000). DC 
generated in vitro from peripheral blood monocytes show increased immuno-stimulatory 
capacity, and produced more nitric oxide in patients with UC (Ikeda et al., 2001).  
 
Lastly, DC can be the source of cytokine production. IL-12-related cytokine, IL-27, is 
increased in lamina propria of UC patients (Christ et al., 1998).  UC was also associated 
with an atypical Th2 response mediated by non-classical NKT cells producing IL-13 
suggesting that DC may regulate NKT cell activity through IL-27 in UC (Fuss et al., 
2004).  
 
Unlike mouse models, studies of human DC in IBD have previously been hampered by the 
lack of adequate tissue, inconsistent phenotype or function of specific DC populations 
with the human intestine. Nonetheless emerging evidence now supports the role of DC as 
important players of the regulation of intestinal immunity in humans. 
 
 
1.4.3 Dysregulated Lymphocyte Homing in Inflammatory Bowel Disease 
 
In IBD, both tissue specific homing of lymphocyte populations and an imbalance of 
regulatory and effector responses are likely to contribute to the dysregulated immune 
response (Eksteen et al., 2008). In animal models of IBD, immune cell trafficking 
pathways play a role in these diseases.  Gut-specific adhesion molecules are increased in 
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CD which makes them potential therapeutic targets (Apostolaki et al., 2008), whereas in 
UC, leukocyte recruitment is less well defined. Thus far no adhesion molecule 
combination is unique to the colon in the way that CCR9/CCL25 is in the small bowel. 
 
In experimental models of colitis such as DSS-induced intestinal inflammation, 
upregulation of MAdCAM-1 expression in the intestinal lamina propria has been 
demonstrated (Farkas et al., 2006; Goto et al., 2006; Kato et al., 2000; Matsuzaki et al., 
2005; Picarella et al., 1997), and anti-MAdCAM-1 treatment resulted in reduction of 
lymphocyte recruitment to the intestine together with an improvement in intestinal 
inflammation (Hesterberg et al., 1996; Podolsky et al., 1993; Rivera-Nieves et al., 2006).  
 
In the cotton top tamarine, a primate which develops spontaneous and chronic intestinal 
inflammation resembling that of UC in humans, treatment with anti-α4 and anti-α4β7 
monoclonal antibodies ameliorated intestinal inflammation and was associated with 
reduced density of mucosal α4β7+ lymphocytes (Rivera-Nieves et al., 2005).  
 
In other models, the inhibition of several integrins is neccessary for effective treatment 
and resolution of inflammation. For example in models of CD-like ileitis (SAMP1/YitFc 
and CD4+ T cell transfer models) pathogenic T cells recirculated to the chronically 
inflamed small intestine via the α4β7/MAdCAM-1 pathway. In addition T cells also 
engaged other recruitment pathways such as α4β1 and L-selectin (Park et al., 2007). In a T 
cell transfer colitis model the ability of T cells to induce colitis was decreased when 
lymphocyte migration into the gut was paralysed due to a mutation in β7 integrin (Schon 
et al., 1999).  
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In human IBD, organ-specific homing pathways have been described (Arihiro et al., 2002; 
Souza et al., 1999). MAdCAM-1 was constitutively expressed on intestinal lamina propria 
high endothelial venules of healthy mucosa but expression was enhanced in IBD tissue. 
The proportion of venular endothelium within lamina propria that expressed MAdCAM-1 
was also enhanced in inflamed tissue of patients with UC or CD compared with non-
inflamed tissue (Arihiro et al., 2002; Souza et al., 1999).  
 
In patients with CD affecting the small intestine but not the colon, there were increased 
CCR9+ lymphocytes in the peripheral blood. In the inflamed small intestine of CD, CCL25 
expression was altered but these findings were not detected in normal or inflamed colon of 
CD patients. Additionally in CD, CCR9+ T cells from small intestine lamina propria 
demonstrated a predominant Th1 and Th17 cytokine profile (Jaensson et al., 2008).  
 
Alterations in the number and function of α4β7hi and CCR9+ gut-homing cells occur in 
both active CD and UC (Arihiro et al., 2002; Briskin et al., 1997; Souza et al., 1999). 
Relapse of disease in UC patients was associated with an increase in both Th1 (TNF) and 
Th2 (IL-4) cytokines by intestinal homing β7+ memory T cells (Hart et al., 2004a).  
 
There is emerging evidence that extra-intestinal manifestations of IBD including skin, eye, 
liver and biliary complications are related to aberrant homing of immune cells. It has been 
suggested that long-lived populations of memory lymphocytes that arise as a consequence 
of bowel inflammation migrate not only to the gut but also to the liver; MAdCAM-1 and 
CCL25, previously thought to be restricted to the gut, were up-regulated in the liver in 
primary sclerosing cholangitis (PSC) (Eksteen et al., 2004; Eksteen et al., 2009), 
providing a mechanism for infiltration of immune cells into the liver. Human gut-derived 
70 
 
DC, like their murine counterparts, induced RA-dependent expression of α4β7 and CCR9 
on CD8 T cells whereas DC from the liver induced only modest levels of these homing 
molecules. Thus the inability of liver DC to imprint gut-tropism implies that α4β7+ CCR9+ 
T cells that infiltrate the liver in PSC are primed in the gut (Eksteen et al., 2009). 
 
The therapeutic efficacy of interupting trafficking of effector lymphocyte populations has 
been demonstrated in controlled clinical trials. Natalizumab, a recombinant humanised 
monoclonal antibody against 4 integrin, was effective in inducing and maintaining 
remission in active CD (Ghosh et al., 2003; Sandborn et al., 2005; Targan et al., 2007). 
Natalizumab inhibits the shared α4 integrin moiety of both α4β7 and α4β1, which imparts 
a broader tissue effect on immune function. Caution is required when inhibition of 
lymphocyte trafficking is not tissue-specific, but has overlap with other organs. It may be 
that inhibition of lymphocyte trafficking and impaired immune surveillance lead to 
reactivation of infections such as progressive multifocal leukoencephalopathy (Van et al., 
2005; Yousry et al., 2006). A second humanised monoclonal antibody, MLN-02 (LDP-
02), developed selectively against 47, was effective in patients with UC and associated 
risks of more widespread immunosuppression have not been observed (Feagan et al., 
2005). More recently, the highly specific CCR-9 antagonist (CCX282-B; Traficet-EN) has 
also shown efficacy in CD (Schreiber et al., 2008). 
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1.5 Therapeutic Management for Inflammatory Bowel Disease 
 
1.5.1 General Principles of Medical Therapy  
 
The treatment of patients with IBD is dependent on several important factors, including 
the anatomical extent of disease (proctitis, left sided colitis, extensive or pancolitis), the 
severity of disease (mild, moderate, severe, fulminant), disease chronicity (acute as 
opposed to chronic active) and disease complications (Kornbluth and Sachar, 2004; Stange 
et al., 2008; Stange and Travis, 2008). Therapy is sequential, first to treat acute disease, 
then to maintain remission.  
 
1.5.2 Ulcerative Colitis  
 
UC affects only the large intestine and is characterised by a chronic relapsing disease 
course. For the treatment of mild to moderately active UC, oral and / or rectal 5-
aminosalicylic acid (ASA) is the first line therapy (Marshall and Irvine, 1997; Marshall 
and Irvine, 2000; Regueiro et al., 2006a). Combination therapy with oral and rectal 5-ASA 
may achieve higher remission rates than either rectal 5-ASA or oral 5-ASA alone in distal 
UC. In patients with active extensive disease, combined rectal and oral 5-ASA is the most 
effective (Marteau et al., 2005; Regueiro et al., 2006b).  Up to 90 percent of patients can 
be maintained in remission using oral once daily 5-ASA therapy (Dignass and Veerman, 
2008; Kamm et al., 2008a; Kamm et al., 2008b; Kruis et al., 2008).   
  
In patients with persistently active, steroid-dependent or steroid–refractory UC, 
immunomodulators, azathioprine (AZA) or 6-mercaptopurine (6-MP) should be started. 
Half of the patients who are intolerant of AZA can tolerate 6-MP. Second line therapy 
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includes infliximab and alternative third line options include tacrolimus, methotrexate, 6-
thioguanine or leucocyte apheresis (Ng and Kamm, 2008b). Surgical options should be 
considered and discussed. Continuing pharmacological therapy that does not achieve 
steroid-free remission is not recommended. Probiotics or curcumin may be useful 
adjunctive therapies in patients with active UC (Makharia et al., 2008; Ng and Kamm, 
2008a; Ng and Kamm, 2008b). 
 
 
1.5.3 Crohn’s Disease 
 
Crohn’s disease (CD) encompasses a multisystem disorder with distinct clinical and 
pathogical features. It is characterised by transmural and occasional granulomatous 
inflammation of the GI tract, as well as a relapsing and remitting disease course(Baumgart 
and Carding, 2007). CD is not medically or surgically “curable” and therapeutic 
approaches are aimed mainly at the induction and maintenance of disease remission, 
improvement of quality of life, prevention of disease complications, and recently mucosal 
healing has emerged as a therapeutic goal. Guidelines and recommendations for the 
medical management of CD have been extensively reviewed (Lichtenstein et al., 2009; 
Travis et al., 2006).  
 
In patients with mild to moderate active ileal, ileocolonic or colonic CD, 5-ASA have been 
used as first line therapy although it is only minimally effective compared with placebo 
(Hanauer and Stromberg, 2004). In such patients, controlled-release budesonide has 
demonstrated short term efficacy in controlled clinical trials (Kane et al., 2002; Otley and 
Steinhart, 2005). The hypothesis that CD may be caused or exacerbated by bacteria has led 
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to the use of antibiotics (metronidazole or ciprofloxacin) to treat active luminal or perianal 
disease (Ishikawa et al., 2003b; Rubin and Kornblunth, 2005). In patients with moderate 
to severe CD, induction of remission can be achieved with 40 to 60mg of prednisolone 
daily. More than 50 percent of patients treated with steroids will develop steroid-
dependent or steroid-refractory disease (Faubion, Jr. et al., 2001) and AZA, 6-MP, or 
parenteral methotrexate are effective in maintaining steroid-free remission in such patients 
(Lichtenstein et al., 2006; Travis et al., 2006). The anti-TNF antibodies, infliximab, 
adaliumumab and certolizumab pegol have been shown to be effective in patients who are 
intolerant to, or fail to respond to immunosuppressants (Colombel et al., 2007; Hanauer et 
al., 2002; Schreiber et al., 2007). Infliximab monotherapy and infliximab combined with 
AZA is more effective than AZA in patients with moderate to severe disease who have 
failed to respond to first line therapy with mesalazine or corticosteroids, and who are naive 
to immunosuppressive or biological agents (Colombel et al., 2008; Lemann et al., 2006). 
 
 
1.6 Probiotics and Prebiotics 
 
1.6.1 The Concept of Probiotics and Prebiotics 
 
Since Metchnikoff’s time more than 100 years ago, it was well recognised that certain 
organisms appear to have therapeutic value to human health. In 1907 Metchnikoff 
suggested that fermented milk containing lactobacilli were the reason for the longevity of 
the Balkan people (Morelli, 2000). 
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Experiments in murine models and clinical observations in man suggest that luminal 
contents provide the constant antigenic stimulus for intestinal inflammation. The rationale 
for using probiotics and prebiotics in IBD stems from studies of dysbiosis in the intestinal 
microbiota in UC, CD and pouchitis, detected using conventional anaerobic culture or 
molecular probes (Manichanh et al., 2006; Swidsinski et al., 2002). The dysbiosis theory, 
reviewed by Tamboli et al., suggests a breakdown in the balance between putative species 
of "protective" versus "harmful" intestinal bacteria, which leads to chronic intestinal 
inflammation (Tamboli et al., 2004). The number of different commensal bacteria is 
altered in IBD patients with increased bacteroides, adherent or invasive E. coli, and 
enterococci, and reduced bifidobacterium, lactobacillus species and F. prausnitzii (Neut et 
al., 2002; Sokol et al., 2008; Sokol et al., 2009b; Swidsinski et al., 2002) (Section 1.4.1). 
 
Probiotics have been defined as living non-pathogenic microorganisms which, when 
ingested, in sufficient quantities exert a positive influence on host health or physiology 
(Schrezenmeir and de, 2001). Probiotics may be used either as a single strain, a 
combination of various strains or as genetically modified probiotics. They can also be used 
in food or as food supplements. Beneficial effects are demonstrated with dead organisms 
or bacterial DNA, and the current definition should be broadened to include these other 
microbial factors (Hord, 2008). 
 
Another approach to therapeutically modify the microbiota involves the manipulation of 
its energy sources. This can be achieved by altering the collective metabolic output of the 
microbiota, using dietary supplementation with bacterial fermentative substances such as 
complex carbohydrates, in the form of prebiotics (Lim et al., 2005).  Prebiotics have been 
defined as non-digestible food ingredients that beneficially affect the host by selectively 
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stimulating the growth and/or number of bacteria in the colon, such as bifidobacteria or 
lactobacilli, thus improving host health (Macfarlane et al., 2008). The most widely studied 
of these are the non-digestible oligosaccharides, which include galacto-oligosaccharides 
(GOS), lactulose, inulins and their fructo-oligosaccharides (FOS) derivatives (Macfarlane 
et al., 2006). Unlike probiotics, prebiotics can only affect the growth of organisms that are 
already present in the gut.  The use of Synbiotics which consist of a combination of 
probiotics and prebiotics is a relatively a new concept in the treatment of IBD. Table 1 
shows the examples of commonly used prebiotics, prebiotics and synbiotics. 
 
Table 1: Examples of common probiotics, prebiotics and synbiotics 
 
 
Probiotics
Lactobacilli
L. acidophilus
L. casei
L. delbrueckii subsp. bulgaricus
L. reuteri
L. brevis
L. cellobiosus
L. curvatus
L. fermentum
L. plantarum
Gram positive cocci
Lactococcus lactis subsp. cremoris
Streptococcus salivarius subsp. thermophilus
Enterococcus faecium
S. diaacetylactis
S. intermedius
Bifidobacteria
B. bifidum
B. adolescentis
B. animalis
B. infantis
B. longum
B. thermophilum
Examples of common probiotics, prebiotics and synbiotics
Prebiotics
FOS (eg. Oligofructose and neosugar)
Inulin
GOS
Lactulose
Lactitol
Synbiotics
Bifidobacteria + FOS
Lactobacilli + Lactitol
Bifidobacteria + GOS
FOS, fructooligosaccharides; GOS, galactooligosaccharides
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1.6.2 Probiotics in Inflammatory Bowel Disease 
 
1.6.2.1 Animal Studies of Probiotics 
 
Illuminating work from Gordon’s laboratory provided evidence that manipulating the 
microbiota with probiotics can influence the host (Sonnenburg et al., 2006). Germ free 
mice were colonized with Bifidobacterium (B) thetaiotaomicron, a prominent component 
of the adult human gut microbiota and B. longum, a commonly used probiotic. B. longum 
repressed B. thetaiotaomicron expression of antibacterial proteins which may promote its 
own survival in the gut, as well as influenced the composition, structure, and function of 
its microbial community (Sonnenburg et al., 2006). Altogether these data suggested that 
exogenously administered bacteria can influence the composition of host bacteria. A 
single microbial molecule from Bacterial fragillis protected its host from inflammatory 
disease caused by Helicobacter hepaticus in an animal model of experimental colitis, 
suggesting that natural anti-inflammatory molecules from the bacteria microbiota can 
actively promote human health, and may potentially be therapies for human inflammatory 
disorders (Mazmanian et al., 2008).   Metabonomic studies showed that probiotics can 
modulate the gut microbiome and the metabolism of short-chain fatty acids (SCFA), 
amino acids, bile acids and plasma lipoproteins; these findings emphasized the diversity of 
synbiotic co-metabolic connections between the gut microbial content and the host (Martin 
et al., 2008). 
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1.6.2.2 Clinical Studies of Probiotics 
 
Evidence that probiotic bacteria provide therapeutic benefits in human IBD is emerging. 
Several recent articles have comprehensively reviewed clinical trials using probiotic 
bacteria to treat patients with IBD (Ewaschuk and Dieleman, 2006; Hedin et al., 2007; 
Isaacs and Herfarth, 2008; Jonkers and Stockbrugger, 2007; Mallon et al., 2007). The 
main studies of probiotics used to treat adult patients with IBD have been shown in detail 
in Tables 2 - 4. 
 
 
Table 2: Controlled clinical trials of probiotics in pouchitis 
 
 
 
 
 
 
 
 
Author Study Therapeutic goal Patient 
no.
Probiotic 
strain
Daily dose 
(no of 
organisms)
Response Duration
Gionchetti
et al. 
RCT Remission 
maintenance 
(post antibiotic -
induced 
remission)
40 VSL#3 6g 15% VSL#3 vs. 100% 
placebo relapsed (p<0.001)
9 months
Mimura et 
al. 
RCT Remission 
maintenance 
(post antibiotic -
induced 
remission)
36 VSL#3 6g 15% VSL#3 vs. 94% 
placebo relapsed 
(p<0.0001)
12 
months
Gionchetti
et al. 
RCT Prophylaxis of 
pouchitis post 
pouch formation
40 VSL#3 3g 10% VSL#3 vs. 40% 
placebo developed 
pouchitis (p<0.01)
12 
months
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Table 3: Clinical studies of probiotics in ulcerative colitis 
 
Table 4: Controlled clinical trials of probiotics in Crohn’s disease 
Author Study Therapeutic 
goal
Patient 
no.
Probiotic 
strain
Daily dose 
(no of 
organisms)
Response Duration
Plein et al RCT Moderately 
active CD
17 S. bourardii 750mg
3x 1011
Significant decrease 
CDAI in S. bourlardii
7 weeks
Guslandi et 
al
RCT Remission 
maintenance
32 S. bourlardii 1000mg
4 x 1011
6% S bourladii vs 38% 
mesalazine relapsed 
(p=0.04)
6 months
Prantera et 
al
RCT Prophylaxis 
of post-
operative CD
32 L. GG 12 billion 60% L. GG vs. 35% 
placebo endoscopic 
recurrence (p=0.29)
12 months
Marteau et 
al
RCT Prophylaxis 
of post-
operative CD
98 L. johnsonii
LA1
4 x 109 49%  L. jonhsonii vs. 
64% placebo 
endoscopic recurrence 
(p=0.15)
6 months
Van Gossum
et al
RCT Prophylaxis 
of post-
operative CD
70 L. johnsonii
LA1
1X1010 Similar endoscopic and 
clinical recurrence rates
3 months
Author Study Therapeutic 
goal
Patient 
no.
Probiotic
strain
Daily dose 
(no of 
organisms)
Response Duration
Kruis et al RCT Remission 
maintenance
120 E. Coli Nissle 5 x 1010 16% E coli vs. 11% 
mesalazine relapsed (ns)
3 
months
Kruis et al RCT Remission 
maintenance
327 E. Coli Nissle 5 x 1010 36% E coli vs. 34% 
mesalazine relapsed 
(p=0.003)
12 
months
Rembacken
et al . 
RCT Remission 
maintenance
116 E. Coli Nissle 5 x 1010 67% E coli vs. 73% 
mesalazine relapsed (ns)
12 
months
Ishikawa et 
al.
RCT Remission 
maintenance
21 Bifido-
fermented 
milk
- 27% probiotic vs. 90% 
relapsed (p=0.01)
12 
months
Venturi et al Open-
label
Remission 
maintenance
20 VSL#3 1 x 1012 75% remission 12 
months
Bibiloni et 
al
Open-
label
Treatment of 
active mild-
moderate UC
34 VSL#3 3,600 billion 53% remission
24% response
6 weeks
Makharia et 
al (abstract)
RCT Treatment of 
active mild-
moderate UC
147 VSL#3 3,500 billion 42% VSL#3 vs. 18% 
placebo responded 
(p<0.05)
3 
months
Guslandi et 
al
Open-
label
Treatment of  
active mild-
moderate UC
25 S.  Bourlardii 750mg 71% remission 1 month
Kato et al RCT Treatment  of 
moderate 
active UC
20 Bifido-
fermented 
milk
100ml Decrease endoscopic 
and histolgic score
3 
months
79 
 
In summary, the most convincing evidence of the use of probiotics is in the treatment of 
pouchitis. Pouchitis is a complication after ileo-anal pouch anastomosis in patients with 
UC. Positive controlled clinical trials have demonstrated that the probiotic mixture, 
VSL#3, which consists of four strains of  Lactobacillus (L. acidophilus, L. casei, L. 
plantarum, L. delbrueckii), three strains of Bifidobacterium (B. infantis, B. longum, B. 
breve), and one strain of Streptococcus salivarius subsp. thermophilus,  was beneficial in 
maintaining remission in pouchitis (Gionchetti et al., 2000; Mimura et al., 2004), and 
preventing the development of pouchitis in patients following ileo-anal pouch formation 
(Gionchetti et al., 2003) .  
 
In UC, E. coli Nissle 1917 was effective, and equivalent to mesalazine, in maintaining 
remission in UC (Kruis et al., 1997; Kruis et al., 2004; Rembacken et al., 1999). 
Bifidobacteria-fermented milk was superior to placebo in maintaining remission in UC 
(Ishikawa et al., 2003a), and in a small pilot study Saccharomyces bourladii was effective 
in the treatment of active UC (Guslandi et al., 2003).VSL#3 has also recently been shown 
to be effective in the treatment of acute mild to moderately active UC (Bibiloni et al., 
2005; Makharia et al., 2008; Venturi et al., 1999).  
 
In CD, small studies showed that Saccharomyces bourladii may be useful in the treatment 
and maintanence of disease remission (Guslandi et al., 2000; Plein and Hotz, 1993), but 
Lactobacillus GG (Prantera et al., 2002) and Lactobacillus johnsonii LA1 (Marteau et al., 
2006; Van Gossum et al., 2007) were not beneficial in preventing  post-operative 
recurrence in CD. 
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1.6.3 Prebiotics in Inflammatory Bowel Disease 
1.6.3.1 Animal Studies of Prebiotics 
 
Prebiotics ameliorate inflammation in animal models of colitis. In rats with DSS-induced 
colitis, oral prebiotics (400mg inulin/day) resulted in less mucosal inflammation, reduced 
inflammatory prostaglandin E2, thromboxane B2,  leukotriene B4 and tissue 
myeloperoxidase activity, when compared with control rats (Videla et al., 2001). In a 
separate study, rats fed either whey-derived or lactose-derived GOS for ten days before the 
induction of TNBS showed increased levels of faecal bifidobacteria, but no reduction in 
severity of inflammation (Holma et al., 2002). The therapeutic effects of probiotics and 
prebiotics have been compared with controls in 82 mice with TNBS-induced colitis. Both 
FOS and a lactic acid bacteria probiotic (Lactobacillus acidophilus, L. casei subsp 
rhamnosus and Bifidobacterium animalis) demonstrated similar beneficial effects with a 
significant reduction in inflammatory score, myeloperoxidase activities, gut pH and an 
increased in faecal lactate and butyrate concentrations (Cherbut et al., 2003). 
 
Inulin and oligofructose alleviate acute inflammation in animal models of colitis. In 
transgenic HLA-B27 rats, a prebiotic preparation, Synergy I (combination of inulin and 
oligofructose), resulted in reduced pro-inflammatory IL-1B in the caecum, diminished 
production of bacterially stimulated IFN- γ by mesenteric lymphocytes, and increased 
mucosal levels of TGF-β. Prebiotics also stimulated the growth of lactobacilli and 
bifidobacterium in the caecum, and reduced IFN-γ in MLN (Hoentjen et al., 2005). These 
immunoregulatory activities of prebiotic were associated with improved tissue 
inflammation scores and the prevention of colitis. Osman et al. showed that oligofructose 
and inulin together with bifidobacterium induced lower IL-1B and myeloperoxidase 
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production in the colon as well as significantly less bacterial translocation to MLN in 
Spague-Dawley rats with DSS-induced acute colitis  (Osman et al., 2006).  
 
 
1.6.3.2 Clinical Studies of Prebiotics 
 
Three controlled trials and have assessed the use of prebiotics in human IBD, two in UC 
(Casellas et al., 2007; Furrie et al., 2005) and one in pouchitis (Welters et al., 2002). 
Although underpowered, all of them showed promising results (Table 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Clinical studies of prebiotics in inflammatory bowel disease 
 
 
Author Study Therapeutic 
goal
Patient 
number
Prebiotic
preparation
Daily dose 
(no of 
organisms)
Response Duration
Welters et 
al
RCT Chronic 
pouchitis
24 Inulin 24g Inulin-treated patients:
Reduced endoscopic and 
histological pouch disease 
activity index
Reduced faecal pH and 
faecal bacteroides fragilis
Increased faecal butyrate
3 weeks
Furrie et 
al
RCT Treatment of 
mild UC
18 B. longum+ 
FOS/inulin
200 billion  
B. longum + 
12g FOS/ 
inulin
Prebiotics-treated patients: 
Lower endoscopic score 
and reduced inflammatory 
mediators
1 month
Casellas
et al
RCT Treatment of 
mild to 
moderately 
active UC
40 Oligofructose-
enriched inulin
12g Inulin-treated patients: 
Reduction in calprotectin
and disease activity score
2 weeks
Lindsay 
et al
Pilot Treatment of 
moderately 
active 
ileocolonic
CD
10 FOS 15g Decreased Harvey 
Bradshaw index
Increased faecal
bifidobacteria concentration
Increased TLR-2 and TLR-4 
production by DC and IL-
10+DC 
4 weeks
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One possible mechanism of prebiotics in IBD may relate, in part, to the modulation of DC. 
In one uncontrolled study of patients with CD, three weeks of FOS resulted in a 
significantly less disease activity, the proportion of IL-10+ mucosal DC and the proportion 
of DC expressing TLR-2 and -4 increased significantly (Lindsay et al., 2006). A multi-
centre placebo-controlled trial of prebiotics for the treatment of moderately active CD is 
currently in progress. 
 
 
1.6.4 Mechanisms of Action of Probiotics 
 
As described in section 1.6.2.2, controlled clinical trials of probiotic bacteria have 
demonstrated benefit in IBD. The precise mechanisms influencing the cross-talk between 
the microbe and the host remain unclear but there is growing evidence to suggest that the 
functioning of the immune system at both a systemic and a mucosal level can be 
modulated by bacteria in the gut. Recent compelling evidence has demonstrated that 
manipulating the microbiota can influence the host. In summary, several new mechanisms 
by which probiotics exert their beneficial effects have been identified and it is now clear 
that significant differences exist between different probiotic bacterial species and strains; 
organisms need to be selected in a more rational manner to treat disease. Mechanisms 
contributing to altered immune function in vivo induced by probiotic bacteria may include 
modulation of the microbiota itself, improved barrier function with consequent reduction 
in immune exposure to microbiota and direct effects of bacteria on different epithelial and 
immune cell types (Ng et al., 2009) .  
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Probiotic bacteria have multiple and diverse influences on the host as proposed in Table 6. 
Different organisms can influence the intestinal luminal environment, epithelial and 
mucosal barrier function, and the mucosal immune system. They exert their effects on 
numerous cell types involved in the innate and adaptive immune responses, such as 
epithelial cells, DC, monocytes or macrophages, B cells, T cells including T cells with 
regulatory properties, and NK cells (Bohm and Kruis, 2006; Cummings and Kong, 2004). 
Figure 1.5 provides a simplified illustration of the proposed antimicrobial activities of 
probiotic bacteria. 
 
 
Table 6: Mechanisms of action of probiotics 
 
 
 
 
Antimicrobial Activity
Decrease luminal pH
Secrete antimicrobial peptides
Inhibit bacterial invasion
Block bacterial adhesion to epithelial cells
Enhancement of Barrier Function
Increase mucus production
Enhance barrier integrity
Immunomodulation
Effects on epithelial cells
Effects on dendritic cells
Effects on monocytes / macrophage
Effects on lymphocytes
- B lymphocytes
- NK cells
- T cells
- T cell redistribution 
Mechanisms of Action of Probiotics
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Mucus layer
Epithelium
Lamina propria
Lumen
(4) Reduce luminal pH
(2)Competitive inhibition
(1) Secrete bacteriocins/ defensins
Probiotics
Mucosa
(5) ↑ mucus layer
DC
Peyer’s patch
Mesenteric lymph nodes
Enhance 
barrier function
M  
cell
(3) Inhibit bacterial adhesion/translocation
 
Figure 1.5: Inhibition of enteric bacteria and enhancement of barrier function by probiotic 
bacteria. Schematic representation of the cross-talk between probiotic bacteria and the intestinal 
mucosa. Antimicrobial activities of probiotics include the (1) production of bacteriocins/defensins; 
(2) competitive inhibition with pathogenic bacteria; (3) inhibition of bacterial adherence or 
translocation and; (4) reduction of luminal pH. Probiotic bacteria can also enhance intestinal 
barrier function by (5) increasing mucus production. 
 
 
1.6.4.1  In Vitro and Animal Studies  
 
In animal models of IBD the requirement for bacterial colonization to induce an 
inflammatory phenotype is virtually universal (Mizoguchi et al., 2003). Support for a 
“favourable” action of probiotics on intestinal inflammation comes mainly from animal 
models, including DSS- and hapten-induced colitis, HLA-B27 transgenic rats, and IL-10 
and IL-2-deficient mice (Dieleman et al., 2003; Madsen et al., 1999; Rachmilewitz et al., 
2002; Waidmann et al., 2003).  
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Studies in various animal models of colitis are useful in providing mechanistic and 
therapeutic proof of concept. For instance, in the IL-10 knockout mouse model of colitis, 
lactobacillus and bifidobacterium species were effective in reducing established intestinal 
inflammation (Madsen et al., 1999; McCarthy et al., 2003) and in HLA-B27 transgenic 
mice, Lactobacillus GG effectively prevented the relapse of colitis after antibiotic 
treatment  (Dieleman et al., 2003). 
 
 
1.6.4.2  Modification of the Intestinal Microbiota 
  
Probiotic bacteria can antagonise pathogenic bacteria by reducing luminal pH, inhibiting 
bacterial adherence and translocation, or producing antibacterial substances and defensins. 
One of the mechanisms by which the gut flora resists colonisation by pathogenic bacteria 
is by the production of a physiologically restrictive environment, with respect to pH, redox 
potential and hydrogen sulphide production. Probiotic bacteria decrease the luminal pH, as 
has been demonstrated in patients with UC following ingestion of the probiotic 
preparation VSL#3 (Venturi et al., 1999).  
 
In a fatal mouse Shiga toxin-producing E coli O157:H7 infection model, the probiotic B. 
breve produced a high concentration of acetic acid, consequently lowering the luminal pH. 
This pH reduction was associated with increased animal survival (Asahara et al., 2004). 
 
Production of antimicrobial compounds, termed bacteriocins, by probiotic bacteria is also 
likely to contribute to their beneficial activity. Several bacteriocins produced by different 
species from the genus lactobacillus have been described (Klaenhammer, 1988). The 
86 
 
inhibitory activity of these bacteriocins varies; some inhibit other lactobacilli or 
taxonomically-related Gram positive bacteria, and some are active against a much wider 
range of Gram-positive and Gram-negative bacteria as well as yeasts and moulds 
(Nemcova, 1997). For example, the probiotic L. salivarius subsp. salivarius UCC118 
produced a peptide which inhibited a broad range of pathogens such as Bacillus, 
Staphylococcus, Enterococcus, Listeria and Salmonella species (Flynn et al., 2002).  
 
Lacticin 3147, a broad-spectrum bacteriocin produced by Lactococcus lactis subsp., 
inhibited a range of genetically distinct Clostridium difficile isolates from healthy subjects 
and patients with IBD (Rea et al., 2007). A further example is the antimicrobial effect of 
Lactobacillus species on Helicobacter pylori infection of gastric mucosa, achieved by the 
release of bacteriocins and the ability to decrease adherence of this pathogen to epithelial 
cells (Gotteland et al., 2006). 
 
Probiotics can reduce the epithelial injury following exposure to E. coli O157:H7 and E. 
coli O127:H6. The pre-treatment of intestinal (T84) cells with lactic acid-producing 
bacteria reduced the ability of pathogenic E. coli to inject virulence factors into the cells or 
to breach the intracellular tight junctions (Sherman et al., 2005). 
 
Adhesion and invasion of an intestinal epithelial cell line (Intestine 407) by adherent 
invasive E. coli isolated from patients with CD was substantially diminished by co- or pre-
incubation with the probiotic strain E coli Nissle 1917. These findings demonstrated that 
probiotics prevent epithelial injury induced by attaching-effacing bacteria (Malchow, 
1997; Rembacken et al., 1999).   
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Defensins are anti-microbial peptides involved in innate defence mechanisms. The 
probiotic E. coli Nissle strain induced expression of human beta-defensin 2 (hBD-2) in 
Caco-2 intestinal epithelial cells (Wehkamp et al., 2004); this type of effect may 
contribute to an improved mucosal barrier and provide a means of limiting access of 
enteric pathogens. Induction of human beta-defensin 2 by E. coli Nissle 1917 was 
dependent on the NF-kB and AP-1-pathways, mediated through bacterial flagellin (Schlee 
et al., 2007). 
 
 
1.6.4.3  Enhancement of Barrier Function  
 
In addition to the inhibition of growth of “conventional” organisms or potential pathogens, 
probiotics can influence mucosal cell-cell interactions and cellular “stability” by the 
enhancement of intestinal barrier functions through modulation of cytoskeletal and tight 
junctional protein phosphorylation.  
 
Intestinal barrier function is maintained by several interrelated systems including mucus 
secretion, chloride and water secretion and binding together of epithelial cells at their 
apical junctions by tight junction proteins. Disruption of epithelial barrier function is seen 
in several conditions including IBD, both active and inactive, in the healthy relatives of 
patients with IBD (Hilsden et al., 1996; Hollander et al., 1986; May et al., 1993; Peeters et 
al., 1997; Schmitz et al., 1999; Wyatt et al., 1993), enteric infections (Sakaguchi et al., 
2002), coeliac disease and some autoimmune diseases such as Type 1 diabetes (Watts et 
al., 2005). Enhancement of mucosal barrier function may be an important mechanism by 
which probiotic bacteria benefit the host in such diseases (Meddings, 2008). 
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Enhancement of barrier function by probiotic bacteria has been observed both in in vitro 
models and in vivo in the whole animal. The probiotic mixture VSL#3 normalised barrier 
integrity as assessed by short circuit currents, transepithelial potential differences and 
mannitol fluxes in excised tissue from mice  (Madsen et al., 2001). Furthermore, in an in 
vitro culture using T84 epithelial cells, VSL#3, but not the other probiotic bacteria, L. 
reuteri, S. bovis and a non-pathogenic E. coli, decreased monolayer permeability and 
conductance, indicating that the increase in resistance was specific to one or more of the 
bacteria in VSL#3. Increased barrier integrity in response to probiotic bacteria has been 
observed in healthy animals and in animal models of colitis. For example, in healthy rats, 
L. brevis enhanced barrier function as assessed by permeability to mannitol in excluded 
colonic loops (Garcia-Lafuente et al., 2001). In IL-10 deficient mice with chronic colitis 
lactobacillus improved barrier function in vivo (Madsen et al., 1999). In a methotrexate-
induced model of colitis, L. plantarum and L. reuteri enhanced barrier function (Mao et 
al., 1996).  However, enhancement of barrier function was not observed in all models of 
colitis studied. L. plantarum did not enhance the barrier function in the context of TNBS 
colitis (Kennedy et al., 2000). 
 
The mechanisms by which probiotics bacteria enhance gut mucosal barrier function are 
unclear, but may relate to alterations in mucus or chloride secretion or changes in tight 
junction protein expression by epithelial cells. Some probiotic bacteria modify MUC gene 
expression and mucus secretion. For example, L. plantarum 299v increased MUC2 and 
MUC3 mRNA expression when incubated with the epithelial cell line HT-29 (Mack et al., 
1999).  VSL#3 and E. coli Nissle strain increased MUC2, MUC3 and MUC5AC gene and 
protein expression (Otte and Podolsky, 2004).  Some probiotic bacteria can limit chloride 
and water secretion. For example, S. Thermophilus and L. acidophilus reversed the 
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increase in enteroinvasive E. coli-induced chloride secretion by an epithelial cell line 
(Resta-Lenert and Barrett, 2003).   
 
Tight junction proteins are dynamic structures subject to structural changes that dictate 
their functional status. In epithelial cells, the tight junction protein, zonula occludens-1 
(ZO-1) redistributed when exposed to pathogenic bacteria such as S. Dublin (Otte and 
Podolsky, 2004). However, co-culture of epithelial cells with VSL#3 probiotic bacteria in 
addition to S. Dublin prevented the redistribution of ZO-1 and stabilised the barrier 
function, suggesting that probiotic bacteria may be important in the preservation of the 
cytoskeleton architecture. Other probiotic bacteria altered other cytoskeleton structures; 
for example L. acidophilus protected against F-actin rearrangement, which was induced in 
an epithelial cell line on exposure to a pathogenic E. Coli (Lievin-Le Moal et al., 2002). S. 
thermophilus and L. acidophilus maintained (actin, ZO-1) or enhanced (actinin, occludin) 
cytoskeletal and tight junctional protein structures in epithelial cell lines (Resta-Lenert and 
Barrett, 2003).  
 
E. coli Nissle 1917 counteracted the disruptive effects of Enteropathic E. coli (EPEC) on 
T-84 epithelial cells monolayers. This effect was achieved by altering protein kinase C 
signaling and increasing the redistribution and expression of zonulaoccludens-2 (ZO-2), a 
crucial factor in maintaining epithelial tight junction function (Zyrek et al., 2007). 
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1.6.4.4  Immunomodulation 
 
Effects of Probiotic Bacteria on Epithelial Cells 
 
There may be intrinsic differences in how epithelial cells sense commensal or probiotic 
bacteria versus pathogenic bacteria at the level of signal transduction pathways and 
cytokine production. This concept has been demonstrated by Lammers et al. and Otte et 
al. who showed that probiotic bacteria in the VSL#3 combination did not induce IL-8 
secretion by epithelial cells compared with intestinal pathogens such as enteropathogenic 
E. coli, Salmonella dublin, Shigella dysenteriae and Listeria monocytogenes, all of which 
induced secretion of IL-8 (Lammers et al., 2002; Otte and Podolsky, 2004). Furthermore, 
co-culture of the pathogenic bacteria S. Dublin with VSL#3 probiotic bacteria decreased 
IL-8 secretion seen with the pathogenic bacteria alone, indicating that probiotic bacteria 
can override the effects of pathogenic bacteria. However, the probiotic bacteria E. coli 
Nissle 1917 induced IL-8 secretion by intestinal epithelial cell lines in a dose dependent 
manner suggesting that the ability to prevent secretion of IL-8 from epithelial cells was not 
a feature of all probiotic bacteria (Lammers et al., 2002; Otte and Podolsky, 2004). 
 
One other effect of probiotic bacteria on epithelial cells was the ability of commensal 
organisms to act through TLR, such as TLR-2 and TLR-4, possibly on epithelial cells. 
Such interactions induced the production of protective cytokines that enhanced epithelial 
cell regeneration and inhibited epithelial cell apoptosis (Rakoff-Nahoum et al., 2004). L. 
casei prevented the development of acute DSS-induced colitis in TLR-4 mutant (lps-/lps-) 
mice by inhibiting myeloperoxidase activitiy and IL-12p40, and increasing TGF- β and 
IL-10 mRNA (Chung et al., 2008).   
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The signalling pathways which allow epithelial cells to distinguish commensal or 
probiotic organisms from pathogenic organisms appear to be different. Pathogenic bacteria 
induce pro-inflammatory responses in intestinal epithelial cells by activating the 
transcription factor NFB.  In contrast, non-pathogenic species can attenuated pro-
inflammatory responses by blocking the degradation of the counter-regulatory factor IB. 
This method of blocking proinflammatory responses was shown by non-pathogenic 
Salmonella pullorum which attenuated IL-8 secretion elicited by pathogenic Salmonella 
typhimurium (Neish et al., 2000). Another method of avoiding pro-inflammatory 
responses to commensal bacteria has been demonstrated for Bacteroides thetaiotaomicron 
which induced an anti-inflammatory response in epithelial cells by shuttling transcription 
factor, NFκB out of the nucleus by a pathway involving the nuclear hormone receptor, 
peroxisome proliferator activated receptor (PPAR)-, resulting in attenuation of NFB-
mediated inflammatory gene expression independent of the IB pathway (Kelly et al., 
2004).  VSL#3 probiotic bacteria produced soluble factors which inhibited proteosome in 
intestinal epithelial cells thereby inhibiting the NFB pathway (Petrof et al., 2004).  
Furthermore, DNA derived from the probiotic mixture VSL#3 delayed NFB activation, 
stabilised levels of IB, and inhibited proteasome function (Jijon et al., 2004).   
 
Probiotic bacteria may also enable epithelial recovery or prevent apoptosis, as suggested 
by a study in which cytokine-induced apoptosis was prevented in intestinal epithelial cells 
in the presence of L. rhamnosus GG (Yan and Polk, 2002). Culture of probiotic bacteria 
with either mouse or human colon cells activated anti-apoptotic Akt/protein kinase B and 
inhibited activation of the pro-apoptotic p38/mitogen-activated protein kinase by TNF-α, 
IL-1β, or IFN-γ. Inhibition of apoptosis may enhance survival of intestinal cells and 
promote proliferation during recovery from epithelial injury. In addition, a non-pathogenic 
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commensal bacterium S. pullorum, influenced epithelial cell proliferation by “injecting” 
factors into the gut epithelium that blocked β-catenin degradation, a substance which has 
been implicated in epithelial growth control (Neish et al., 2000).  
 
Effects of Probiotic Bacteria on Dendritic Cells 
 
The pivotal position of DC at the intersection of innate and adaptive immunity with their 
ability to recognise and respond to bacterial components, to initiate primary immune 
responses and to direct developing T and B cell responses underlines the importance of 
understanding the functional effects of different bacteria on DC. Various ways of antigen 
sampling by DC have been discussed in Section 1.2.1. The effects of different probiotic 
bacteria on DC have been studied in different experimental systems (whole blood DC, 
freshly isolated lamina propria DC, monocyte-derived DC and bone-marrow derived DC) 
and in different species (human and mouse). 
 
Figure 1.6 illustrates mechanisms of the modulation of DC function by probiotic bacteria. 
In humans the probiotic combination VSL#3 was a potent inducer of IL-10 by both blood 
and lamina propria DC in vitro (Hart et al., 2004c). DC were defined as a population of 
cells which were HLA-DR+ and negative for a set of lineage markers thereby excluding T 
cells, B cells, macrophages, NK cells and myeloid progenitor cells (Bell et al., 2001). 
 
In patients with pouchitis treated with the probiotic combination VSL#3 there were 
enhanced levels of IL-10 in their mucosa and decreased levels of TNF-α, IL-1, inducible 
nitric oxide synthase and matrix metalloproteinase (Ulisse et al., 2001). In agreement with 
the observation that VSL#3 is a potent inducer of IL-10 by DC, Drakes et al. have shown 
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that murine bone marrow-derived DC incubated with VSL#3 increased IL-10 detected by 
ELISA (Drakes et al., 2004). 
 
Individual strains within VSL#3 displayed distinct immunomodulatory effects on DC; the 
most marked anti-inflammatory effects were produced by bifidobacteria strains (B. 
longum, B. infantis and B. breve) which upregulated IL-10 and downregulated IL-12p40 
production by DC. Anti-inflammatory effects of bifidobacteria strains have been described 
in other studies. Using DC derived from human cord blood monocytes, Young et al. 
demonstrated that B. longum, B. bifidum and B. pseudocatenulatum, but not B. infantis, 
induced high levels of IL-10 (Young et al., 2004).  
 
Rigby et al. demonstrated that murine freshly isolated lamina propria DC incubated with 
B. longum secreted IL-10 and IL-12, but a greater proportion of DC produced IL-10 than 
IL-12 (Rigby et al., 2002). In a different experiment, purified human monocytes and 
monocyte-derived DC stimulated with ultra violet-inactivated gram-positive (L. plantarum 
and B. adolescentis) and gram-negative (E. coli and Veillonella parvula) bacterial strains, 
B. adolescentis induced low amounts of IL-12, TNF-α, IL-6 and IL-8; L. reuteri and L. 
casei, but not L. plantarum, primed monocyte-derived DC to result in a regulatory 
response (Braat et al., 2004b; Karlsson et al., 2004)..  These Treg cells produced increased 
levels of IL-10 and were able to inhibit the proliferation of bystander T cells in an IL-10-
dependent fashion. Strikingly, both L. reuteri and L. casei, but not L. plantarum, bound 
the C-type lectin DC-SIGN. Blocking antibodies to DC-SIGN inhibited the induction of 
the Treg cells by these probiotic bacteria, implying that ligation of DC-SIGN can actively 
prime DC to induce Treg cells. Thus the targeting of DC-SIGN by certain probiotic 
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bacteria might explain their beneficial effect in the treatment of a number of inflammatory 
diseases, including atopic dermatitis and CD (Smits et al., 2005).   
 
In contrast to the anti-inflammatory activity of some strains of bifidobacteria and 
lactobacilli, other lactobacilli strains have pro-inflammatory activity. When cultured with 
human monocyte-derived DC, L. reuteri, L. gasseri and L. johnsonii, induced activation 
and maturation of DC, enhanced IL-12 production and induced allogeneic T cell priming 
(Mohamadzadeh et al., 2005). 
 
However, Christensen et al. demonstrated that L. reuteri induced little or no IL-12 
production by DC in an experimental system using murine bone-marrow derived DC and 
inhibited proinflammatory cytokine production (IL-12, IL-6 and TNF-α) by L. casei which 
was a potent inducer of IL-12. These varying effects of probiotic bacteria highlight 
differences which arise when different experimental systems in different animals were 
used (Christensen et al., 2002). However, there appeared to be different responses of 
different bacterial strains even within a genus. In human monocyte-derived DC, L. 
rhamnosus and L. plantarum induced no or low levels of IL-12 (Braat et al., 2004a; Braat 
et al., 2004b; Karlsson et al., 2004; Veckman et al., 2004). in contrast to the high levels of 
IL-12 noted with L. gasseri and L. johnsonii (Mohamadzadeh et al., 2005).  
 
Braat et al. demonstrated that L. rhamnosus may ‘educate” DC to stimulate proliferation 
of peripheral CD4+ T cells and reduced CD3/CD28 stimulated cytokine production in 
vitro. L. rhamnosus resulted in a reduction of IL-4 from peripheral CD4+ T cells of normal 
individuals, and a decreased in IFN-γ and IL-2 production by CD4+ T cells from patients 
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with CD. This observation suggested that a comparable mechanism may exist in humans 
(Braat et al., 2004b). 
 
Dendritic cell
Probiotic bacteria
T cell Th1 cells
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Figure 1.6: Modulation of dendritic cell function by probiotic bacteria.  Pathogen associated 
molecular patterns (PAMPs) derived from probiotic bacteria are recognized by pattern recognition 
receptors, such as toll-like receptors (TLRs) on DC in the epithelium or lamina propria. Probiotic 
bacteria can shape the mucosal immune system towards a non-inflammatory, tolerogenic pattern 
through the induction of T cells with regulatory properties. Probiotics can also downregulate Th1 
response and inhibit the production of proinflammatory cytokines, IL-12, TNF-α and IFN-γ by 
DC. The predominant cytokine profile depends on the nature of the stimulus and the types of 
probiotic bacteria. The IL-23/IL-17-mediated inflammatory axis has recently been implicated in 
the pathogenesis of inflammatory bowel disease but there remain gaps in our knowledge on how 
probiotics influence the differentiation of Th17 cells. This diagram is a simplified synthesis of data 
derived in vitro and in vivo. 
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Effects of Probiotic Bacteria on Monocytes and Macrophages 
 
Blood monocytes and tissue macrophages are effective secondary presenters of antigens to 
memory T cells. L. plantarum increased IL-10 synthesis and secretion in macrophages 
derived from the inflamed colon (Pathmakanthan et al., 2004). In contrast, L. rhamnosus 
GG promoted the production of IFN-γ, IL-12 and IL-18 (Miettinen et al., 1998), and 
induced NFκB and STAT DNA-binding in primary human macrophages. He et al. have 
shown that B. bifidum, B. breve and B. infantis stimulated more IL-10 and less IL-12 and 
TNF- from a murine macrophage-like cell line than B. Adolescentis (He et al., 2002), 
again suggesting strain differences within a genus. DNA derived from the probiotic 
mixture VSL#3 activated NFB and induced low levels of IL-6 and IL-12 by bone-
marrow derived macrophages compared with immunostimulatory oligonucleotides 
(Rachmilewitz et al., 2004).   
 
Effects of Probiotic Bacteria on Lymphocytes 
 
Probiotic bacteria may affect lymphocytes directly or secondarily via changes in 
stimulation induced by alterations in antigen presenting DC or macrophages. These effects 
have been demonstrated for different types of lymphocytes. 
 
B lymphocytes - Probiotic bacteria may exert beneficial effects and modulate the immune 
response to potentially harmful antigens via B lymphocytes and antibody production. For 
example, L. rhamnosus GG administered to children with acute gastroenteritis resulted in 
an increase in IgG, IgA and IgM secretion from circulating lymphocytes (Kaila et al., 
1992). B. bifidum enhanced the antibody response to ovalbumin, and yoghurts containing 
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L. acidophilus, L. bulgaricus, S.  thermophilus, B. bifidum and B. infantis stimulated the 
IgA response to cholera toxin in mice (Tejada-Simon et al., 1999).  
 
The effects of probiotic bacteria on B lymphocytes and antibody production have also 
been evaluated in vaccination trials. The immunogenicity of rotavirus vaccination was 
enhanced in children who received L. rhamnosus GG compared with those who received 
placebo (Isolauri et al., 1995). Similarly increased Salmonella-specific IgA levels were 
found in subjects who received a combination of L. rhamnosus GG and Salmonella 
vaccination (Fang et al., 2000).   
 
Natural Killer (NK) Cells - The synbiotic L. casei ssp. casei with dextran (prebiotic) 
significantly elevated the NK cell activities in spleen mononuclear cells from BALB/c 
mice, and oral administration of this symbiotic to healthy volunteers induced NK cell 
activities, and increased production of IL-12 in human peripheral blood mononuclear cells 
(PBMC) (Ogawa et al., 2006). Takeda et al. showed that L. casei Shirota can enhance NK 
cell activity in vivo and in vitro in humans; this effect may be dependent on IL-12 (Takeda 
et al., 2006).  
 
T Cells - The type of T cell response, whether it be a Th1, Th2, Th3 / Tr1 or Th17 
response is controlled predominantly by interactions between DC and T cells (Maloy and 
Kullberg, 2008). In humans, VSL#3 potently induced IL-10 by DC and co-culture of naïve 
T cells with probiotic-treated DC led to a decrease in Th1 polarised cells (Hart et al., 
2004c). In a different experimental system in which monocyte-derived DC were cultured 
with the probiotic L. rhamnosus and the subsequent effect on T cells assessed, decreased T 
cell proliferation and T cell cytokine production, particularly IL-2, IL-4 and IL-10, has 
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been demonstrated (Braat et al., 2004b). This in vitro effect of L. rhamnosus on DC and 
subsequent T cell hyporesponsiveness was reflected in in vivo studies in which healthy 
controls and patients with CD were fed L. rhamnosus for two weeks. Ingestion of L. 
rhamnosus reduced IFN-γ and IL-2 production by peripheral T cells in CD patients and 
also reduced IL-4 production in healthy controls (Braat et al., 2004b).  
 
Probiotic bacteria influenced the generation of regulatory T cells in a murine model of 
contact dermatitis. Daily oral administration of fermented milk containing the probiotic L. 
casei DN-114 001 reduced antigen-specific skin inflammation by controlling the antigen-
specific T cell response in hapten 2,4-dinitrofluorobenzene, a model of allergic contact 
dermatitis mediated by CD8+ CTL and controlled by CD4+ regulatory T cells. The 
alleviation of contact hypersensitivity by prior feeding with L. casei was due to 
downregulation of the hapten-specific CD8+ T cell response as indicated by a decrease in 
expansion of hapten-specific IFNγ-producing CD8+ effectors. Furthermore, experiments in 
mice deficient in CD4+ cells indicated that CD4+ cells were mandatory for the effect of L. 
casei on contact hypersensitivity. It has been proposed that L. casei reduced contact 
hypersensitivity by direct or indirect activation of regulatory CD4+ T cells (Chapat et al., 
2004). Von der Weid et al. have also reported that in vitro a different probiotic organism, 
L. paracasei NCC2461, induced the development of a population of CD4+ T cells with 
regulatory properties in that they had low proliferative capacity and produced TGF-β and 
IL-10 (von der et al., 2001).   
 
Probiotic bacteria also induced regulatory T cells in the context of intestinal inflammation.  
In TNBS colitis, the probiotic combination VSL#3 ameliorated intestinal inflammation; 
the beneficial effect of VSL#3 was attributable to IL-10-dependent-regulatory CD4+ T 
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cells bearing surface TGF-β (Di Giacinto et al., 2005). These cells appeared to be similar 
to CD25+ regulatory T cells that inhibited cell-transfer colitis by a TGFβ - dependent 
mechanism (Oida et al., 2003).  
 
Effects of Probiotic Bacteria on T Cell Redistribution  
 
Dalmasso et al. have reported a novel biological property of probiotics, the capacity to 
affect immune cell redistribution by improving the competence of lymphatic endothelial 
cells to trap T lymphocytes. In Saccharomyces boulardii-fed mice, IFN-γ production by 
CD4+ T cells was reduced in the colon but increased in the MLN.  S. boulardii has a 
unique action on inflammation by a specific alteration of the migratory behavior of T cells 
causing accumulation of these cells in MLN (Dalmasso et al., 2006; Nakamura et al., 
2004).  
 
 
1.6.4.5  Mechanisms of Probiotics in Clinical Diseases 
  
A number of studies in IBD have shown that probiotics can induce regulatory cytokines, 
including IL-10 and TGF-ß, and suppress pro-inflammatory cytokines, such as TNF, in the 
mucosa of patients with CD and pouchitis (Borruel et al., 2002; Pathmakanthan et al., 
2004; Ulisse et al., 2001). 
 
In a study aimed at assessing the anti-inflammatory effects of probiotics, healthy controls 
and IBD patients consumed L. rhamnosus GR-1 and L. reuteri RC-14 supplemented 
yogurt for 30 days. The proportion of putative regulatory CD4+ CD25high T cells in 
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peripheral blood increased significantly in IBD patients, after treatment, but not in controls 
(Lorea et al., 2007). The basal proportion of TNF-α+ IL-12+ monocytes and myeloid DC 
decreased in patients with IBD and healthy controls. In addition serum IL-12 
concentrations and the proportion of IL-2+ and CD69+ T cells from stimulated cells 
decreased in IBD patients. Thus probiotic yogurt intake was associated with significant 
anti-inflammatory effects that parallel the expansion of the peripheral pool of putative 
Treg cells in IBD patients with few effects in controls (Lorea et al., 2007). 
 
Adhesive E. Coli has been implicated in the pathogenesis of UC. Studies using a 16S 
rRNA technique have shown reductions in bifidobacteria (Macfarlane et al., 2005; 
Mylonaki et al., 2005), and lactobacilli in patients with UC (Bullock et al., 2004). Using a 
short term synbiotic treatment, there was an increased bifidobacterial colonization of the 
rectal mucosa. In a separate experimental system, colonic biopsies from UC have been co-
cultured for 24 hours with B. longum. The concentrations of TNF and IL-8 in supernatants 
of inflamed UC tissue co-cultured with probiotics were lower than those cultured alone. 
The number of LPMC with NFκB  p65 positive in co-cultured tissues was also reduced 
(Bai et al., 2006). Release of TNF- by inflamed CD mucosa was significantly reduced by 
co-culture L. casei or L. bulgaris, but not L. crispatus and E coli. No change in TNF- 
production was seen in experiments with non-inflamed Crohn’s mucosa and control 
mucosa. Certain probiotic bacteria may therefore interact with immunocompetent cells at 
the mucosal interface and thus modulate local production of pro-inflammatory cytokines 
by inflamed tissue (Borruel et al., 2002).  
When the mucosal explants of CD were incubated with L. casei or its genomic DNA, or E 
coli, live L. casei counteracted the proinflammatory effects of E. coli on CD inflamed 
mucosa by specific downregulation of key proinflammatory mediators including TNF-α, 
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IFN-γ, IL-2, IL-6, IL-8 and CXCL1; these effects have not been reproduced by L. casei 
DNA (Llopis et al., 2008).  
 
1.6.4.6  Systemic Anti-inflammatory Activities of Probiotics  
 
The anti-inflammatory effects of probiotic bacteria could be systemic, at least in part, 
rather than localized. Beneficial effects have been observed after parenteral administration 
of inactivated and fractionated bacteria (Rachmilewitz et al., 2004; Sheil et al., 2004). In 
one study, co culture of L. casei or L. bulgaris with mucosal explants from affected 
intestinal mucosa of CD reduced the inflammatory response induced by co-culture of 
bacteria. This was associated with a significant reduction in pro-inflammatory cytokines 
including TNF-α, a reduction in the number of CD4 cells as well as TNF-α expression 
among intraepithelial lymphocytes, suggesting that the anti-inflammatory effect might be 
systemic (Borruel et al., 2002).  
 
Investigators from Cork, Ireland, administered L. salivarius subcutaneously to IL-10 
knockout (KO) mice, which ameriolated the severity of colitis and suppressed collagen 
induced arthritis, suggesting that the oral route may not be essential for probiotic anti-
inflammatory effects and that responses were not disease specific (Sheil et al., 2004).  
Probiotics may not need to encounter the mucosal immune system directly to exert an 
effect. The faecal microflora remained unchanged following subcutaneous administration, 
but TNF and IL-12 levels from splenocytes stimulated by Salmonella typhimurium 
decreased and TGF-β levels were maintained, suggesting a mechanism of action distinct 
from colonic flora modulation (Sheil et al., 2004).  
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1.6.4.7  Probiotic Bacterial DNA  
 
One of the tenets of bacteriotherapy is that viable bacteria are required to have a beneficial 
effect. Recent studies suggest that bacterial DNA sequences may provide the same effects 
as live bacteria (Jijon et al., 2004; Rachmilewitz et al., 2002). Bacterial DNA contains 
non-methylated CpG motifs which bind to TLR-9. TLR-9 signaling is dependent on the 
adaptor protein MyD88. In the presence of both TLR-9 and MyD88, non viable bacteria 
may have the ability to signal and elicit beneficial effects. In an experiment that used 
methylated and non-methylated genomic DNA isolated from the probiotic preparation 
VSL#3, DNAse-treated probiotics, and E. coli genomic DNA, the authors demonstrated 
that genomic DNA (but not methylated DNA, calf thymus DNA or DNAse-treated 
probiotics) ameliorated the severity of colitis in DSS-induced, TNBS-induced and 
spontaneous colitis in IL-10 knock-out mice. In the same study, intragastric and 
subcutaneous administration of gamma-irradiated nonviable bacteria and live bacteria 
produced similar beneficial effects (Rachmilewitz et al., 2004).  Lammers et al. 
demonstrated that Bifidobacterium genomic DNA induced the secretion of IL-10 by 
PBMC from healthy donors, demonstrating the immunomodulatory effects of bacteria 
DNA (Lammers et al., 2003).  By using a VSL#3 conditioned medium, Petrof et al. 
showed that early proteasome inhibition may account for NFkB inhibition and heat shock 
protein induction in cell line from the intestinal epithelium of mice. The use of VSL#3 
conditioned medium further challenged the concept that to exert beneficial effects 
probiotics must be live bacteria (Petrof et al., 2004).   
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1.6.5 Mechanisms of Action of Prebiotics 
 
The definition and clinical efficacy of prebiotics in IBD have been described in Section 
1.6.3. Prebiotics can influence host immunity and defence (Saulnier et al., 2009). Several 
potential mechanisms of prebiotic-induced immunomodulation have also been reported 
(Gibson and Roberfroid, 1995; Macfarlane and Cummings, 1999; Macfarlane et al., 2006). 
Firstly, prebiotics can selectively increase specific bacteria that modulate local cytokine 
and antibody (IgA) production. Prebiotics influence host defence by selectively 
stimulating the growth and/or activity of beneficial intestinal bacteria which include 
bifidobacteria and lactobacillus (Lomax and Calder, 2009). The increase in beneficial 
bacteria leads to increased competition with pathogenic bacteria for binding sites on the 
intestinal epithelium and nutrients. Furthermore, bifidobacteria (Berg, 1996), or microbial 
substances such as cell wall components and cytoplasmic antigens (De et al., 1987), may 
also cross the intestinal barrier directly  into Peyer’s patches to activate immune cells. 
Antibacterial substance produced by bifidobacterium and lactobacillus species can also 
suppress the growth and survival of pathogens (Gibson and Wang, 1994). Prebiotics in the 
form of FOS stimulated the growth of both faecal and mucosal bifidobacteria in healthy 
subjects (Ichikawa et al., 2002; Kripke et al., 1989).  
 
Secondly, prebiotics can potentially increase intestinal short-chain fatty acids (SCFA) 
production and enhance binding of SCFA to G-coupled protein receptors on immune cells 
within the gut-associated lymphoid tissues (Wong et al., 2006). SCFA are produced by 
microbial fermentation of inulin or oligofructose in the colon and terminal ileum. High 
concentrations of SCFA affect immune cell functions in the Peyer’s patches. In addition, 
colonic infusion of SCFA or butyrate enhanced epithelial proliferation in distant intestinal 
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segments, suggesting that SCFA produced in the colon induced beneficial effects 
throughout entire GI tract (Bourriaud et al., 2005; Probert et al., 2004). 
 
Fermentation of prebiotics by bifidobacteria species in vitro resulted in the production of 
SCFA, including lactate and butyrate. The generation of SCFA provided an acidic colonic 
environment which was detrimental to pathogenic bacteria such as bacteroides, clostridia 
and coliforms (Gibson and Wang, 1994; Millard et al., 2002).    In addition, acidification 
of the colon enhanced mucin production which strengthened barrier function (Barcelo et 
al., 2000). 
 
In vitro butyrate suppressed lymphocyte proliferation, inhibited Th1 cytokine production 
by lymphocytes, induced T cell apoptosis and up-regulated DC IL-10 production  
(Cavaglieri et al., 2003; Kurita-Ochiai et al., 2003; Saemann et al., 2000). 
.  
In one study, butyrate affected DC maturation and cytokine production in vitro, altering 
the balance of IL-12 and IL-10 secretion towards a regulatory profile (Millard et al., 
2002). Butyrate is also a putative ligand for PPAR-γ (Kinoshita et al., 2002), a nuclear 
receptor expressed by DC amongst other cells (Desreumaux et al., 2001; Dubuquoy et al., 
2003). Therefore, prebiotics may have effects on the intestinal immune system that are 
independent from direct manipulation of the intestinal microbiota. The generation of 
bifidobacteria or SCFA-producing bacteria may also alter the presence of PAMPs in the 
intestinal lumen including endotoxin or LPS, and unmethylated CpG motifs of DNA 
(Welters et al., 2002) (Akira et al., 2001).   
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Enhanced SCFA production in the gut after prebiotic supplementation increased SCFA 
supply to immune cells located along the GALT;  these cells can be activated via SCFA 
receptors (Bach Knudsen et al., 2003). Another mechanism of prebiotics includes the 
interaction of prebiotic carbohydrates with carbohydrate receptors on intestinal epithelial 
cells and immune cells. 
 
In animal models of colitis increasing dietary FOS decreased disease activity, enhanced 
luminal bifidobacteria and inhibited intracellular transcription factors such as NFkB 
(Gibson et al., 1995; Van et al., 1995).  Healthy rats fed with a mixture of FOS and a 
probiotic bifidobacteria demonstrated enhanced IL-10 release from Peyer’s patches and 
increased caecal secretory IgA levels (Roller et al., 2004).  A small randomised double 
blind controlled trial of patients with UC showed that supplementation with B. Longum, 
inulin and oligofructose improved inflammation and significantly reduced intestinal 
mRNA levels of the proinflammatory cytokines IL-1B and TNF-α (Furrie et al., 2005). 
 
Altogether prebiotics can enhance the proliferation of beneficial microbes or probiotics, to 
maximize sustainable changes in the human microbiome. Immune tolerance, intestinal 
barrier function and the bioavailability of nutrients, may be modified by changing the 
composition and functions of the microbial communities by such strategies. 
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We have cited evidence throughout the first chapter that intestinal DC are central 
immunoregulators of the response to commensal bacteria. In the intestine, DC can be 
divided into CD11c+ myeloid cells and CD11c- cells.  Most studies on intestinal DC, in 
particularly in human IBD, have focused almost exclusively on myeloid DC. The nature of 
the CD11c- cells in the human intestine has not been formally characterised. We therefore 
examine the phenotype and functional properties of these cells in IBD (Chapter 3). 
Secondly, in view of the importance of DC in controlling T cell responses, we explore 
cytokine production by DC in IBD, and correlate these cytokines with disease acitivity and 
the intestinal microbiota (Chapter 4). In vitro, probiotic bacteria modulate DC to increase 
regulatory cytokines and to downregulate proinflammatory cytokines but whether similar 
effects can be seen in the in vivo setting remains unknown.  We determine the role that DC 
may play in the modification of gut inflammation by therapy for IBD which include 
probiotic bacteria, and a conventional immunosuppressant, corticosteroids. We assess the 
effects of exogenously administered probiotic bacteria and corticosteroids on DC 
functions in vivo in patients with active UC (Chapter 5). Lastly, DC control lymphocyte 
homing to sites of intestinal inflammation, and we examine the expression of homing 
molecules on colonic DC in UC (Chapter 6). 
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1.7 Hypothesis 
 
Colonic dendritic cells are central to gut bacterial recognition, orchestrating the 
inflammatory process, T cell homing to the gut, and the response to medical therapy 
in patients with inflammatory bowel disease. 
 
 
1.8 Aims 
 
To test the above hypotheses, the specific aims of the project were: 
 
(1) To identify and characterise colonic CD11c- HLA-DR+ lin-/dim cells in UC and 
controls, and to compare their phenotype and function with that of CD11c+ 
myeloid DC population 
 
(2) To assess the functions of CD11c+ DC in IBD, and to correlate cytokine 
 production with disease activity and faecal micobiota 
 
(3) To determine the effects of (i) probiotic preparation VSL#3, (ii) corticosteroids and 
(iii) placebo on intestinal DC function in vivo, as part of a controlled clinical trial 
assessing the effects of VSL#3 in active UC 
 
(2) To assess CD103 expression on human intestinal DC in healthy controls and UC, 
and to compare the repertoire of homing markers on T cells activated by lamina 
propria mononuclear cells from UC  
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Chapter 2 
General Materials and Methods 
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2.1 Materials 
 
2.1.1 Human Intestinal Tissue  
 
Human intestinal biopsies were obtained at colonoscopy or flexible sigmoidoscopy from 
patients with UC (active and inactive), CD (active) and healthy controls. Between six to 
ten mucosal biopsies (30 to 60 mg of tissue) were taken per patient. Tissues were stored in 
medium and ice and transported immediately for processing. Patients who had a 
colonoscopy had received bowel preparation with Citramag and Senna; patients with 
active UC who underwent flexible sigmoidoscopy did not receive any bowel preparation. 
Patients’ demographics have been described in Section 2.2.1. Ethical approval and written 
informed consents were obtained from all patients. 
 
2.1.2 Whole Blood Samples 
 
Five millilitres (ml) human venous blood samples were obtained from healthy volunteers 
in lithium heparin tubes. 
 
2.1.3 Buffers and Media 
 
Complete medium: RPMI-1640 Dutch Modification (Sigma Aldrick Co. Ltd, Irvine, UK) 
containing 10% FCS, 20mM L-glutamine, 100 µg/ml streptomycin, 100 units/ml penicillin 
and 25µg/ml gentamicin (for processing and culture of intestinal biopsy). 
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Culture medium: RPMI-1640 Dutch Modification (Sigma Aldrick Co. Ltd, Irvine, UK) 
containing 10% FCS, 20mM L-glutamine, 100 µg/ml streptomycin and 100 units/ml 
penicillin (For processing and culture of whole blood cells or peripheral mononuclear 
cells). 
 
FACS Buffer: PBS supplemented with 2% FCS, 0.02% sodium azide and 1mM EDTA. 
 
Phosphate Buffered Saline (PBS) (Dulbecco’s): Calcium- and magnesium-free balanced 
salt solution - maintains the integrity of mammalian cells in vitro (Sigma, Poole). 
 
 
2.1.4 Reagents 
 
Antibody beads: Used in multiplex ELISA. Anti-cytokine monoclonal antibody-
conjugated microbeads – each bead type is filled with a distinct combination of fluorescent 
dyes that confer a unique spectral signature (Bender Medsystems, Austria). 
 
Collagenase digestion medium: contains 1mg/mL collagenase D (Roche Diagnostics Ltd, 
Lewes, England), 20µg/mL deoxyribonuclease I (Roche Diagnostics Ltd) and 2% fetal 
calf serum in RPMI 1640 Dutch modification used for enzymatic digestion of the tissue. 
 
4',6-diamidino-2-phenylindole (DAPI): a fluorescent stain that binds strongly to DNA, 
used in fluorescent microscopy 
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Dithiothreitol (DTT): Supplemented to calcium- and magnesium-free HBSS to remove 
mucus and faeces. Working concentration 1mM (Sigma-Aldrich). 
 
EDTA: Chelates ions to prevent cell clustering (Sigma, Dorset). Supplemented to calcium- 
and magnesium-free HBSS to remove epithelial cells. 
 
Foetal calf serum (FCS): supplement for cell culture media. FCS blocks non-specific 
binding during monoclonal antibody labelling. Stored in aliquots at -80ºC (Tissue culture 
systems). 
 
Ficoll-Paque: Density gradient used to separate PBMC from whole blood (Amersham 
Pharmacia Biotech AB, Uppsala, Sweden). 
 
Flow-countTM Fluorespheres: Flow cytometry beads (Beckman Coulter, Bucks) used as a 
reference population for the calculation of absolute cell numbers. 
 
Hanks’ balanced salt solution (HBSS): calcium- and magnesium-free HBSS (Gibco 
BRL, Paisley, Scotland) used to wash tissue cell suspension. 
 
Leucoperm A: Cell fixative reagent used in intracellular cytokine staining of lamina 
propria mononuclear cells (LPMC) (Serotec, UK).  
 
Leucoperm B: Cell permealisation agent used in intracellular cytokine staining of LPMC 
(Serotec, UK). 
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Monensin: Inhibits intracellular protein transport and causes newly synthesized cytokine 
to be trapped with the Golgi apparatus of cells. (Sigma, MO, USA). 
 
Nycoprep: Density gradient – used to separate low density cell from the non-adherent 
fraction of PBMC following overnight culture (Axis-Shield, Oslo). 
 
Optilyse C: Erythrocyte lysing solution (Beckman Coulter, UK) used to disrupt red blood 
cells during intracellular labeling of whole blood cells. 
 
Paraformaldehyde (PFA): Fixative (BDH chemicals, Poole). 1% PFA dissolved in saline 
by slow heating to 60ºC to pH 7.0-7.4. Stock solution stored at 4ºC. 
 
Sodium azide: Prevents capping and shedding of monoclonal antibody bound to target 
antigens on viable cells (Sigma, MO, USA). 
 
Tryptan blue: 0.4 % working concentration. Dye excluded by live cells that is used to 
calculate then proportion of viable cells in suspension (Sigma, Poole).  
 
 
2.1.5 Antibodies 
 
Antibodies (Abs) with the following specificities and fluorochrome labels were used and 
isotype- matched controls were obtained from the same manufacturers (Table 7). 
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Ab 
Specificity 
Clone Conjugate Isotype Manufacturer 
HLA-DR G46-6 APC mIgG2a BD Pharmingen 
CD11c B-ly6 PE  BD Pharmingen 
CD11c KB90 FITC mIgG1 Dako 
Cytomation 
DC 
Exclusion 
Cocktail 
S4.1/TUK4/3G8/SJ25-
C1/581 
PC5  Serotec 
CD40 LOB7/6 FITC mIgG1 Serotec 
CD86 BU63 FITC mIgG1 Serotec 
BDCA-2 AC144 PE mIgG1 Miltenyi Biotec 
BDCA-4  AD5-17F6 PE mIgG1 Miltenyi Biotec 
CD123 9F5 PE mIgG1 BD Bioscience 
TLR-2 TLR2.1 FITC mIgG2a Serotec 
TLR-4 HTA125 FITC mIgG2a Serotec 
CD138 B-A38 FITC  Serotec 
CD56 N901 PE mIgG1 Beckman 
Coulter 
NKG2D 1D11 FITC mIgG1 Abcam 
NKp44 PNIM3710 PE mIgG1 Beckman 
Coulter 
NKp30 FAB1849P FITC mIgG1 R&D systems 
CD103  FITC mIgG1 BD Bioscience 
B7 Integrin FIB504 PE rIgG2a BD Pharmingen 
 
CD3 UCHT1 PE/PE-Cy5 mIgG1 BD Pharmingen 
CD8 RPA-T8 PE mIgG1 BD Pharmingen 
CD8 SK1 FITC/APC mIgG1 BD Bioscience 
CD8 B9.11 PE-Cy5 mIgG1 Beckman 
Coulter 
CD14 RMO25 PE-Cy5 mIgG2a Beckman 
Coulter 
CD16 3G8 PE-Cy5 mIgG1 Beckman 
Coulter 
CD19 J4.119 PE-Cy5 mIgG1 Beckman 
Coulter 
CD34 581 PE-Cy5 mIgG1 Beckman 
Coulter 
CD45RA HI100 PE-Cy5 mIgG2b BD Pharmingen 
 
IL-10 JES3-9D7 PE rIgG1 Serotec 
IL-12p40 C11.5 PE mIgG1 BD Pharmingen 
IL-6 #1936 PE mIgG2b R&D systems 
IL-13 32007.111 PE mIgG1 R&D systems 
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mIgG1 X40 FITC/PE N/a BD Bioscience 
mIgG1 679.1Mc7 PE-Cy5 N/a Beckman 
Coulter 
mIgG2a G155-178 PE/PE-Cy5 N/a BD Pharmingen 
mIgG2a X39 APC N/a BD Bioscience 
rIgG2a LODNP-16 PE/PE-Cy5 N/a Beckman 
coulter 
mIgG2b 133303 PE N/a R&D systems 
mIgG2b 27-35 PE-
Cy5/APC 
N/a BD Pharmingen 
rIgG2b A95-1 APC N/a BD Pharmingen 
 
Table 7: Monoclonal antibody list 
 
 
2.1.6 Study Drug 
 
VSL#3 (VSL Pharmaceuticals, Inc., Fort Lauderdale, USA ) sachets contained 900 billion 
viable lyophilized bacteria consisting of four strains of lactobacillus (L. casei, L. 
Plantarum, L. acidophilus, and L delbrueckii subsp. bulgaricus), three strains of 
Bifidobacterium ( B. longum, B. breve, and B. infantis), and one strain of Streptococcus 
salivarius subsp. thermophilus. The placebo was provided in the form of identical sachets 
containing maize starch. For patients with UC, each patient received two sachets twice per 
day of oral VSL#3 (3,600 billion bacteria), or placebo, daily for eight weeks.  Patients 
treated with oral corticosteroids received prednisolone 40mg each day. The steroid dose 
was reduced by 5mg each week over eight weeks. 
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2.2 METHODS 
 
2.2.1 Patients and Controls 
 
Diagnosis for patients with IBD was made using clinical parameters, radiographic studies, 
endoscopic and histologic criteria. Disease activity for UC was assessed using the UC 
disease activity index: UCDAI, range of scores 0 (no active disease) to 12 (maximum 
disease) (Singleton, 1987). Disease activity for patients with CD was assessed using the 
Crohn’s disease activity index (CDAI). The CDAI incorporates 8 variables: numbers of 
stools per day, severity of abdominal pain, general well-being, extraintestinal 
manifestation, abdominal mass, use of anti-diarrhoeal drugs, haematocrit and body weight. 
These items yield a composite score ranging from 0 to 600. A score of <150 is generally 
regarded as reflecting clinical remission, whereas a score above 400 indicates severe 
disease (Best et al., 1976a; Best and Becktel, 1981).  The control group consisted of 
patients with macroscopically and histologically normal intestine who had been referred 
with symptoms of rectal bleeding or a change in bowel habits.   
 
Demographic details of each patient and full medical history were obtained. Baseline 
characteristics of patients, including concurrent medical therapy, are described in Table 8. 
Table 8 represents patients analysed in Chapters 3 and 6. 
 
A subgroup of patients with active UC were recruited as part of a multi-centre, double 
blind, placebo-controlled therapeutic trial evaluating the effectiveness of the probiotic 
preparation VSL#3 for the treatment of mild to moderately acute UC  (Harrow Research 
Ethics Committee: 05/Q40405/71). Twenty-eight patients with acute UC were included in 
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this sub-study and their baseline characteristics have been described separately (Table 12 - 
Chapter 5). Written, informed consent was obtained from all patients and the study was 
approved by the Local Research Ethics Committee.  
 
Active UC Inactive UC      Active Crohn’s Disease      Controls
(N=44)                  (N=10) (N=28) (N=22)
Age(mean) 43  37 44 45
Sex (F/M) 20/24 5/5 16/12 9/13
Disease location
Distal 24 0 - -
Extensive 7 2 - -
Total 13 8 - -
UCDAI score
<3 - 10 - -
3 to 8 39 - - -
>8 5 - - -
CDAI score (mean) - - 280 -
Medication
5-ASA 29 8 13 -
AZA/6-MP 6 - 21 -
Steroids 2 - 4 -
No medication 10 2 6 -
5-ASA: 5-aminosalicylic acid
AZA:   azathioprine
6-MP: 6-mercaptopurine  
Table 8: Patients’ baseline characteristics 
 
2.2.2 Intestinal Tissue Sampling and Processing 
 
Isolation of Lamina Propria Mononuclear Cells (LPMC) 
 
The method used was described in detail in previous work from the Antigen Presentation 
Research group (Bell et al., 2001). Approximately ten rectal biopsies were taken from each 
UC patient and control. Biopsy specimens were collected in ice-cold RPMI 1640 Dutch 
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modification (Sigma-Aldrich, Dorset, England) supplemented with 10% fetal calf serum, 
25µg/mL gentamicin, and 100U/mL penicillin/streptomycin (complete medium).  Tissues 
were incubated with occasional agitation in calcium- and magnesium-free Hank’s 
balanced salt solution (HBSS) (Gibco BRL, Paisley, Scotland) containing 1 mmol/L 
dithiothreitol (Sigma-Aldrich) for 20 minutes in a T25 tissue culture flask to remove 
mucus and faeces.  Biopsies were blotted and weighed.  The epithelium was removed 
using two 30-minute treatments with 1 mmol/L EDTA in HBSS at 37C with gentle 
agitation.  The biopsy samples were washed in HBSS between each treatment until the 
supernatant was macroscopically free of released epithelial cells.  
 
Tissue digestion was performed using 25ml of collagenase digestion medium in a T25 
flask on a shaker for 90 to 150 minutes at 37C in a tightly capped flask.  LPMC released 
from the tissue samples were passed through a cell strainer and washed in complete 
medium.  The total number of mononuclear cells in suspension was calculated by Trypan 
blue viability count. Approximately 2X106 LPMC were extracted from ten colonic 
biopsies. 
 
 
2.2.3 Cell Surface Labelling  
 
LPMC were labelled in phosphate-buffered saline (PBS) containing 1 mmol/L EDTA and 
0.02% sodium azide (fluorescence-activated cell sorter FACS buffer).  A minimum of 
50,000 LPMCs were used per antibody labeling.  Antibodies were added at predetermined 
optimal concentrations and labelling was performed on ice for 20 minutes.  The cells were 
then washed twice by centrifugation in FACS buffer (300g, 10 minutes, 4C), and fixed in 
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paraformaldehyde (500µL of 1%).  The samples were stored protected from the light at 
4C until acquisition on the flow cytometer within 24 hours.  
 
 
2.2.4 Cytokine Labelling 
 
For intracellular cytokine labelling, paired cultures of LPMC, one incubated with 
monensin to maintain cytokine within the golgi apparatus of cells and the other incubated 
without monensin, were cultured for 4 hours at 37C in a humidified atmosphere of 5% 
CO2 in air.  Cells were labelled for surface markers for 20 minutes on ice, fixed with 50µL 
leucoperm A and permeabilized with100µL leucoperm B. Five µL of anti-cytokine 
antibody (IL-10-PE, IL-12-PE, IL-6-PE, IL-13-PE) were added for 20 minutes on ice.  The 
cells were then washed twice in FACs buffer and fixed in 1% paraformaldehyde (500 µL 
of 0.5%).  Samples were stored at 4C until acquisition within 24 hours. 
 
 
2.2.5 Dendritic Cell Sorting  
 
LPMCs were extracted as previously described, washed for 5 minutes and resuspended in 
Mini Macs buffer (PBS supplemented with 2mmol/L EDTA and 0.5% bovine serum 
albumin).  Cells were labelled with an antibody mixture containing CD11c- PE, lineage 
cocktail, and HLA-DR-APC for 20 minutes on ice before sorting on a Becton Dickinson 
FACS Calibur machine (Oxford, England) as a CD11c- HLA-DR+ lin-/dim population.  
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2.2.6  Peripheral Blood Mononuclear Cells (PBMC) 
 
Human whole blood was obtained by venipuncture into sodium-heparin Vacutainers 
(Beckton-Dickinson) and diluted 2:1 with RPMI-1640 Dutch modification. Peripheral 
blood mononuclear cells (PBMC) were obtained by centrifugation of whole blood over 
Ficoll-paque density gradient 650g for 20 minutes at room temperature. PBMC were 
harvested from the interface and washed twice by centrifugation at 650g for 10 minutes, 
and re-suspended in 1ml complete medium.  The total number of mononuclear cells in 
suspension was calculated by Trypan blue viability count. 
 
 
2.2.7 Enrichment of Blood Dendritic Cells (Low Density Cells) 
 
For use in functional assays, DC-enriched low density cells (LDC) were prepared from 
blood of healthy donors. LDC were prepared by culturing PBMC overnight in complete 
medium at 4X106/ml in T25 flasks (Falcon) at 37C in a humidified atmosphere of 5% 
CO2 and then separating non-adherent cells on hypertonic nycoprep (14.5g added to 
100ml of complete medium). Cells recovered from the interface were washed twice by 
centrifugation (650g for 10 minutes), re-suspended in complete medium, counted and used 
as a source of blood DC in stimulation assays. 
 
2.2.8 Mixed Leucocyte Reaction (MLR) 
 
The stimulatory capacity of LPMC, blood LDC and sorted CD11c- cells was assessed in 
an allogeneic MLR.  Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled 
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naïve (CD45RO-) CD4+ T cells or CFSE-labelled CD14- cells were used as responders, 
and LPMC, sorted CD11c- cells and LDC, enriched for DC, as stimulators.  To obtain 
responder cells, PBMC were obtained from healthy controls as described above and 
resuspended in 0.5ml MiniMACS buffer (PBS containing 0.5% BSA and 2mM EDTA) 
and labelled with a mixture of immunomagnetic microbeads coupled with anti-CD19 (40 
µl), anti-CD14 (40 µl) and anti-HLA-DR (50 µl) (All from Miltenyi biotech, Bisley, UK) 
and with allophycocyanin (APC) conjugated antibodies to CD45RO (20 µl) and CD8 (20 
µl) (BD Biosciences, Oxford, UK)  for 20 minutes at 4C. The cells were washed twice in 
cold mini-Macs buffer (480g, 5 min) and labelled with anti-APC microbeads (Miltenyi) on 
ice for 30 minutes. After washing the cells twice in Mini-Macs buffer, the resultant cells 
were separated on LD magnetic Mini-MACS columns (Miltenyi Biotec), washed twice 
(500g, 4C, 5 min) and resuspended in 0.5ml PBS. Cells not retained on the column were 
collected as a source of naïve CD4+ T cells.  An equal volume of CFSE in PBS solution 
was added to the cell suspension to give a 5µM final concentration.  After incubation for 3 
minutes at room temperature, 1ml FCS was added to the reaction mixture to prevent 
further labelling.  The CFSE-labelled cells were then washed twice in complete medium 
and enumerated. 
 
The CFSE-labelled CD4+ naïve T cells were plated out in 96-well round bottom plate at a 
concentration of 4X105 cells per well.  The stimulator cell populations were added at a 
concentration of ~8000 cells per well in 200µl total volume Complete medium (medium 
alone was added as a negative control). After 5 days of culture, cells were harvested and 
analysed by flow cytometry to assess for lymphocyte proliferation.  Dividing cells were 
identified by the reduction in CFSE staining intensity. The numbers of dividing cells were 
determined by reference to FlowCount beads. 
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2.2.9 Multiple Enzyme Linked Immunoabsorbent Assay (ELISA) 
 
Supernatants were harvested from tissues cultured overnight in the incubator. The 
cytokine contents of the supernatants were measured using multiplex ELISA kits (human 
Th1/Th2 10plex Kit II BMS7 16FF, Bender Medsystems, Austria). The amount of ten 
cytokines in the supernatant was quantified. The ten cytokines assayed and respective limit 
of detection of each analyte are shown in Table 9. According to manufacturer’s 
instructions, the antibody beads, biotinylated detector antibodies and streptavidine-PE 
were diluted to a 1 X working concentration. 25µl aliquots of supernatant (or 
corresponding standards of known analyte concentration) were pipetted into a 96-well 
filter bottom microplate and incubated with 25µl mixed antibody beads and 50µl 
biotinylated conjugate mixture per well in the dark for 2 hours at room temperature on a 
plate shaker (500rpm). After washing, the beads were stained with streptavidine-PE (50) 
for 1 hour in the dark on a plate shaker. After further two washes with 100µl assay buffer 
using vacuum manifold to aspirate, 200µl of assay buffer was added to each well, the 
contents were mixed and transferred into a FACS tube. The mixture was topped up with 
300µl assay buffer to a final volume of 0.5ml per tube. The samples were stored at 4ºC 
and resuspended thoroughly before acquisition on flow cytometer within 24 hours. The 
quantities of cytokine in the supernatant were determined against a standard curve for 
known concentrations of that cytokine. 
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Analyte Sensitivity 
IL-1β 4.5 pg/ml 
IL-2 8.9 pg/ml 
IL-4 6.4 pg/ml 
IL-5 5.3 pg/ml 
IL-6 4.7 pg/ml 
IL-8 6.4 pg/ml 
IL-10 6.9 pg/ml 
TNF-α 7.9 pg/ml 
IL-12p70 9.7 pg/ml 
IFN-γ 7.0 pg/ml 
 
Table 9: Analytes and sensitivity for Multiplex ELISA 
 
 
2.2.10 Cytospins and Immunofluorescence Staining 
 
Assisted by Hafid Omar-Al-Hassi of the Antigen Presentation Research Group 
Indirect immunofluorescence labelling was performed on sorted CD11c- HLA-DR+ lin-/dim 
cells using cytospins.  Slides were washed in PBS for 5 minutes and fixed in 1:1 acetone / 
methanol for 4 minutes at room temperature.  Cytospins were incubated with anti-HLA-
DR, followed by anti-CD123 and anti-BDCA-2. Slides were then rinsed in PBS for 5 
minutes and mounted under coverslips. 
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2.2.11 Electron Microscopy 
 
Performed by Nicholas English of the Antigen Presentation Research Group 
Approximately 12X103 sorted CD11c- cells were mixed with a 10-fold excess human red 
blood cells in order to provide bulk for subsequent processing, and fixed in 3% 
glutaraldehyde in 0.1M sodium phosphate buffer (pH7.4) for 12 hours at 4C.  Cells were 
embedded as a pellet in low gelling temperature agarose (Sigma).  Cells were washed 
twice with the buffer and fixed in 1% osmium tetroxide in 0.1% (pH 7.4) sodium 
phosphate buffer for 1 hour.  After washing with water to remove the sodium phosphate 
and keeping in water overnight, cells were block stained in 2% uranyl acetate for 2 to 4 
hours.  The cells were washed with distilled water, dehydrated using an acetone gradient, 
and gradually infiltrated with araldite resin.  After at least 2 changes of araldite over 4 to 8 
hours, the cells were embedded in the araldite resin and cured for 18 hours at 65C.  The 
blocks were cut into 100nm sections using a Reichert-Jung Ultracut E microtome and 
collected on 200 mesh copper grids.  The ultrathin sections were stained with Reynold’s 
lead citrate and viewed on a Jeol JEM-1200 EX electron microscope. 
 
 
2.2.12 Flow Cytometry 
 
Multi-colour flow cytometry characterizes and measures the physical properties of 
individual cells in suspension as they pass through one or more focused laser beams. 
During acquisition, 10µl of flow-count fluorospheres at a known concentration was added 
to each tube. Blood samples were acquired for approximately 5 minutes at high flow rate, 
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and tissue samples were acquired for approximately 8 minutes. All data were then saved as 
list-mode data files and transferred to a computer for analysis. 
 
(i) FACs Analysis 
Data were acquired using a FACs Calibur flow cytometer (Becton Dickinson, Oxford, 
England) using CellQuest software for partial online colour compensation. Completion of 
compensation and analysis of listmode data was carried out offline using WinList software 
(Verity Software House, Maine). For compensation, a region was made around the 
lymphocyte area of the side scatter (SSS) versus forward scatter (FSC) plot and the CD8 
marker was evaluated in each channel using the compensation toolbox on the Winlist 
software programme. Live cells (viability gauged by size and granularity) were analysed 
on a plot of HLA-DR versus lineage cocktail staining. Lineage cocktail comprised specific 
monoclonal antibody labels for T cells (CD3), monocytes (CD14, CD16), B cells (CD19), 
and stem cells (CD34).  DC were identified as HLA-DR+ lin-/dim cells. Using multi-colour 
analysis, CD11c+ and CD11c- populations within a HLA-DR+ lin-/dim gate were assessed 
for expression of surface markers and cytokine production. Two methods were used to 
analyse the flow cytometry data: (a) Region Gating and, (b) Enhanced Normalized 
Subtraction (ENS).  
 
(ii) Region Gating 
The percentage of cells expressing a given surface marker was measured by determining 
the proportion of antibody stained cells falling beyond the distribution of staining with an 
isotype matched control antibody.  For example, a region is drawn that excludes irrelevant, 
isotype matched control mAb or non specific staining. All events that fall within this 
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region exceed istopye control staining intensity and is regarded as positively labeled cells 
(Figure 2.1). WinListTM calculates the proportion of positive cells amongst the total DC 
population.  This method was used because it (1) discounts all events that fall within the 
distribution of the control histogram; (2) more accurately delineates subpopulations based 
on surface antigen expression; (3) reduces impact of differences in fluorochrome (antibody 
binding and free fluorochrome variation between batches of antibody).  The region method 
was used to generate percentage positive cells in all phenotypic analysis.  
 
(iii) Enhanced Normalised Subtraction 
Enhance Normalised Subtraction (WinList software) was used to measure (1) the level of 
staining for cell surface marker and; (2) the percentage of cytokine-positive cells. 
The level of staining for surface markers, expressed as an intensity ratio (IR) representing 
the ratio of median value of positive events in the test histogram to median value of 
staining with an isotype-matched control antibody was measured using Enhanced 
Normalised Subtraction (ENS) on WinList software (Verity Software House, Maine) 
(Panoskaltsis et al., 2002) (Figure 2.2). 
 
The percentage of cytokine-positive cells was determined by superenhanced Dmax  (SED) 
normalized subtraction. Normalized cumulative histograms of staining of cells cultured 
without monensin (control sample - used as a reference sample allowing for gain or loss of 
cytokine to be measured) were subtracted from histograms of the staining in the presence 
of monensin (test histogram), allowing the build-up of trapped synthesized protein to be 
detected in a 4 hour window (Holden et al., 2008); To minimise the effects of non-specific 
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binding, control cells were treated in the absence of monensin but  fixed, permeabilised 
and labelled with identical antibody as the test sample staining, hence we felt that the 
inclusion of an isotype control was not necessary. Monensin is an ionophore originating 
from Streptomyces cinnamonensis that disrupts protein transportation from the Golgi 
apparatus leading to the trapping of newly synthesised protein within the cytoplasm of 
cells (Mollenhauer et al., 1990).  
 
To discriminate positive from negative events in the test histograms, we used WinlistTM 
software and Enhanced Normalised Subtraction technique which can sensitively detect 
intracellular cytokine in non-stimulated DC. When there is an obvious separation between 
the test and control histograms, flow cytometry analysis software can generate cut off 
markers to accurately define the positive events. In some cases, secreted protein binds 
back to the surface of cell in the no monensin sample together with the loss of pre-existing 
cytokine from cells in the monensin sample, which contribute to the overall loss of 
cytokine. In such situation the subtraction process can be reversed to generate negative 
results. In this system, the control sample does not represent zero but represents a 
reference point on which to quantify the build up of cytokine in our test sample. The no 
monensin sample may contain cytokine positive cells. It is therefore important to quantify 
the reduction in cytokine production compared with background control as labelling these 
negative results as zero would be inaccurate. The optimisation of this technique to detect 
ongoing cytokine production in un-stimulated DC has been described, and this modified 
technique may complement both secretion and gene expression techniques (Holden et al., 
2008). 
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The subtraction technique allows a more accurate calculation of the proportion positively 
labeled cells especially when events are low or when the test and controls histograms 
overlap. An example is shown in Figure 2.3. 
The level of staining (IR) for cytokine positivity was determined using ENS, as a ratio of 
median value of positive events in test histograms to median value of control histograms 
(Gupta et al., 2007).  
 
mIgG1
% positive cell 
43%
A B
 
Figure 2.1: Cell surface labelling by region gating.  A region is in drawn that excludes non-
specific staining or isotype matched control monoclonal antibody staining (A-R1). The same 
region (R2) is applied to the phenotype staining histogram (B). All events that fall within this 
region and exceed isotype control staining (with a cut-off of <0.5% cells within R1) was calculated 
by WinList and regarded as positively labelled cells. This method was used in the generation of all 
percentage positive cells data for phenotypic analysis as it more accurately delineates 
subpopulations based upon surface antigen expression.  
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Figure 2.2: Positive Intensity Ratio (PIR). (A) is the isotype control which represents the level 
of non specific staining with an irrelevant isotype matched control monoclonal antibody whereas 
(B) is the staining of the surface marker CD40; this represents specific labelling for CD40 
combined with an element of non specific staining. Using Enhanced Normalised Subtraction 
(ENS), WinList software generates positive IR after subtracting the non specific binding 
component from the phenotype labelling histogram. The median channel of fluorescence and 
distribution of each histogram is compared and the proportion of positive events calculated (B-
shaded area). This is the ratio of linearised fluorescence median of only the positive events after 
subtraction to the linearised control median. The IR compare the relative intensities of positive 
events in a test sample (B) compared with all events in control distributions (A).  
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Figure 2.3: Intracellular cytokine production by colonic DC measured with Enhanced 
Normalised Subtraction (ENS). Detection of ongoing intracellular cytokine production in 
unstimulated DC was measured by ENS. This figure shows one-parameter histograms for the 
intracellular staining of IL-12p40 in CD11c+ DC in the absence (B - No Monensin), and presence 
(A + Monensin) of monensin. Using Super-enhanced Normalised Subtraction from Winlist 
software, cytokine production was determined by the subtraction of staining in the sample with 
monensin from staining in sample without monensin. The shaded area (C) on the right panel 
represents the proportion of cells staining positive for IL-12p40 after subtraction. When more 
“positive events” in the control histogram were detected compared with test histogram, subtraction 
was reversed with the generation of negative events in the test histogram. Staining cells from 
control and test histogram in the same way ensured minimal difference in non-specific binding 
between test and control samples. The result is representative of ongoing cytokine production in 
the absence of exogenous stimulation.   Specificity of antibody labelling has been previously 
confirmed in competition experiments with unlabelled relevant and irrelevant antibodies. Using 
unlabelled antibodies, specific blocking antibodies blocked cytokine staining but irrelevant 
blocking antibodies were not able to inhibit staining production. 
 
 
 
(iv) Absolute Cell count 
Absolute cells counts were obtained by simultaneous acquisition of Flow-Count 
fluorospheres (Coulter Immunotech). Fluorescent counting beads were identified and 
enumerated on a FL1 versus SCC plot. Based on the number of events in the cell region of 
interest and on the number of events in the bead region, the number of cells per µl can be 
calculated.  
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Number of cells per µl    
=      Number of events in gated region                                         X    bead conc/µl 
         Number of beads in gated region  X  volume of sample 
                                                                     volume of beads 
 
 
2.2.13 Fluoresecent in-situ Hybridisation (FISH) 
 
Performed by Jane Benjamin/Kevin Whelan (collaborators at Kings College Hospital) 
 
Constituents of the fecal microbiota were quantified using FISH (Franks et al., 1998b; 
Harmsen et al., 2002). The fecal microbiota were fixed and hybridized with 
indocarbocyanin (Cy3) labelled oligonucleotide DNA probes targeting total bacteria cells 
4’ 6-diamidino-2-phenylindole (DAPI), bifidobacteria, Bacteroides-prevotella, 
Clostridium coccoides-Eubacterium rectal (EREC), and Faecalibacterium (F.) praustnitzii 
(Microsynth, Switzerland).  These bacterial groups were chosen because they have been 
shown to be altered in patients with IBD (Seksik et al., 2003; Sokol et al., 2008; Sokol et 
al., 2009b; Swidsinski et al., 2002; Tamboli et al., 2004). 
 
Faecal bacteria from fresh faecal samples were immediately harvested in PBS (0.1mol/L; 
pH 7.0) with the use of glass beads and centrifugation, and fixed overnight in 4% (w/v) 
paraformaldehyde. Bacteria were then washed with PBS (0.1mol/L; pH 7.0) three times 
and suspended in a 1:1 solution of PBS and 96% ethanol.  This solution was then stored at 
-20ºC. Fixed bacteria were spotted on 3-aminopropyltriethoxysilane treated eight-well 
slides, air dried and serially dehydrated in 60%, 80%, and 96% ethanol (Maddox and 
Jenkins, 1987).  Total cells counts were quantified using a nucleic acid stain, 4, 6-
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diamidino-2-phenlindole (Kapuscinski, 1995).  Individual species were quantified using 
hybridisation with indocarbocyanin (Cy3)-labelled oligonucleotide probes targeting 
specific regions of 16SrRNA (Table 10).  The fixed bacteria was then hybridised with the 
oligonucleotide probes according to a previously published protocol (Amann et al., 1990). 
Briefly, probes were diluted to a concentration of 4.5 ng/μl in sterile hybridisation buffer 
(0.9 M NaCl; 0.02M Tris/HCl; 0.01% sodium dodecycl sulphate) and 10 μl added to each 
well which was then incubated at 46°C overnight in a light-free saturated humidity 
chamber. Slides were washed to remove unbound probe prior to quantification within 24 
hours (Mylonaki et al., 2005). 
 
Hybridized fecal microbiota were manually quantified by viewing the slides under an 
Axioplan 2 imaging microscope (Zeiss, Germany) equipped with an HBO-100 fluorescent 
lamp (Osram, Germany) and filterset number 15 (Zeiss, Germany). Fifteen random fields 
were selected in duplicate for each probe. Faecal bacterial concentrations were expressed 
as cells per gram of dry faeces in order to standardise the comparison between patient 
samples with varying consistency.   Faecal bacterial concentrations were expressed as cells 
per gram of dry faeces in order to standardise comparison between samples. 
  
 
Target bacterial Group Probe Sequence (5’-3’) 
Bifidobacteria Bif 164 (Langendijk et al., 1995) -CAT CCG GCA TTA CCA CCC- 
Bacteroides Bac 303 (Manz et al., 1996) -CCA ATG TGG GGG ACC TT- 
Clostridium coccoides-
Eubacterium rectal 
EREC 482 (Franks et al., 1998a) -GCT TCT TAG TCA RCT ACC G 
Faecalibacterium 
prausnitzii 
Fprau-0645 (Suau et al., 2001) -CCT CTG CAC TAC TCA AGA 
AAA AC- 
 
Table 10: Target bacteria group, indocarbocyanin (Cy3)-labelled oligonucleotide probes and 
targeted regions of 16SrRNA   
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2.2.14 Statistical Analysis 
 
Assisted by Paul Bassett 
Statistical analyses were carried out using Sigma stat software (SPSS Inc Chicago). 
Pooled data were expressed as median values ± mean standard error. Two-tailed t tests 
were employed to compare normally distributed data and Mann-Whitney Rank-Sum tests 
were used to analyse non-normally distributed data.  
 
Stata (version 9.2) by StataCorp (4905 Lakeway Drive, College Station, Texas 77845 
USA) software was used for statistical analyses of pre and post treatment values using the 
Wilcoxon matched-pair test. Association between variables was examined using Pearson 
correlation. Associations between variables were assessed using Pearson’s (for normally 
distributed data) or Spearman’s (for skewed distribution) rank correlation. These methods 
measure the strength of the association between two variables on a scale between -1 and 
+1. A correlation coefficient of near to -1 implies a strong negative relationship (as one 
measure increases, the other decreases), a correlation coefficient near to 0 implies little 
evidence of a relationship between the two measures, whilst a correlation coefficient near 
to +1 implies a strong positive relationship (as one measure increases, the other also 
increases). For most data, values p<0.05 were considered significant, whereas for 
multiplex and correlation analyses, due to the large number of different analyses there is 
more possibility of a significant result due to chance alone and the Bonferonni correction 
is important, and so a more stringent level of significance is used. Only analyses with a p-
value of less than 0.01 were considered to be statistically significant in this analysis. 
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2.2.15 Definition of Clinical Outcome 
 
The Ulcerative Colitis Disease Activity Index (UCDAI) is the sum of scores from four 
criteria (stool frequency, rectal bleeding, sigmoidoscopic mucosal appearance, physician’s 
global assessment), each ranked zero to three giving a maximum of 12 points (Singleton, 
1987). Clinical remission was defined as a UCDAI of ≤ 2 points. Clinical response was 
defined as a decrease in UCDAI ≥3 points or a final score ≤3.  
 
 
2.2.16 Grading of Histologic Inflammation 
 
The severity of histologic inflammation in each rectal biopsy specimen was reported by an 
expert pathologist. The degree of inflammation for each rectal biopsy was graded as: 0, 
inactive/quiescent/normal (No epithelial infiltration by neutrophils); 1, mild (neutrophil 
infiltration of <50% of sampled crypts or cross sections, no ulcers or erosions); 2, 
moderate (neutrophil infiltration of ≥50% of sampled crypts or cross sections, no ulcers or 
erosions, or 3, severe (erosions or ulceration, irrespective of other features) (Gupta et al., 
2007). 
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Chapter 3 
 
Characterisation of Human Colonic CD11c- Cells in 
Inflammatory Bowel Disease 
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3.1 Abstract 
 
Introduction: Intestinal DC are heterogeneous, comprising phenotypically and 
functionally distinct subpopulations.  They sample luminal bacteria and are key players in 
the regulatory events that normally limit inflammatory responses to commensal bacteria.  
In human IBD, colonic myeloid DC, identified as CD11c+ cells within a HLA-DR+ lin-/dim 
population, are activated. The nature of CD11c- cells, also present within this population, 
remains unclear. We hypothesized that this hitherto poorly characterized population in the 
gut may be involved in intestinal inflammation.  
Methods: HLA-DR+ lin-/dim cells were identified in freshly isolated lamina propria 
mononuclear cells by multicolour flow cytometry. Proportion and number of CD11c+ and 
CD11c- cells, surface expression of activation markers CD40, CD86, TLR-2, TLR-4, and 
CD56 (natural killer - NK marker), were determined on these cells extracted from tissue of 
patients with UC (54), CD (28), and controls (22).   
Results: HLA-DR+ lineage-/dim cells represented approximately 3% and 0.7% of all lamina 
propria mononuclear cells in UC and controls, respectively. Lamina propria colonic 
CD11c- HLA-DR+ lin-/dim cells were significantly increased in tissues from UC (inflamed 
and “non-inflamed”) and CD compared with controls.  In contrast, numbers of CD11c+ 
HLA-DR+ lin-/dim cells were unchanged.  CD11c- cells decreased after inflammation 
resolved in UC. Fewer CD11c- cells expressed activation markers, TLR or produced IL-10, 
IL -12p40, IL-6 and IL-13, compared with their CD11c+ counterparts. CD11c- cells were 
weakly stimulatory in mixed leucocyte reactions.  Few colonic CD11c- cells expressed 
plasmacytoid DC markers (BDCA-2, BDCA-4 and CD123) but a major subset expressed 
high levels of CD56.  
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Conclusions: Intestinal inflammation in IBD is associated with the presence of cells that 
share phenotypic features of both DC and NK cells.  This novel population of human 
colonic CD56+ HLA-DR+ cells may function in immune regulation or tissue repair.  Their 
increase in inactive UC may be a marker of sub-clinical inflammation. 
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3.2 Introduction 
 
The pathogenesis of UC remains unclear but emerging evidence suggests that it involves a 
dysregulated immune response to the enteric intestinal microflora in genetically 
predisposed individuals (Podolsky, 2002). 
 
Discrimination between the beneficial commensal organisms and potentially harmful 
pathogens is a central component of the essential role that gut immune cells play in 
maintaining the balance between oral tolerance and immune activation.  In the gut, DC are 
likely to play a pivotal role in the initiation and perpetuation of immune responses 
(Steinman, 1991).  Within intestinal mucosa tissues, aggregates of DC, ultimately derived 
from bone marrow precursors, are present in small numbers in organized lymphoid tissues, 
MLN, and the lamina propria of the small and large intestine (Banchereau et al., 2000; 
Iwasaki and Kelsall, 1999; Kelsall et al., 2002; Maric et al., 1996). Intestinal DC have 
tissue-specific properties distinct from those of their non-mucosal counterparts, probably 
as a reflection of adaptations to their microbe rich external environment (Stagg et al., 
2003). 
 
Functionally distinct subsets of DC have been defined in mice and humans based on their 
cell-surface phenotype and functional properties.  In humans, these subsets include 
conventional myeloid (CD11c+ BDCA2-, BDCA4- CD123lo) DC and plasmacytoid 
(CD11c-, BDAC2+, BDCA4+, CD123hi) DC.  DC present in inflammatory sites are 
functionally different from those found in the tissues under steady state conditions (Le et 
al., 2006; Salazar-Gonzalez et al., 2006) and studies in animal models of colitis and in 
human IBD strongly suggest a role for DC in driving intestinal inflammation (Krajina et 
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al., 2003; Leithauser et al., 2001). In patients with active IBD, DC are reduced in number 
in the peripheral blood (Baumgart et al., 2005), but increased in the intestinal tissue 
(Middel et al., 2006; te Velde et al., 2003)  suggesting DC recruitment to and / or retention 
within the GI tract during inflammation. 
 
Previous work from this laboratory has characterised HLA-DR+ lineage (lin)-/dim (lin = 
anti-CD3, 14, 16, 19, 34) cells isolated from the human colonic lamina propria (Hart et al., 
2005). This population comprises a CD11c+ subset together with a variable number of 
CD11c- cells.  The CD11c+ cells have phenoptypic, morphologic and functional properties 
of myeloid DC, and disease-associated changes in these cells occur in IBD (Bell et al., 
2001). For instance, in CD, more colonic CD11c+ DC expressed TLR-2, TLR-4 and 
produced more IL-12/23p40 (Hart et al., 2005). In contrast to the detailed analysis of the 
CD11c+ HLA-DR+lin-/dim colonic subset, the CD11c- population has not been 
characterised.  In peripheral blood, cells with a CD11c- HLA-DR+lin-/dim phenotype 
comprise plasmacytoid DC but the nature of the cells with this phenotype in colonic tissue 
and the potential contribution of such cells to the development or regulation of intestinal 
inflammation, remain to be investigated.  
 
 
3.3 Hypothesis  
 
Lamina propria CD11c- HLA-DR+ lin-/dim cells are involved in the inflammatory process 
that underlies active inflammatory bowel disease. 
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3.4 Aims: 
 
- To identify human intestinal lamina propria DC in inflamed and normal tissue.  
- To characterise lamina propria CD11c- population in patients with UC and 
 controls, and to compare these cells with their CD11c+ counterparts. 
 
 
3.5 Identification of Human Intestinal Lamina Propria Dendritic Cells 
 
LPMC were obtained from colonic biopsies by immediate collagenase digestion. DC were 
identified in LPMC as HLA-DR+ lineage-/dim populations on four-colour flow cytometry 
(Figure 3.1).  In the human intestine, DC have been categorized into two subsets: CD11c+ 
myeloid DC and CD11c- cells.  HLA-DR+ lineage-/dim cells represented approximately 3% 
and 0.7% of all LPMC in UC and controls, respectively. In controls, lamina propria DC 
were predominantly myeloid cells. 
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Figure 3.1: Identification of intestinal lamina propria dendritic cells. The LPMC are shown on 
a forward scatter (FSC) versus side scatter (SCC) plot. DC were identified in LPMC as HLA-DR+ 
lineage-/dim (lin = CD3-, CD14-, CD16-, CD19-, CD34-) populations, labelled DC gate. HLA-DR+ 
cells were gated with reference to the isotype control antibody labelling.  Within the DC gate, 
CD11c+ and CD11c- cells were present.  
 
 
3.6 Lamina Propria CD11c- HLA-DR+ lineage-/dim Cells are Increased in 
 Ulcerative Colitis 
 
The number of HLA-DR+ lineage-/dim cells and DC subsets in both UC and control tissues 
were determined with reference to simultaneous acquisition of FlowCount beads. Based 
on the number of events in the cell region of interest and on the number of events in the 
bead region and a known bead concentration, the number of cells per milligram tissue was 
determined as described in Section 2.2.12(iv). There was a significant increase in the 
number of HLA-DR+ lin-/dim cells from inflamed tissue in UC (median± SEM, 503±101 / 
mg tissue) compared with control tissue (164±22 cells / mg tissue; n=44; p<0.05) 
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(Figure 3.2).  In Figure 3.2, even when the two high “outliers” (> 2000 HLA-DR+ lin-/dim 
cells/mg) were excluded, the number of cells remained significantly different between UC 
and controls. In addition, the proportion of HLA-DR+ lin-/dim cells that was CD11c- was 
significantly greater in LPMC from UC patients compared with the proportion in healthy 
controls (p<0.001) (Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Number of HLA-DR+ lineage-/dim cells in UC and controls. This figure shows the 
total number HLA-DR+ lineage-/dim cells per milligram tissue in active UC patients and controls. 
Each dot represents one subject. Horizontal line represents median value (UC=44; controls=22). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Proportion of CD11c- cells in active UC and controls. This figure shows the 
proportion of CD11c- cells within the HLA-DR+ lineage-/dim region (putative DC gate). Horizontal 
line represents median value. Each dot represents one subject (UC=44; controls=22). 
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The increase in proportion of CD11c- cells was due to increased numbers of this 
population rather than a loss of CD11c+ cells in disease (Figure 3.4A). The number of 
colonic CD11c- HLA-DR+ lin-/dim cells was significantly greater for UC patients than 
controls (UC 447±94 vs. control 102±17 / mg tissue, p<0.001). In contrast, the number of 
CD11c+ DC did not differ significantly between UC patients and controls (p=ns) (Figure 
3.4B).  Overall, these data indicate that there were more HLA-DR+ lin-/dim cells in the 
colons of UC patients and that this difference was attributable to a selective increase in 
CD11c- cells. 
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Figure 3.4: Absolute numbers of CD11c- cells and CD11+ DC in active UC and controls  
(A)  Number of CD11c- cells and; (B) Number CD11c+ DC per mg tissue in UC (n=44) and 
controls (n=22).  All samples were taken from colonic tissue. Horizontal line represents mean 
value. 
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To determine whether the increase in CD11c- HLA-DR+ lin-/dim cells was also present in 
“inactive” or quiescent disease, two approaches were taken.  Firstly, in 10 active UC 
patients, repeat tissue sampling was performed following symptom resolution. Resolution 
in macroscopic inflammation (sigmoidoscopy score ≤ 2) was associated with decreased 
numbers of CD11c- cells (399±154 to 92±23 / mg tissue; p<0.05).  Conversely, there was a 
non-significant trend towards increased number of CD11c- HLA-DR+ lin-/dim cells in 
patients who had persistent or worsening macroscopic inflammation at repeat sampling 
(Figure 3.5). There was, however, no significant change in the number of CD11c+ DC, 
from either tissue with resolved inflammation (69±29 to 40±7 / mg tissue; p=ns) or from 
those with persistent inflammation (56±17 to 77±12 / mg tissue; p=ns). Thus CD11c- cells, 
but not CD11c+ DC, are likely to be markers of intestinal inflammation. 
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Figure 3.5: Changes in number of CD11c- cells with and without reduction of macroscopic 
inflammation. In ten active UC patients, repeat tissue sampling was performed to determine the 
changes in the number of CD11c- cells in tissue (A) after resolution of inflammation and (B) with 
persistent inflammation. 
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Secondly, numbers of CD11c- HLA-DR+ lineage-/dim cells in ‘non-inflamed’ tissue from 
UC patients were directly compared with numbers from inflamed UC tissue and control 
tissue.  Non-inflamed UC tissue was from patients with inactive UC undergoing 
surveillance (n=6) or from macroscopically uninvolved tissue from patients with subtotal 
colitis in which there was a clear demarcation between inflamed and ‘non-inflamed’ tissue 
(n=4).  There was significantly more CD11c- HLA-DR+ lineage-/dim cells in ‘non-inflamed’ 
tissue from UC patients compared with tissue from healthy controls (p<0.05) (Figure 3.6).  
In the patients where paired biopsy specimens were taken from both non-inflamed and 
inflamed sections, the number of CD11c- cells was significantly higher in inflamed than in 
‘paired’ “non-inflamed” UC tissue (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Number of CD11c- cells in active UC, inactive UC and controls. This figure shows 
the absolute numbers of CD11c- cells from inflamed tissue from patients with active UC, non-
inflamed tissue from patients with inactive UC (red triangles represent biopsies from previously 
involved colonic tissue but currently macroscopically normal; unfilled triangles represent 
uninvolved  colonic tissue), and normal tissue from controls.  
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3.7 Lamina Propria CD11c- Cells are Increased in Crohn’s Disease 
 
To assess whether this population is specific for UC, we used patients with CD as our 
inflammatory controls. There was a significant increase in the absolute number of HLA-
DR+ lineage-/dim cells from inflamed CD tissue (1701±635 / mg tissue) compared with both 
non-inflamed CD tissue (187±28 / mg tissue; p<0.001) and control tissue (152±18 / mg 
tissue; p<0.001). Numbers of putative DC was comparable between non- inflamed CD 
tissue and control tissue (152±18 / mg tissue; p=0.348) (Figure 3.7A). 
 
When we analysed CD11c- cells from inflamed CD tissue the number of these cells were 
markedly higher (1602±621 / mg tissue) compared with non inflamed CD tissue (91±17 / 
mg tissue p<0.001) and control tissue (89±13 / mg tissue; p<0.001) (Figure 3.7B). 
Consistently, the increase in proportion of DC was due to an increase in the number of 
CD11c- cells as there were no differences between numbers of CD11c+ DC between 
inflamed CD, non inflamed CD and control tissues (Figure 3.7C). We assessed whether 
there was an association between disease activity in patients with UC and Crohn’s disease 
and CD11c- cells. There were no significant correlation between the UCDAI and CDAI 
and the number of CD11c- cells. 
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B                            C 
Figure 3.7: Absolute number of HLA-DR+lin- cells, CD11c- cells and CD11c+ DC in CD and 
controls. (A) Numbers of HLA-DR+ lin- cells; (B) Numbers of CD11c- cells; (C) Numbers of 
CD11c+ DC ; inflamed Crohn’s tissue (n=10); non inflamed Crohn’s tissue (n=18); control tissue 
(n=22). 
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3.8 Few Lamina Propria CD11c- Cells in Ulcerative Colitis are Plasmacytoid 
 Dendritic Cells 
 
Having established increased numbers of CD11c- cells in UC, we further determined the 
phenotype and functions of this population in the human gut. In peripheral blood cells 
with a phenotype CD11c- HLA-DR+ lineage-/dim are BDCA2+, BDCA4+ CD123hi 
plasmacytoid DC (Dzionek et al., 2000). However, very few colonic CD11c- cells from 
UC patients expressed CD123 (4.3±2.7%; n=5), BDCA-2 (1.8±1.1%; n=5), and only a 
small proportion expressed BDCA-4 (12±10.5%; n=5) suggesting that the majority were 
unlikely to be equivalent to the CD11c- DC population identifiable in peripheral blood 
(Patterson et al., 1991) (Figure 3.8). No detectable staining of CD11c- cells was obtained 
with antibodies to IgG kappa light chain or to plasma cells marker CD138. Together with 
the lack of staining with anti-CD19 in the lineage cocktail (CD3-, CD14-, CD16-,      
CD19-, CD34-) these findings argued against the presence of B cells in the CD11c- 
population.  
 
To confirm that a small subset of colonic CD11c- cells expressed plasmacytoid DC 
markers, CD11c- HLA-DR+ lin-/dim cells were purified by cell sorting and cytospins 
prepared.  Immunofluorescent labeling with antibody to HLA-DR, CD123 and BDCA-2 
showed expression of these surface markers on some of the CD11c- cells (Figure 3.9).  As 
the immunofluorescence studies suggested that sorted CD11c- cells express BDCA-2 in 
intracellular compartments, we repeated the flow cytometric analysis using permeabilised 
cells.  However, there was no increased detection of BDCA-2 expression on CD11c- cells 
following permeabilisation.       
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Figure 3.8: Surface expression of CD123, BDCA-2 and BDCA-4 on colonic CD11c- cells in 
UC patients. The percentage of expression of CD123, BDCA-2 and BDCA-4 on CD11c- cells was 
assessed on multi-colour flow cytometry. The figure shows pooled data from 5 experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Immunohistochemistry of BDCA-2 and CD123 expression on sorted colonic 
CD11c- cells. Immunofluorescence was carried out on cytospins of sorted CD11c- HLA-DR+ 
lineage-/dim cells derived from inflamed tissue of a patient with UC. In the upper 4 panel, sorted 
CD11c- cells from UC tissue were stained for HLA-DR and CD123. The lower 4 panels showed 
expression of HLA-DR and BDCA-2 by equivalent cells from UC tissue. DAPI stained theDNA of 
cells. 
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3.9 Tissue Processing Does Not Affect Plasmacytoid Marker Staining  
 
To rule out the possibility that exposure to dithiothreitol, EDTA, collagenase or DNase 
removes these markers from the surface of colonic cells during their extraction, expression 
of CD123, BDCA-2 and BDCA-4 was examined on PBMC that had been exposed to the 
enzymatic mixture used for colonic tissue.  Expression of CD123, BDCA-2, BDCA-4, 
CD138 and IgG kappa light chain was not affected by exposure to the colonic tissue 
processing (Figure 3.10).  There was also no enhancement of expression of plasmacytoid 
markers on colonic cells following culture for four hours at 37C to allow for potential re-
expression of these markers following isolation. These data strongly suggested that the 
majority of the CD11c- HLA-DR+ lineage-/dim cells extracted from colonic DC did not 
belong to the plasmacytoid DC lineage.  Analysis by electron microscopy, flow cytometry 
and immunofluorescence staining of sorted cells did indicate the presence of a few 
plasmacytoid DC (~5%) but there were insufficient of these cells for further detailed 
analysis.  It is conceivable that they represented blood-derived contaminants. 
 
 
 
 
 
 
 
 
Figure 3.10: Effect of enzymatic digestion on CD123, BDCA-2 and BDCA-4 expression on 
blood DC. PBMC were exposed to the tissue digestion process which include DTT, EDTA and 
collagenase used for intestinal biopsy digestion. The proportion of CD123+, BDCA-2+ and BDCA-
4+ CD11c- cells within PBMC in the presence of enzymatic digestion processing is shown. 
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3.10 CD11c- Cells have Morphology of Immature Dendritic Cells 
 
 
We next attempt to define more precisely the nature of the UC-associated CD11c- HLA-
DR+ lineage-/dim colonic population.  Following cell sorting the morphology of this 
population was assessed by electron microscopy. Although only a small number of cells 
were present, CD11c- HLA-DR+ lin-/dim cells appeared homogenous, and had features of 
small myeloid cells, possibly immature DC with a heterochromatic nucleus or partly 
euchromatic nucleus (small type 1 and small type 1 to 2 DC) (Patterson et al., 1991).  
Type I DC have numerous short pseudopodia, irregularly shaped nuclei, abundant 
mitochondria, irregular surfaces with numerous projections and cytoplasmic vacuoles but 
exhibit few lysosomes or endocytic vacuole. In contrast, type 2 DC have a paler nucleus 
with a thin rim of dense heterochromatin, cytoplasm devoid of organelles, less vacuoles 
and a smooth cell boundary with few processes (Van Voorhis et al., 1982; Van Voorhis et 
al., 1983).  No rough endoplasmic reticulum was present in our cells, and these cells 
contained some vacuoles of different sizes which covered a large proportion of their 
cytoplasm (Figure 3.11).   
 
 
 
 
 
 
 
 
 
Figure 3.11:  Electron Microscopy of sorted CD11c- cells. Sorted CD11c- HLA-DR+ lineage-/dim 
cell from inflamed tissue of a patient with active UC patient (magnification X11500). Scale 
bar=1µm. 
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3.11 In Ulcerative Colitis Lamina Propria CD11c- Cells Express Less CD40 
 and CD86 than Their CD11c+ Counterparts 
 
Expression of HLA-DR by the CD11c- LPMC population suggests they may function as 
antigen presenting cells.  To explore this potential function further, the expression of co-
stimulatory molecules and pattern recognition receptors was assessed. An example of a 
histogram of surface marker expression (CD40) on CD11c- and CD11c+ cells determined 
by the gating method is shown in Section 2.2.12(ii). CD40+ and, to a lesser degree, CD86+ 
cells were detectable within the CD11c- HLA-DR+ lin-/dim population from UC patients.  In 
Figure 3.12, a smaller proportion of these CD11c- cells expressed CD40 (26±4%, n=30) 
and CD86 (7±2%, n=30; p<0.05) compared with their CD11c+ counterparts (CD40: 
72±5%; CD86: 58±5%).  The level of expression of CD40 (Positive-intensity ratio [IR]: 
6±0.6) and CD86 (3±0.3) by CD11c- cells was also lower than the CD11c+ cells (CD40: 
19±2; CD86: 16±2; p<0.05).  However, the proportion of CD11c- cells that expressed 
CD40 (UC 26±4% vs. control 30±9%) and CD86 (UC 7±2% vs. Control 10±4%) did not 
differ significantly between UC patients and controls (data not shown). 
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Figure 3.12: Percentage and level of expression of CD40 and CD86 on CD11c- cells and 
CD11c+ DC in UC. This figure shows (A) percentage of expression and (B) level of staining 
expressed as positive intensity ratio (PIR) of CD40 and CD86 on colonic CD11c- cells and CD11c+ 
DC in patients with UC (n=30).   
 
 
 
3.12 Few Lamina Propria CD11c- cells from Ulcerative Colitis Express TLR-2 
 and TLR-4 
 
In addition, very few CD11c- cells expressed pattern recognition molecules, TLR-2 
(CD11c- 3±1% versus CD11c+ 14±3%; p<0.05) and TLR-4 (CD11c- 3±1% versus CD11c+ 
12±2%; p<0.05) compared with their CD11c+ counterparts in UC patients (Figure 3.13).  
Although there was no statistical significant difference between the level of expression 
(PIR) of TLR-2 and TLR-4 between CD11c- and CD11c+ cells, there was a trend towards 
lower intensity of TLR expression on CD11c- cells compared with CD11c+ DC. When the 
level of staining is low as seen with the TLR, the subtraction method used to generate the 
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PIR may underestimate the true value. There was no significant difference between the 
proportion of CD11c- TLR-2+ and CD11c- TLR-4+ cells between UC patients and controls 
(data not shown). Overall, the percentage of expression and level of staining of CD40, 
CD86, TLR-2 and TLR-4 on CD11c- cells were lower compared with their CD11c+ 
counterparts but these data were more convincing for CD40 and CD86 compared to TLR-
2 and TLR-4. 
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Figure 3.13: Percentage and level of expression of TLR-2 and TLR-4 on CD11c- cells and 
CD11c+ DC in UC. This figure shows (A) percentage of staining and (B) level of staining  
expressed as PIR of TLR-2 and TLR-4 on colonic CD11c- cells and CD11c+ DC in UC patients 
(n=30).   
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3.13 Most Lamina Propria CD11c- HLA-DR+ lineage-/dim cells Express CD56 in 
 Ulcerative Colitis 
 
A major subset of the CD11c- HLA-DR+ lin-/dim cells stained brightly for the NK cell 
marker, CD56 (Figure 3.14A). A similar proportion was CD56bright in cells extracted from 
UC and healthy tissue (Figure 3.14B). However there was a significant increase in the 
number of CD11c- CD56+ cells extracted from the inflamed colonic tissue of UC patients 
and a non-significant trend towards increased numbers in the small number of samples of 
non-inflamed UC tissue examined compared with control tissue (Figure 3.14C).  
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Figure 3.14: Expression of CD56 on colonic CD11c- cells  (A) One-parameter histogram 
showing the expression of CD56 on CD11c- cells in UC. On the left is the matched isotype control. 
The PIR represents the intensity of staining after subtraction from the isotype control. Results are 
representative of 8 experiments; (B) The proportion of CD56+ CD11c- cells in UC and controls; 
(C) The absolute number of CD56+ CD11c- cells in active UC, inactive UC and controls; (D) 
Expression of CD3 and CD56 on colonic CD11c- cells in control and UC. Left hand panel (in blue) 
indicates the isotype control (representative of 3 experiments). 
 
 
3.14 CD56+ CD11c- HLA-DR+ lineage-/dim Cells are Scattered throughout the 
 HLA-DR versus Lineage Plot 
 
Backgating of total CD56bright cells in LPMC onto the HLA-DR versus lineage plot 
demonstrated that only a minority of CD56bright cells were HLA-DR+ and fell within the 
HLA-DR+  lin-/dim gate. The majority of CD56bright cells were HLA-DR- and either lin- or 
lindim, presumably representing a mixture of conventional NK cells and NK T cells.  This 
backgating also confirmed that CD56bright cells were scattered throughout the plot and did 
not represent a population inadvertently captured at the margins of the gate (Figure 3.15).  
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Figure 3.15: Backgating of CD56+ CD11c- cells on HLA-DR versus lineage Plot. The left panel 
shows the isotype control for CD56, middle panel shows the staining of CD56 on CD11c- cells 
(red area)  in a UC patient. Right panel demonstrates backgating of the CD56+ CD11- cells on 
HLA-DR lineage plot (red dots). 
 
 
We next determined whether these cells expressed other NK cell markers. In active UC, a 
proportion of lamina propria CD11c- cells expressed CD161 and NKG2D, but the majority 
lacked expression of NKp30 or NKp44 (Figure 3.16). Positive labeling of cells within the 
lymphocyte light scatter gate was used to provide controls for all antibodies. We were 
unable to examine co-expression of NK cell markers due to limitation of the four colour 
flow cytometer. 
 
Overall these data suggest that inflammation in UC is associated with the presence in the 
colon of a previously undescribed atypical population of cells which shares features of DC 
and NK cells.  In addition a population of CD56- CD11c-HLA-DR+lin-/dim is also increased 
in number in UC and remains to be further characterized. 
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Figure 3.16:  Examples of expression of NK cell markers on CD11c- cells from UC. This 
figure shows examples of expression of NK cells markers: NKG2D, NKp30, NKp44 and CD161 
on CD11c- cells extracted from UC tissue. Shaded area towards the right of isotype control 
represents percentage positive cells. 
 
 
 
3.15 Functional Attributes of Lamina Propria CD11c- Cells 
 
3.15.1 Lamina propria CD11c- HLA-DR+ lin-/dim cells are Weak Stimulators of 
 Allogeneic T cell Proliferation 
 
The T cell stimulatory capacity of CD11c- HLA-DR+ lin-/dim cells was tested in an 
allogeneic MLR.  Sorted intestinal CD11c- population extracted from UC tissue as shown 
in Figure 3.17A were used to stimulate naive T cells. We also assessed the stimulatory 
capacity of LPMC (whole cells extracted from UC tissue) and enriched DC population 
(Low density cells - LDC) obtained from peripheral blood of healthy controls; the latter 
acts as positive control for our experiment. Naïve CD4+ T cells were used as responder 
cells in all stimulation experiments. Preparation of enriched DC population or LDC has 
been described in methods under section 2.2.7. LDC were obtained from PBMC using 
100 101 102 103 104
mIgG1
0
10
0
20
0
30
0
40
0
50
0
N
um
be
r
R8
100 101 102 103 104
NKG2D
0
50
10
0
15
0
20
0
25
0
30
0
35
0
N
um
be
r
R18
100 101 102 103 104
mIgG1
0
20
40
60
80
10
0
12
0
N
um
be
r
R8
100 101 102 103 104
NKp30
0
20
40
60
80
10
0
12
0
N
um
be
r
R18
NKG2DmIgG1
NKp30mIgG1
100 101 102 103 104
CD161
0
20
40
60
80
N
um
be
r
R18
100 101 102 103 104
mIgG1
0
20
40
60
80
10
0
12
0
N
um
be
r
R8
CD161mIgG1
100 101 102 103 104
mIgG1
0
20
40
60
80
10
0
12
0
N
um
be
r
R8
100 101 102 103 104
NKp30
0
20
40
60
80
10
0
12
0
N
um
be
r
R18
NKp44mIgG1
0
10
0
20
0
30
0
40
0
50
0
N
um
be
r
0
50
10
0
15
0
20
0
25
0
30
0
35
0
N
um
be
r
0
20
40
60
80
10
0
12
0
N
um
be
r
0
20
40
60
80
10
0
12
0
N
um
be
r
0
20
40
60
80
N
um
be
r
0
20
40
60
80
10
0
12
0
N
um
be
r
0
20
40
60
80
10
0
12
0
N
um
be
r
0
20
40
60
80
10
0
12
0
N
um
be
r
158 
 
nycoprep.  There was a dose dependent proliferation stimulated by blood LDC and by an 
unfractionated LPMC population. Proliferation was also detectable in cultures stimulated 
by the sorted CD11c- population (>3x background) although the number of proliferating 
cells was lower than in cultures stimulated either by LDC or unfractionated LPMC 
(Figure 3.17). Thus, consistent with their low expression of costimulatory molecules, 
CD11c- HLA-DR+ lin-/dim cells were probably weak stimulators of T cell proliferation.  
However, low numbers of the sorted CD11c- population precluded a detailed dosimetric 
analysis that would have dissected this response further. 
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Figure 3.17: Stimulation of allogenic T cell proliferation by sorted colonic CD11c- cells from 
inflamed tissue of a UC patient. (A) The two-parameter histograms of HLA-DR and lineage 
(CD3, CD14, CD16. CD19, CD34) indicate the cells before and after the sorting process. The 
single-parameter histogram of CD11c indicates the expression of CD11c on these cells, which 
consist mainly of CD11c- cells post sort. (B) Medium only (No DC), sorted colonic CD11c- HLA-
DR+ lineage-/dim cells, unfractionated LPMC, and blood LDC, were cultured for 5 days in round-
bottom well plates with CFSE-labelled CD4+ naïve T cells (Figure representative of 2 independent 
experiments). Numbers in bold indicate the absolute number of dividing cells per well, percentage 
figures indicate the proportion of plotted cells that are dividing (C) The absolute numbers of 
proliferating cells per well, by sorted CD11c- cells, and three different concentrations of LPMC 
and LDC are shown in this bar chart. 
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3.15.2 Lamina propria CD11c- HLA-DR+ lin-/dim Cells are Poor Spontaneous Producers 
of IL-12p40 and IL-6 
 
Ongoing intracellular cytokine production of IL-10, IL-12p40, IL-6 and IL-13 by colonic 
CD11c- cells was assessed in the absence of exogenous stimulation. We examined these 
cytokines as previous work from our group showed that DC production of IL-10, IL-
12p40 and IL-6 were altered in patients with CD (Hart et al., 2005). We also measured IL-
13 as lamina propria T cells from UC patients produced greater IL-13 than control cells 
(Fuss et al., 2004). An example of the method used to determine cytokine production has 
been described in detail in Section 2.2.12 (iii). Compared with the CD11c+ DC, a smaller 
proportion of CD11c- cells produced IL-12p40 (CD11c- 18±9% versus CD11c+ 50±10%; 
p<0.05) in patients with UC. No IL-6 was detected in the CD11c- cells (-44±19%) when 
compared with the CD11c+ cells (43±19%; p<0.05) (Figure 3.18). There was however no 
significant difference between the proportion of IL-10 and IL-13 producing CD11c+ and 
CD11c- cells.  In addition, there was no significant difference in the proportion of CD11c- 
cells producing IL-10, IL-12p40, IL-6 and IL-13 between patients with UC and healthy 
controls (data not shown). 
 
We have only assessed the production of IL-10, IL-12p40, IL-6 and IL-13 by CD11c- cells 
and future work should involve the proteomic analysis of additional pro-inflammatory 
cytokines such as IL-1β and IL-8 . 
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Figure 3.18:  Percentage of cytokine production by CD11c- cells compared with CD11c+ DC 
in UC.  Cytokine production by DC was assessed by intracellular cytokine staining and Super-
enhanced Dmax normalised subtraction. The bar chart shows the mean percentage from pooled data 
of IL-12p40, IL-6, IL-10 and IL-13 production by CD11c- cells and CD11c+ DC in UC patients 
(n=30). When more “positive events” in the control histogram were detected compared with test 
histogram, subtraction was reversed with the generation of negative events in the test histogram.  
 
 
 
3.15.3 Lamina Propria CD56+ CD11c- HLA-DR+ lin-/dim Cells are Non-Stimulatory 
 
In preliminary experiments, the T cell stimulatory capacity of sorted CD56+ CD11c- HLA-
DR+ lineage-/dim cells was tested in an allogenic MLR.  The sorted CD56+ CD11c-  
population from colonic tissue of UC patient, and LDC enriched for DC, were used as 
stimulator cells, and naïve CD4+ T cells as responder cells.  There was no proliferation in 
the medium only culture, and minimal proliferation in cultures stimulated by CD56+ 
CD11c- cells. Conversely, proliferation was detectable in cultures stimulated by blood 
LDC (X2 more than CD56+ CD11c- culture).  The number of proliferating cells was also 
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lower in cultures stimulated by CD56+ CD11c- cells compared with LDC, but this was 
comparable with cultures with medium only (Figure 3.19). This suggested that CD56+ 
CD11c- cells are most likely non-stimulatory. However, low numbers of the sorted 
population again precluded a detailed dosimetric analysis that would have analysed this 
response further. 
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Figure 3.19: Stimulation of allogeneic T cell proliferation by colonic CD56+ CD11c- cells from 
UC. (A) Medium only (1st panel), sorted colonic CD56+ CD11c- HLA-DR+ lineage-/dim cells (2nd 
panel), and blood LDC (3rd panel) were cultured for 5 days in round-bottom well plates with 
CFSE-labelled CD4+ naïve T cells (Figure representative of 2 independent experiments). Numbers 
in bold indicate the absolute number of dividing cells per well, percentage figures indicate the 
proportion of plotted cells that are dividing. (B) Absolute numbers of proliferating cells per well, 
by three different concentrations of sorted CD56+ CD11c- cells and LDC. 
 
 
 
3.16 Discussion 
 
We have previously shown that intestinal CD11c+ DC are altered in IBD; and that more 
CD11c+ DC expressed CD40 and CD86 in CD than controls (Hart et al., 2005). The role 
of intestinal CD11c- cells falling within the DC gate in IBD remains unclear. Here we 
have identified increased number of CD11c- cells in tissues from UC patients compared 
with controls. Absolute number analysis demonstrated that there was a real increase of 
CD11c- cells in the colon of UC rather than a loss of the CD11c+ population. Patients with 
quiescent (macroscopically normal intestine) and active (macroscopically inflamed 
intestine) UC were included, and both demonstrated an increase in this subset of cells. 
Endoscopic and histological intestinal inflammation have been shown to be risk factors for 
dysplasia and potentially colorectal cancer in patients with long standing UC (Gupta et al., 
2007; Rutter et al., 2004),  analysis of CD11c- cells in apparently quiescent disease 
required further investigation in this regard.  
 
Increased CD11c- cells in inflamed UC tissue subsequently reduced in number when 
inflammation resolved, while number of CD11c+ DC was unchanged. Altogether these 
data suggested that CD11c- cells may be markers of intestinal inflammation.  In addition, 
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we established that CD11c- cells were also increased in CD suggesting that they are 
associated with intestinal inflammation and not specific to UC. Alterations in colonic 
CD11c- cells were unlikely to be secondary to concurrent treatment as patients have been 
on stable doses of medication although we were not able to exclude the possibilities of the 
accumulative effects of therapy on these cells. 
 
During inflammation, the composition of cells resident in the intestinal mucosa is 
enormously altered. Infiltration of large numbers of T cells, monocytes, macrophages and 
DC into inflamed mucosa has been described in IBD patients (Boirivant et al., 1999; 
Schreiber, 2001; Seegert et al., 2001; Zareie et al., 2001). Inflamed IBD mucosa contains 
an increased number of CD4+ CD25+ Foxp3+ T cells, although this increase was 
significantly lower compared with other inflammatory controls  (Maul et al., 2005). More 
mature myeloid DC, that expressed CCR7, have also been found trapped at site of 
inflammation in CD (te Velde et al., 2003).  
 
CD11c- cells demonstrated some features of DC. Firstly, they expressed MHC class II and 
had morphological features of DC. The expression of HLA-DR by CD11c- cells suggested 
that they may function as APC.  CD11c- cells from UC tissue had a less mature phenotype 
than their CD11c+ counterparts. Consistent with their lack of co-stimulatory marker 
expression CD11c- DR+ lin- cells were poor stimulators of proliferative T cell responses. It 
is conceivable that presentation of antigen by this population in the absence of co-
stimulation may lead to the induction of regulatory response but we have yet to examine 
this possibility.  
 
165 
 
We examined DC cell surface expression of TLR-2, a receptor for peptidoglycan and 
lipoproteins from gram positive bacteria (Michelsen et al., 2001; Schwandner et al., 1999) 
and TLR-4, which interacts with LPS from gram negative bacteria (Chow et al., 1999) and 
found little expression of these markers on CD11c- cells.  Limited DC cell surface 
expression of TLR-2 and TLR-4 on CD11c- cells suggest that they may play a less direct 
role in bacterial recognition, compared to the CD11c+ cells, although we have not assessed 
other TLR such as TLR-9.. We studied, in particularly, these TLR as they have been 
shown to be activated in IBD (Hart et al., 2005). Functional studies on the small numbers 
of human intestinal CD11c- cells showed that they were poor producers of IL-12p40 and 
IL-6 but weakly stimulated T cells. The extraction of DC from the human lamina propria 
can be challenging and low numbers of the sorted population precluded a detailed 
dosimetric analysis that would have dissected the stimulatory response further.  It remains 
possible that larger numbers of sorted CD11c- CD56+ cells would reveal the potential 
stimulatory capacity of these cells. 
 
In peripheral blood CD11c- HLA-DR+ lin-/dim cells are predominantly plasmacytoid DC. 
Here very few CD11c- cells from UC tissue expressed CD123 and BDCA-2 (Colonna et 
al., 2004), suggesting that they formed a population distinct from blood plasmacytoid DC. 
Flow cytometry and immunofluorescence staining of sorted CD11c- cells indicated that 
majority of the colonic CD11c- HLA-DR+ lin-/dim cells were not typical plasmacytoid DC. 
Control experiments on blood DC confirmed that lack of plasmacytoid markers on colonic 
DC was not an artefact of enzyme digestion or tissue processing. Permeabilization of 
colonic DC before labelling did not increase the staining with anti-BDCA2 antibody, 
arguing against intracellular redistribution of this marker.  Middel et al. have shown that 
there were no significant differences in the number or distribution of plasmacytoid DC 
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between controls and colonic tissue affected by CD (Middel et al., 2006). The 
plasmacytoid DC were randomly distributed within the submucosa and lamina propria and 
were not associated with T cell clusters, suggesting that plasmacytoid DC from affected 
tissue of CD are less likely to play a significant role in antigen presentation or T cell 
stimulation (Middel et al., 2006; Neurath et al., 2002). Reports of NK cell neoplasms 
characterised by a CD3-/CD4-/CD56+/CD13-/CD33- phenotype, thought to be derived from 
plasmacytoid DC rather than NK cells have been described (Chaperot et al., 2001; Herling 
et al., 2003; Siu et al., 2002).  
 
A high proportion of CD11c- cells from patients with UC stained brightly for the NK cell 
marker, CD56, and there were elevated numbers of CD11c- CD56+ cells in UC tissue 
compared with control tissue.  CD56 defines functionally distinct subsets of NK and T 
cells (Miranti and Brugge, 2002). In humans, NK cells are characterised phenotypically by 
the presence of CD56 and lack of CD3, phenotypic features which is consistent with the 
cells described here.  However, their low expression of other NK cell markers including 
NKG2D, NKp30 or NKp44 suggested that they may not represent traditional NK cells. 
 
We found both CD56bright and CD56dim CD11c- cells in UC tissue, but increased numbers 
of the former; it is possible that CD56bright cells differentiate to CD56dim cells with 
resolution of inflammation.  In this regard, expansion of CD56bright  human NK cells have 
been described at sites of inflammation (Dalbeth et al., 2004). It has been proposed that 
CD56dim NK cells, upon differentiation from CD56bright NK cells in the periphery, alter 
chemokine receptor expression and consequently leave inflammatory sites and lymphoid 
tissue to “re-enter” the peripheral circulation (Chan et al., 2007). The physiologic site of 
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CD56+ CD11c- cells in the inflamed human mucosa provides a framework for the pursuit 
of further studies on this novel population.  
 
NK cells have also been reported as the first immune effector cells to arrive at sites of 
inflammation (Mailliard et al., 2005; Mandelboim et al., 2001; Martin-Fontecha et al., 
2004). Increased localization of these cells in inflamed non-lymphoid peripheral organs, 
including the lungs, liver and intestine suggest that they may stimulate effector T cells 
(Fehniger et al., 2003; Ferlazzo et al., 2004; Hanna et al., 2003). Other authors have, in 
vivo, reported that NK cells are able to express MHC class II and T cell receptor co-
stimulatory molecules.  Of interest, activated NK cells with antigen presenting cell-like 
phenotype, can “fine-tune” T cell activation, when there is direct insult to the peripheral 
organs (Hanna et al., 2004).  
 
Accumulating data also suggest a potential overlap in phenotypic and functional 
characteristics between NK cells and DC. For instance, in mouse autoimmune diabetes 
model, a unique regulatory DC subset that express NK specific marker DX5 (bitypic 
DC/NK cells) but lack basic NK cell functions has been described (Homann et al., 2002), 
whilst Hanna et al. showed that human NK cells from tonsils and uterine decidual samples 
have APC-liked properties and can directly regulate T cell activation (Hanna et al., 2004). 
We have compared our cell population with several recently described NK cells in the 
intestine, and showed that they shared similar phenotype of CD3-, CD56+ and CD16-.  In 
contrast, our cells are HLA-DRbright and lin-, and lacked expression of other NK cells 
markers. We have not examined their production of IL-22. Several studies have reported 
the presence of intestinal lamina propria NK cells (CD3-, CD56+, CD16- and NKp46+) that 
produced IL-22 in the healthy mouse and human tissues (Cella et al., 2009; Luci et al., 
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2009; Mela et al., 2007; Sanos et al., 2009). To the best of our knowledge only one study 
has studied NK cells in inflamed Crohn’s tissue; these cells were CD3-, CD56+, Lin-, c kit+ 
and secrete IFN-γ (Chinen et al., 2007). Our cell population from inflamed and non-
inflamed IBD tissue share similar phenotypic characteristics (CD3-, CD56+, CD16-, Lin-) 
and weakly stimulate naïve T cells.  
 
In patients with human immunodeficiency virus (HIV) lamina propria and intraepithelial 
NK cells in the intestine have been reported to have distinct phenotype compared with 
those in the peripheral blood.  The majority of CD3- CD56+ cells in healthy and HIV-1 
infected colonic and duodenal lamina propria lacked CD16 (Mela et al., 2007).  These 
intestinal NK cells expressed natural cytotoxicity receptors, NKp44 and NKp46, but 
lacked CD16, suggestive of their helper functions.  The helper functions of lamina propria 
NK cells have been described by other investigators (Chinen et al., 2007; Leon et al., 
2003). Lamina propria NK cells may differentiate in response to infection or inflammatory 
mediators. 
 
Recently a CD56+ NKp44+ NK cell subset that produced IL-22 and IL-26 and induced 
epithelial cell proliferation and IL-10 secretion has been demonstrated in the human small 
intestine (Cella et al., 2009), whereas NKp46+ CD3- NK cells that co-express RORγt and 
produced IL-22 in response to signals from commensal microflora, have been identified in 
the murine intestine (Colonna, 2009; Sanos et al., 2009). 
 
Fuss et al. found that LPMCs from inflamed tissue of UC patients contain CD4+ cells that 
express CD161, but lacked expression of invariant NKT cell receptors, and produced 
increased IL-13 and IL-5 (Fuss et al., 2004). In our study, the cell population of interest 
from inflamed UC tissue were CD3- and CD161-, they are therefore, by definition, not 
169 
 
conventional NKT cells. The morphology of the CD11c- cells is more consistent with that 
of immature DC than T cells. 
 
We speculate that lamina propria CD56+ CD11- cells may have several functions in UC. 
Human NK cells with antigen presenting cell-liked features have been shown to regulate T 
cell activation (Hanna et al., 2004), express MHC class II and T cell receptor co-
stimulatory molecules in vivo.,  as well as “fine-tune” T cell activation when there is direct 
insult to the peripheral organs (Hanna et al., 2003). When activated, human NK cells 
express MHC class II and have the ability to present antigens directly and stimulate CD4+ 
T cell proliferation in vitro (Hanna et al., 2004). The human intestinal NK cells examined 
here were weakly stimulatory, but could become stimulatory after appropriate activation. 
Given that CD56+ CD11c- cells were poorly stimulatory and few produced cytokine, it is 
conceivable, although speculative, that they may play a role in intestinal tissue repair in 
acute UC; or the generation of T regulatory cells. The latter function will need to be 
determined in further experiments. NK cells have been shown to have a protective role in 
supporting tissue repair and promoting adaptive immune responses (Martin-Fontecha et 
al., 2004). 
 
One possibility is that CD11c- cells may be precursors of CD11c+ DC, and that in the gut, 
CD11c- cells become CD11c+ DC following stimulation with inflammatory cytokine and / 
or bacterial components.  Alternatively, CD56+ CD11c- cells may have migrated from 
peripheral blood to the lamina propria in response to homing signals secreted by epithelial 
cells under inflammatory conditions. In the peripheral blood human NK cells express α4β7 
which enable them to recirculate to intestinal lamina propria (Perez-Villar et al., 1996). 
α4β7 is detected on the majority of CD3- CD56+ lamina propria NK cells and the integrin 
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αE (CD103) is expressed on only a small proportion of CD3- CD56+ lamina propria NK 
cells (Chinen et al., 2007; Leon et al., 2003). 
 
Unlike CD11c+ HLA-DR+lin- cells, CD11c- cells did not produce IL-10, IL-12p40, IL-6 or 
IL-13, and so are less likely to contribute to the pathogenesis of IBD in this way. We 
hypothesise that the gut microenvironment including its endogenous commensal and 
pathogenic microbes play a role in controlling NK cell response. Whilst one subset of 
lamina propria NK cells may act to promote pathogen specific immune responses to 
enhance Th1 response via the production of IFN-γ, another subset may be involved in 
innate immunity and have a “repair” function by regenerating the intestinal epithelial 
barrier. The distinct subset of CD56+ CD11c- cells described here may be involved in the 
latter function, to limit the already established inflammation in IBD. 
 
In conclusion, we have reported an increase in a newly-defined distinct subset of immune 
cells in the inflamed colonic tissue of UC patients.  These cells morphologically resemble 
conventional immature DC, express MHC class II molecules, and are CD56bright . Ex vivo 
CD11c- cells can weakly stimulate naïve T cells.  These cells may represent a functionally 
distinct cell subset in intestinal inflammation, different to previously described NK cells, 
and their potential role in immunoregulation or tissue repair warrants further 
investigations. 
. 
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Chapter 4 
 
Cytokine Production by Colonic Myeloid Dendritic Cells in 
Active Ulcerative Colitis and Crohn’s Disease 
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 4.1 Abstract 
 
Introduction: Altered DC function, associated with dysregulated cytokine production, is 
likely to contribute to the altered response to bacteria that drives inflammation in IBD. We 
hypothesize that DC function varies between different stages of inflammatory disease and 
that their function correlates with disease activity and the intestinal microbiota in IBD. We 
assessed intracellular cytokine production by DC and faecal microbiota in patients with 
active IBD. 
Methods: CD11c+ DC were identified by multi-colour flow cytometry of cells extracted 
from collagenase digested intestinal tissue from patients with UC (n=28), CD (n=28) and 
controls (n=12). Spontaneous IL-10, IL-12, IL-6, and IL-13 production by lamina propria 
DC and lymphocytes was measured by intracellular staining of permeabilised cells in the 
absence of exogenous stimulation. Intestinal microbiota were analysed by fluorescent in 
situ hybridisation of fresh faecal samples using a DNA stain to detect total bacterial cells 
and oligonucleotide probes targeting 16S rRNA of bifidobacteria, bacteroides, C. 
coccoides-E. rectale and Faecalibacterium praustnitzii. 
Results:  In acute UC, a significantly greater proportion of CD11c+ DC produced IL-10 
and IL-12p40 than cells from control tissue. Level of staining of IL-10 and IL-12p40 by 
CD11c+ DC was also significantly greater in UC. In active CD, IL-12p40+ DC increased 
and correlated positively with the ratio of pro:anti inflammatory bacteria, namely 
bacteroides:bifidobacteria. In CD, the proportion of IL-6+ DC increased and correlated 
with the Crohn’s disease Activity Index and serum C-reactive protein, but negatively with 
anti-inflammatory Faecalibacterium praustnitzii. 
Conclusions: Acute UC is associated with increased IL-10 and IL-12p40 production by 
DC. Bacterially-driven local IL-6 production by intestinal DC may overcome regulatory 
activity and lead to unopposed effector function and tissue damage in CD.  The balance of 
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pro-inflammatory and immuno-regulatory luminal microbiota is associated with altered 
mucosal DC function in patients with CD, supporting the concept that intestinal DC 
function is influenced by the composition of the commensal microbiota. 
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4.2 Introduction 
 
In Chapter 3, we have shown that human colonic CD11c- cells are increased in IBD, and 
we have further characterised this novel population. The numbers of the CD11c+ cells 
were however not different between IBD patients and controls. We therefore aim to 
determine whether the functions of CD11c+ cells differ between IBD and controls. 
Secondly, we wish to assess whether these functional characteristics correlate with disease 
phenotype and gut microbiota in patients with IBD. Human colonic CD11c+ cells have 
been previously classified as myeloid DC based on morphology, phenotype and functions 
(Bell et al., 2001). Functionally, these cells displayed endocytic activities, which was 
intermediate between that of lymphocytes (non-endocytic) and monocytes (highly 
endocytic), and they were potent stimulators of a primary allogeneic leukocyte reaction 
upon maturation (Bell et al., 2001).   
 
UC and CD are heterogenous disorders. Clinicopathologic and genetic differences 
between patient subsets may reflect diverse immunological profiles (Baumgart and 
Carding, 2007). Cytokine profile is likely to be different between the early and late phases 
of disease progression in IBD (Spencer et al., 2002). This hypothesis has been 
demonstrated in animal models of colitis (Spencer et al., 2002). Although early colonic 
lesions displayed a mucosal cytokine pattern that involved high levels of TNF-α and IL-
12, these cytokines were almost undetectable in the late phases of experimental colitis and 
ileitis. In IL-10-deficient mice, LPMC synthesized large amounts of IL-12 and IFN-γ in 
early colitis.  The production of both cytokines dramatically declined and returned to pre-
disease levels in the late phase of colitis, whereas IL-4 and IL-13 production increased 
progressively from pre-, to early to late disease, indicating that other immune mechanisms 
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sustained chronic inflammation (Spencer et al., 2002). Furthermore a distinct cytokine 
pattern profile has been detected in early and chronic ileal lesions of adult patients with 
CD (Desreumaux et al., 1997). For example, early ileal lesions of patients with CD were 
associated with a marked increase of IL-4 mRNA and a decrease of IFN-γ mRNA 
compared with the normal mucosa of patients with CD or controls, whereas a Th1-type 
pattern was observed in the chronic ileal lesions. These observations strongly support the 
concept that disease varies according to its clinical course and stage (Desreumaux et al., 
1997).  
 
Work from our laboratory has previously shown that in a small group of patients with CD, 
more myeloid colonic DC produced pathologically relevant cytokines including IL-6 and 
IL-12p40 than control DC. Conversely, in patients with chronic active UC, there was no 
difference between IL-12p40 and IL-6 production from myeloid colonic DC, compared 
with control DC (Hart et al., 2005). 
 
Following encounter with antigens, Th lymphocytes differentiate into Th1, Th2 or Th17 
effector populations under the influence of the local cytokine milieu and following 
activation by DC (Maloy and Kullberg, 2008). Strict Th1 polarization has been thought to 
underlie the pathogenesis of inflammation in CD, supported by high levels of IFN-γ, IL-12 
and TNF-α (Fuss et al., 1996; Monteleone et al., 1997). In contrast, UC was thought to 
display a tendency towards Th2 polarization with upregulation of IL-5, and the lack of 
IFN-γ and IL-4. This concept of Th1/CD versus Th2/UC polarization has been challenged 
by studies that described increased IL-4 and IL-5 in CD (Desreumaux et al., 1997), and 
Th1-related cytokines in UC (Sawa et al., 2003; Tsukada et al., 2002).  Recently, an 
additional subset, known as Th17 cells, associated with the cytokine IL-23, has further 
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illustrated the complexity and diversity of effector CD4 + T cells in IBD (Maloy and 
Kullberg, 2008). Although originally thought to have a deleterious role in autoimmune 
tissue pathology, the IL-23 / Th17 axis has now been associated with protective immunity 
at mucosal surfaces (Ahern et al., 2008; Maloy, 2008). 
 
We hypothesize that distinct cytokine production by DC favours the dominance of effector 
responses in human IBD. These responses are influenced by the stage and activity of 
disease. In the first part of this chapter, we assessed global cytokine production from 
intestinal tissue which involved examination of production of cytokines from the 
supernatant of LPMC cultured overnight from patients with IBD, irritable bowel syndrome 
(IBS) and healthy controls using multiplex ELISA. Diagnosis of patients with IBS were 
confirmed based on the ROME III criteria for functional bowel disorders (Drossman and 
Dumitrascu, 2006; Thompson et al., 1999).   
 
In the second part of the experiments, we analysed specific cytokines produced by lamina 
propria myeloid DC from tissues of patients with active IBD and healthy controls. Studies 
in rodents showed that intestinal bacterial composition changed with colonic inflammation 
(Lupp et al., 2007). In human IBD, faecal and mucosa-associated microbial communities 
are consistently less diverse with increased temporal instability (Dicksved et al., 2008; 
Martinez et al., 2008; Ott et al., 2008) and reduced Bacteroidetes and Firmicutes (Frank et 
al., 2007; Swidsinski et al., 2008). Altered microbial composition can increase immune 
stimulation, in particularly by DC. Whether the commensal microbiota influence DC 
function in patients with IBD remains unknown. Hence, in patients with active CD, we 
correlated DC cytokine changes with both disease activity and the intestinal microbiota. 
Patients examined in this chapter represent a well defined group of patients recruited into a 
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therapeutic intervention trial of probiotics (UC) and prebiotics (CD). Results presented 
here are data before any therapeutic intervention. 
 
4.3 Aims 
 
-  To assess global cytokine production by LPMC from patients with IBD, 
 functional bowel disorders and healthy controls. 
- To assess ongoing production of intracellular IL-10, IL-12p40, IL-6 and IL-13 by 
lamina  propria DC in patients with IBD, and to correlate these changes with 
disease acitivity and intestinal microbiota. 
 
4.4 Patient Characteristics  
No of patients Age        Gender Medication          Disease
(mean) Male activity
Ulcerative colitis 28 44 12 5-ASA - 18           Mild to
AZA/6MP- 3           Moderate
None - 9
Crohn’s Disease 28 44 12 5-ASA - 13          Moderate
AZA/6MP- 21
Steroids - 4
None - 6
Irritable bowel 8 38 2 Nil -
syndrome
Controls 12 45 5 Nil -
5-ASA: 5-aminosalicylic acid
AZA:   azathioprine
6-MP: 6-mercaptopurine  
Table 11: Baseline characteristics of patients for cytokine analysis 
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4.5 Amount of Cytokine in Supernatants was not different between Colonic 
Tissues from Inflammatory Bowel Disease, Irritable Bowel Syndrome and 
Controls 
 
To obtain a global assessment of cytokine production, ten cytokines (IL-6, IL-8, IL-2, IL-
12p70, IL-1β, IFN-γ, TNF-α, IL-10, IL-4, IL-5) were measured from supernatants of 
tissue cultured overnight in medium from patients with IBD, IBS, and controls, using a 
Multiple ELISA kit as described in section 2.2.9. Figure 4.1 showed an example of the 
measurement of cytokine on flow cytometry. The quantities of cytokine in the 
supernantant were determined against a standard curve for known concentrations of that 
cytokine. The amount of cytokine production was corrected for tissue weight. 
 
 
 
(I)       (II) 
 
  
 
 
 
 
 
 
 
Figure 4.1: Multiplex ELISA of cytokines from supernatant measured by flow-cytometry. (I) 
Two distinct bead populations (A and B) were identifiable based on size and granularity; (II) Both 
bead populations (A and B) contain 5 different bead subsets with distinct FL3 fluorescence 
profiles. Each bead subset is coated with a different anti-cytokine antibody. On FL2 signal strength 
indicates amount of cytokine detected in sample. 
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In patients with UC, CD, IBS and controls, there were no significant differences between 
the four groups for any of the cytokines examined. IL-1β, IL-10 and IL-6, were detected in 
all gut biopsies from patients with UC, CD, IBS and controls. We speculated that these 
cytokines may be associated with “tissue trauma”. However, as this method of cytokine 
assessment showed no difference between inflammatory bowel disease and control tissues, 
we proceeded to a more specific approach by assessing the amount of ongoing cytokine 
produced by DC.  
 
 
 
4.6 More Colonic CD11c+ Dendritic Cells Produce IL-10 and IL-12p40 in Acute 
Ulcerative Colitis than in Controls 
 
The technique used to assess cytokine production by lamina propria DC was initially 
developed in human peripheral blood and has been described in detail in section 2.2.12 
(Bell et al., 2001). Spontaneous intracellular cytokine production of IL-10, IL-12p40, IL-6 
and IL-13 by colonic DC was assessed in the absence of exogenous stimulation in patients 
with UC and controls.  Proportion of cytokine-positive cells was assessed by intracellular 
cytokine staining and SED normalized subtraction.  
 
In acute UC, a significantly greater proportion of CD11c+ DC produced IL-10 (median 
±SEM; 26±11%) and IL-12p40 (50±10%) than equivalent cells from control tissue where 
there was no detectable IL-10 (-39±12%; p<0.05) and IL-12p40 (-20±14%; p<0.05) 
production by DC. Although not statistically significant, there was a trend towards 
increased IL-6 production by CD11c+ DC in UC. It is possible that larger sample numbers 
may produce a significant result. In contrast, CD11c+ DC production of IL-13 did not 
differ significantly between patients with UC and controls (Figure 4.2).  
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We also assessed the intensity of cytokine staining. The level of cytokine staining 
expressed as a mean positive intensity ratio (PIR), of IL-10 (UC 2.2 ± 0.5 vs. controls 1.0 
± 0.4; p<0.05) and IL-12p40 (UC 1.5 ± 0.2 vs. controls 1.2 ± 0.4; p<0.05) by CD11c+ DC 
was also significantly greater in UC tissue than control tissue (Figure 4.3). Conversely, 
the level of staining did not differ for IL-6 and IL-13 between UC and control. 
 
 
Figure 4.2: Percentage of cytokine production by CD11c+ DC in acute UC and controls. 
LPMC were cultured in complete medium with and without monensin for 4 hours, surface labelled 
with monoclonal antibody, washed, fixed and permealised for intracellular cytokine staining. 
Enhanced normalised subtraction was used to assess the proportion of positively labelled cells (%) 
in the monensin treated cultures compared with non-treated cultures. By subtracting control 
histograms (no monensin) from test histograms the accumulation of cytokine was determined. 
Results are presented as ± cytokine percentage containing cells after subtraction. This method 
allows the measurement of loss and gain of function. In cases where secreted protein binds back to 
the surface of cell in the no monensin sample, this sample may contain cytokine positive cells. In 
such situation the subtraction process can be reversed to generate negative results. In this system, 
the control sample does not represent zero but represents a reference point on which to quantify the 
build up of cytokine in our test sample. It is therefore important to quantify the reduction in 
cytokine production compared with background control as labelling these negative results as zero 
would be inaccurate. This figure shows the percentage of IL-10, IL-12p40, IL-6 and IL-13 
  IL-10 IL-12p40 IL-6 IL-13
UC       Controls UC       Controls UC       Controls UC       Controls
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produced by CD11c+ DC in patients with active UC (n=28) and controls (n=10). Results are 
calculated as median ± SEM. P<0.05 is determined by paired students’s t test. 
 
 
 
 
Figure 4.3: Positive Intensity Ratio (IR) of cytokine in acute UC and controls.   
LPMC were cultured in complete medium with and without monensin for 4 hours, surface labelled 
with monoclonal antibody, washed, fixed and permealised for intracellular cytokine staining. 
Enhanced normalised subtraction was used to assess the level of staining expressed as positive 
intensity ratio (PIR) of labelled cells in the monensin treated cultures compared with non-treated 
cultures. This figure shows the PIR of IL-10, IL-12p40, IL-6 and IL-13 produced by CD11c+ DC 
in patients with active UC (n=28) and controls (n=10). 
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4.7 More Colonic CD11c+ DC Produce IL-12p40 in Active Crohn’s Disease 
 than Controls 
 
 
We compared the production of intracellular cytokine production by CD11c+ DC in 
patients with moderately active CD and healthy controls. These results represent the pre-
interventional data for patients with moderately active CD who were recruited into a 
placebo-controlled trial to assess the clinical, immunological and microbiological effects 
of a high fructo-oligosaccharide diet. Intracellular cytokine production post-treatment is 
part of an ongoing project. In patients with moderately active CD pre-intervention, 
significantly greater proportion of CD11c+ DC produced IL-12p40 (48±11%) than 
equivalent cells from control tissues (-30±11%; p<0.05).  CD11c+ DC from CD produced 
IL-10 and IL-6, but there was no significant difference between DC from CD and controls 
(IL-6: CD 29±8% versus control 23±21%, p=0.39; IL-10: CD 34±12% versus controls -
27± 12%; p=0.10) (Figure 4.4). The amount of IL-10, IL-6 and IL-12p40 staining by DC, 
measured as positive intensity ratio (PIR) was significantly increased in CD compared 
with controls (Figure 4.5). 
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Figure 4.4: Percentage cytokine production by CD11c+ DC in CD and controls 
This figure shows the percentage of IL-10, IL-12p40 and IL-6 produced by CD11c+ DC in patients 
with active CD (n=28) and controls (n=12). Results are calculated as median ± SEM. P<0.05 is 
determined by paired students’s t test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Positive Intensity Ratio (PIR) of cytokine in CD and controls 
This figure shows the PIR of IL-10, IL-12p40 and IL-6 produced by CD11c+ DC in patients with 
active CD (n=28) and controls (n=12). 
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4.8 Correlation of Dendritic Cell Cytokine Production with Crohn’s Disease 
 Phenotype and Disease Activity 
 
4.8.1 In Crohn’s Disease, Dendritic Cells Produce More IL-12p40 in Colonic  Disease 
 than Ileocolonic Disease 
 
For patients with CD, 17 patients had ileocolonic disease and 11 had colonic disease. 
There was significantly more IL-12p40 production by DC in patients with colonic CD 
compared with those with ileo-colonic disease (71% ±17 vs. 32%±14; p=0.037) but there 
was no difference for IL-10 or IL-6 by DC for disease site (data not shown). 
 
 
4.8.2 In Crohn’s Disease, Proportion of IL-6+ Dendritic Cell Correlates Positively with 
the Crohn’s Disease Activity Index (CDAI) 
 
The CDAI is a global measure of activity of CD, mainly in relation to luminal disease.  It 
incorporates eight variables: numbers of stools per day, severity of abdominal pain, 
general well-being, extraintestinal manifestation, abdominal mass, use of anti-diarrhoeal 
drugs, haematocrit and body weight. These items yield a composite score ranging from 0 
to 600. A score of <150 is generally regarded as reflecting clinical remission, whereas a 
score above 400 indicates severe disease (Best et al., 1976b). The proportion of IL-6+ DC 
showed positive correlation with the CDAI in patients with CD (Pearson correlation 
coefficient, r=0.425; p=0.024) (Figure 4.6A).   Pearson correlation was used for all 
normally distributed data. Although not statistically significant, the level of IL-6 staining 
by DC also showed a trend towards positive correlation with the CDAI (r=0.385; p=0.072) 
(Figure 4.6B).  Conversely, the proportion and staining of IL-10 and IL-12p40 on DC did 
not correlate with CDAI (data not shown). 
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Figure 4.6: Correlation between percentage and intensity of staining of IL-6+ DC and CDAI 
in patients with CD. Correlation curves between (A) the proportion IL-6+ DC and CDAI; (B) the 
positive intensity ratio of IL-6 and CDAI (n=28). PC: Pearson correlation. 
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4.8.3 In Crohn’s Disease, Level of IL-6 Staining on Dendritic Cells Correlates 
Positively with the Serum C-reactive Protein (CRP) 
 
The level of IL-6 staining on DC, but not the proportion of IL-6+ DC,  correlated 
positively with the serum CRP in patients with CD (Pearson correlation coefficient, 
r=0.643; p=0.004) (Figure 4.7). In contrast, the level of staining of IL-10 and IL-12p40 on 
DC did not correlate with CRP (data not shown). 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% IL-6+ DC
PC 0.195
P=0.370
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Figure 4.7: Correlation between percentage and level of staining of IL-6+ DC and CRP in 
patients with CD. Correlation curves between (A) the proportion IL-6+ DC and CRP; (B) the 
positive intensity ratio of IL-6 and CRP (n=28). 
 
 
4.9 Correlation of Dendritic Cell Function with Faecal Microbiota in  
 Crohn’s disease 
 
In patients with CD, the ratio of bacteroides:bifidobacteria in faecal samples correlated  
positively with the level of staining (PIR) of IL-12p40+ DC (Pearson correlation  
coefficient, r=0.535, p=0.003) (Figure 4.8A&B). The proportion of bifidobacteria  
correlated positively with PIR of IL-10+ DC  (r=0.395; p=0.038) (Figure 4.9).  
IL-6+ DC were detected in 21 of 28 patients with CD. Patients with IL-6+ DC had lower  
proportions of F. praustnitzii (6.4%±1.9) than those without  IL-6 producing DC  
(25.0%±11.0, p=0.013). Thus IL-6+ DC also correlated negatively with the proportion of  
F. praustnitzii (r=-0.50; p=0.008). (Figure 4.10). 
PC 0.643
P=0.004
Intensity Ratio 
IL-6
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A       B 
 
Figure 4.8 Correlation between Bacteroides:bifidobacteria and positive intensity ratio of  
IL-12p40+ DC. This figure shows correlation curves between the (A) ratio of bacteroides:  
bifidobacteria and PIR of IL-12p40+ colonic DC; (B) ratio of (bacteroides+EREC): bifidobacteria  
and PIR of IL-12p40+ colonic DC in patients with CD (n=28). Even when the two outliers with  
high levels of IL-12p40 staining were removed from analysis, the correlation coefficient and  
p value remain significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Correlation between the percentage of bifidobacteria and positive intensity ratio 
of IL-10+ DC in CD. This figure shows the correlation curve between the percentage of faecal 
bifidobacteria and positive intensity ratio of IL-10+ DC in patients with active CD (n=28). 
PC: 0.534
P=0.003
PC: 0.496
P=0.007
PC: 0.395
P=0.038
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A       B   
 
 
Figure 4.10: Correlation between the percentage of Faecalibacterium praustnitzii  
and percentage and PIR of IL-6+ DC in CD. (A) This figure shows a negative correlation curve 
between the percentage of faecal F. praustnitzii and percentage of IL-6+ DC in patients with active 
CD (n=28). (B) There was however no significant association between the percentage of F.  
praustnitzii and PIR of IL-6+ DC although there was a trend towards negative correlation. 
  
 
 
4.10 Discussion 
 
Cytokine production by human colonic DC is altered in IBD. Here we have shown that in 
acute UC there was increased production of both IL-10 and IL-12p40 by colonic myeloid 
DC compared with control DC, whereas in chronic active CD, IL-12+ DC increased, and 
IL-6+ DC correlated with both the disease activity and serum CRP. In addition, the balance 
of immunoregulatory and proinflammatory intestinal bacteria was associated with altered 
DC function in patients with CD. IL-12p40+ DC were associated with pro-inflammatory 
bacteroides, IL-10+ DC were associated with immunoregulatory bifidobacteria, and IL-6 
PC: -0.499
P=0.008
PC:-0.197
P=0.400
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correlated negatively with anti-inflammatory F. praustnitzii. We measured IL-10, IL-12p40 
and IL-6 as previous work from our group have shown that production of these cytokines 
were altered in patients with IBD (Hart et al., 2005). We also assessed IL-13 in UC as 
studies have shown that UC was characterised by Th2 response with increased IL-13 
production (Fuss et al., 2004; Heller et al., 2005b). These data have been achieved with 
limited numbers of DC extracted from human colonic tissue. 
 
One possible explanation for the raised IL-10 and IL-12p40 in acute UC is that in acute 
mucosal inflammation, IL-10 and IL-12p40 may act synergistically, and that IL-10 was 
insufficient to suppress the acute inflammatory response mediated by IL-12. Alternatively, 
IL-10 at high levels may have a pro-inflammatory effect (Furukawa et al., 1999; Santin et 
al., 2000). Synergism between production and effects of Th1 and Th2 cytokines has been 
described in animal studies (Kanai et al., 2006; Wirtz and Neurath, 2007). Cytokines exert 
their biological functions through Janus tyrosine kinases and STAT transcription factors. 
STAT3 was most strongly tyrosine phosphorylated in human UC and CD patients as well 
as in DSS-induced colitis in mice. Suzuki et al. showed that in transgenic mice, 
hyperactivation of STAT3 resulted in severe colitis. In UC, IL-10 may mediate signalling 
in the inflamed tissue via increased levels of STAT-3 (Suzuki et al., 2001).   
 
Both the proportion and amount of staining of IL-12p40+ DC were also increased in acute 
UC. This was in contrast to previous data in patients with chronic UC which showed no 
difference in the proportion of IL-12p40+ colonic DC when compared with controls (Hart 
et al., 2005).  A recent genome-wide association study has implicated the IL-10 gene as an 
important candidate gene in adult patients with UC. A single nucleotide polymorphishm 
rs3024505 of the IL-10 gene on chromosome 1q32.1 was associated with UC (Franke et 
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al., 2008); this association has now been extended to the paediatric population with CD 
(Amre et al., 2009), suggesting that defective IL-10 function is likely to be central to the 
pathogenesis of the UC. 
 
Using quantitative real-time RT-PCR, Melgar et al. have shown enhanced IL-10 mRNA 
levels in T lymphocytes in UC tissue which correlated with disease activity. IL-10 positive 
cells were scattered in the basal lymphoid aggregates in UC colon and increased number 
of these cells have been detected in the lamina propria (Melgar et al., 2003). In patients 
with UC, increased IL-10mRNA expression in the serum and colonic tissue have also been 
described (Kucharzik et al., 1995; Niessner and Volk, 1995). In vitro activation of human 
intestinal T cells also induced IL-10 production in lamina propria lymphocytes.  
 
IL-10 is involved in both cell-mediated and humoral immune responses. It has both pro-
inflammatory and anti-inflammatory effects. It is also a growth factor for down-regulatory 
Treg cells (Groux et al., 1997). Anti-inflammatory effects of IL-10 include the induction 
and maintenance of tolerance and appear to be executed through inhibiting the production 
of pro-inflammatory cytokines by T cells and APC (Fiorentino et al., 1991b; Fiorentino et 
al., 1991a). Pro-inflammatory actions of IL-10 have been reported in both man (Furukawa 
et al., 1999; Santin et al., 2000) and mice (Balasa and Sarvetnick, 1996; Wogensen et al., 
1993). For instance, in patients with CD treatment with recombinant human IL-10 induced 
IFN-γ production (Tilg et al., 2002). IL-10 might also induce a pro-inflammatory response 
instead of the inhibition of intestinal lamina propria lymphocytes in CD (Colpaert et al., 
2002). Altogether these data suggest that the consequences of IL-10 production are likely 
to be governed by the local milieu, the type of target cells as well as the concentration of 
the cytokine. 
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In animal models of colitis mucosal cytokines differ between the induction and 
maintenance phases of intestinal inflammation. In a SAMP1/YitFc mouse model of ileitis, 
the initiation of disease was Th1 mediated with upregulation of IFN-γ and TNF-α which 
preceded the histologic injury, whereas the establishment of chronic disease was 
characterised by increased IL-13 and IL-5 mRNA expression (Bamias et al., 2005). We 
measured DC IL-13 production in patients with UC given that non-classical IL-13 
producing NK T cells has been associated with UC (Fuss et al., 2004). Furthermore, IL-13 
has been implicated as a major mediator of intestinal fibrosis (Bamias et al., 2005; Wynn, 
2003). In an animal model of chronic 2,4,6-TNBS colitis, intestinal fibrosis was dependent 
on development of an IL-13 response by NKT cells (Fichtner-Feigl et al., 2007).  In our 
study there was lack of IL-13 production by DC. It remains possible that DC production of 
IL-13 may increase if measured in the later stages of UC inflammation, or that the cellular 
source of IL-13 is from NKT cells and not DC.  
 
Alex et al. used a comprehensive serum multiplex cytokine profiling with biometric 
immunosandwich ELISA to assess the modulation of Th1, Th2, Th17 cytokines in acute 
and chronic murine models of DSS and TNBS-induced colitis (Alex et al., 2008). In 
TNBS colitis, there was increased IL-12 and IL-17 production in chronic disease. In 
contrast, DSS colitis switched from a Th1/Th17-mediated acute inflammatory profile with 
high TNF-α, IL-6 and IL-17, to a predominant Th2-mediated inflammatory response with 
raised IL-4 and IL-10 and concomitant reduction in TNF-α, IL-6 and IL-17 in the chronic 
state. Thus distinctive disease-specific cytokine profiles correlated significantly with 
disease activity and duration (Alex et al., 2008). 
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In patients with CD, an increase in production of pro-inflammatory cytokines has been 
demonstrated (Fichtner-Feigl et al., 2007; Fuss et al., 1996).  Lamina propria T cells from 
inflamed CD mucosa showed increased IFN-γ secretion; this was due to an increased 
number of IFN-γ-secreting CD4+ T cells. In contrast, IL-2, IL-4 and IL-5 production by 
CD lamina propria T cells was decreased compared with that of control T cells (Fuss et 
al., 1996).  In cells from healthy controls, there were little or undetectable cytokine 
production by colonic DC suggesting a role of DC in maintaining tolerance in such an 
environment (Harper et al., 1996). DC producing IL-12p40 were also prominent in cells 
from patients with moderately active CD. This is consistent with previous work 
demonstrating that IL-12p40 is expressed by both colonic DC (Hart et al., 2005), and 
LPMC in CD (Monteleone et al., 1997).   
 
Although the frequency of IL-6+ DC were not different between subjects, the level of IL-6 
staining by DC was increased in CD, which correlated with both disease activity and a 
systemic marker of inflammation, CRP.  We have correlated DC cytokine production with 
CDAI, CRP and faecal microbiota. When making multiple comparisons between several 
variables, it is important to adjust the threshold and apply the Bonferroni correction, as 
discussed under methods in section 2.2.14. 
 
Therefore IL-6+ DC may have significance in the systemic inflammatory response. IL-6 
has multiple well-characterised functions during acute phase response and B cell 
differentiation. IL-6-deficient mice were resistant to autoimmune diseases (Ohshima et al., 
1998; Okuda et al., 1998), and were less susceptible to colitis (Suzuki et al., 2001). Jones 
et al. recently showed higher serum IL-6 concentrations in CD patients with more severe 
endoscopic disease activity (Jones et al., 2008). IL-6 plays a major role in T cell activation 
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in vitro and in vivo due to its ability to overcome suppression mediated by Treg. Pasare et 
al. demonstrated that the production of IL-6 by DC in response to TLR ligation during 
infection was critical for T cell activation by overcoming the suppressive effects of CD4+ 
CD25+ Treg cells (Pasare and Medzhitov, 2003). 
 
The cytokine network in IBD is a complex, dynamic system and there is likely to be 
interplay between various cytokines. We used multiplex ELISA to assess the overall 
inflammatory infiltrate in IBD and the interplay between various cytokines. These 
included Th1 cytokines (IL-1b, IL-12p70, IL-6, IL-8, TNF-α and IFN-γ) and Th2 
cytokines (IL-4, IL-5 and IL-10). In patients with IBD, IBS, and controls, cytokines 
associated with “tissue trauma”, IL-1β, IL-10 and IL-6, were detected in gut biopsies from 
all subjects. The source of these cytokines could be from macrophages, DC or T cells.  
 
CD has been considered to be a typical Th1 disease, characterised by excess IFN-γ 
production in the inflamed intestine (Fuss et al., 1996; Kobayashi et al., 2008; Matsuoka 
et al., 2004), whereas UC has been traditionally referred to as a “Th2- like” or “mixed” 
phenotype as this disease does not exhibit clearly distinct phenotype (Heller et al., 2005a; 
Okazawa et al., 2002). Since this work has been completed, Th17 cells, which exclusively 
produces the pro-inflammatory cytokine IL-17 has been proposed to play a role in the 
pathogenesis of murine model of colitis and human IBD (Annunziato et al., 2007; 
Annunziato et al., 2008; Fujino et al., 2003; Nielsen et al., 2003; Zhang et al., 2006).  IL-
23 can promote IL-17 production by Th17 cells (Mangan et al., 2006).  
 
We have focused on IL-12 composed of the p40 and p35 subunits in our experiments; IL-
12 shares the p40 unit with IL-23; IL-23 is composed of p40 and the subunit p19 
195 
 
(Oppmann et al., 2000). The functional role of IL-12 has been reevaluated given that 
earlier studies which used antibodies directed against the IL-12/23p40 subunit, was also 
part of the IL-23 heterodimer.  Mouse models of intestinal inflammation have since 
demonstrated a more important role of IL-23 than IL-12 in driving inflammation. Hue et 
al. showed that IL23p19 antibodies suppressed chronic intestinal inflammation in T cell 
deficient Helicobacter hepaticus-infected RAG knockout mice (Hue et al., 2006). In a 
transfer colitis model, recipient mice deficient in IL-23p19 and IL-12/IL-23p40 were 
protected against colitis, whilst mice deficient in IL-23p19 developed colitis (Kullberg et 
al., 2006). IL-23 also play a role in human IBD (Duerr et al., 2006; Elson et al., 2007; 
Fuss et al., 2006; Kobayashi et al., 2008; Neurath, 2007; Schmidt et al., 2005).  
Upregulation of IL23p19 mRNA was found in the colonic mucosa of UC and CD patients 
(Kobayashi et al., 2008; Schmidt et al., 2005) and lamina propria macrophages from CD 
patients produced large amounts of IL-23 (Fuss et al., 2006). Kobayashi et al. recently 
demonstrated that recombinant IL-23 enhanced IL-17 production by lamina propria CD4+ 
T cells in UC, but had a lesser effect on lamina propria CD4+ T cells in CD (Kobayashi et 
al., 2008). The mucosal IL-23p19 expression levels correlated with IL-17 in UC and IFN-
γ in CD, suggesting that IL-23 may play important roles in controlling the differential 
Th1/Th17 balance in both UC and CD (Kobayashi et al., 2008). We have not assessed IL-
23 or IL-17 in our patients as the importance of these cytokines in intestinal inflammation 
came about after this work has completed. 
 
A separate T cell-derived cytokine, IL-21, has been reported to be increased in IBD.  IL-
21 plays a role in controlling Th17 cell responses in both DSS colitis and TNBS-relapsing 
colitis. IL-21-deficient mice were largely protected against both colitides and failed to up-
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regulate Th17-associated molecules during gut inflammation, hence suggesting a role for 
IL-21 in controlling Th17 cell responses (Fina et al., 2008).  
 
DC directly interact with trillions of non-invasive intestinal bacteria in vivo, and their 
functions are likely to be influenced by distinct bacteria subsets (Christensen et al., 2002; 
Zeuthen et al., 2006). Distinct commensals confer different properties to in vitro-generated 
DC. Fink et al. showed that freshly isolated DC from murine Peyer’s patches, MLN and 
spleen, matured similarly in response to bacterial stimuli but intestinal DC demonstrated 
tissue-dependent functions (Fink and Frokiaer, 2008). For instance, MLN and Peyer’s 
patches DC produced mainly IL-10 and little IL-12 and IFN-γ in response to E. coli and B. 
longum, but MLN DC produced more IFN-γ and less IL-10 in response to L. acidophilus 
(Fink and Frokiaer, 2008). Other ex vivo studies showed that DC from the human colon 
lamina propria produced IL-10 but no IL-12 upon exposure to entero invasive Salmonella 
(Rimoldi et al., 2005) and the probiotic mixture VSL#3 (Hart et al., 2004c). Thus 
individual strains of commensal bacteria have varying immunomodulatory properties and 
can polarize the distinct immune response.  
 
We have shown that in patients with active CD, IL-12p40 production by DC was 
associated with the proinflammatory bacteria, bacteroides and EREC, whereas IL-10 
secreted by DC correlated with bifidobacteria. These data suggest that resident commensal 
bacteria in patients with IBD can influence intestinal DC function in vivo. The phylum 
Firmicutes, particularly the species F. praustnitzii, were consistently reduced in patients 
with IBD and infectious colitis (Sokol et al., 2009b; Swidsinski et al., 2008). F. 
praustnitzii can be considered an immunoregulatory bacteria; In vitro, PBMC stimulation 
by F. praustnitzii reduced IL-12 and IFN-γ production and enhanced IL-10 secretion. In 
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TNBS colitis, administration of live F. praustnitzii or its supernatant decreased the 
severity of colitis (Sokol et al., 2008). We demonstrated that patients with CD who had 
undetectable IL-6 production had more F. praustnitzii than those with IL-6+ DC. We 
speculated that F. praustnitzii may create an anti-inflammatory environment by 
suppressing IL-6 production by DC in vivo. Alternatively, in patients with CD who had 
altered F. praustnitzii, intestinal DC activated by microbial stimuli blocked the 
suppressive effects of CD4+ CD25+ Treg cells and that this process was dependent on IL-6 
production (Pasare and Medzhitov, 2003).  Upon in vivo stimulation with E. coli, MLN 
and Peyer’s patches DC produced TGF-β which concomitantly increased IL-6, possibly 
leading to the induction of Th17 cells, and the enhancement of epithelial barrier function 
(Weaver et al., 2006). Human DC exposed to commensal-related bacteria in the absence 
of inflammatory signals, upregulated costimulatory molecules, produced IL-1β and IL-6. 
DC also converted naive CD4+ T cells into hyporesponsive T cells that displayed 
suppressor function (Baba et al., 2008). Furthermore, when DC were selectively depleted 
in mice before the initiation of DSS-induced colitis, the disease was more severe, 
compared with that of DC-intact mice (Qualls et al., 2009). Increased IL-6 expression in 
colon tissues correlated positively with increased colitis severity in DC-depleted mice 
(Qualls et al., 2009). Consistent with our data, regulation of IL-6 production may 
contribute to DC-mediated control of intestinal inflammation, which is associated with the 
severity of disease. 
 
Our current work from human tissue suggests that distinct DC cytokine production is 
likely to be influenced by the disease stage and activity in CD and UC. Resident 
commensal bacteria also play specific roles in modulation DC functions in intestinal 
inflammation.  
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Chapter 5 
 
The Effects of Therapy on Intestinal Dendritic Cells Phenotype 
and Function in Inflammatory Bowel Disease 
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5.1 Abstract 
 
Introduction: In UC gut bacteria drive the inflammatory process. Bacterial recognition 
and T cell responses are shaped by intestinal DC; the therapeutic effects of probiotic 
bacteria may relate to their modulation of intestinal DC function. We aimed to assess the 
effect of probiotics and steroids in acute UC, clinically and in relation to their effects on 
colonic DC ex vivo.  
Methods: Rectal biopsies were obtained from patients with active UC before and after 
treatment with the mixed probiotic preparation VSL#3, corticosteroids or placebo, and 
from healthy controls. Myeloid colonic DC were identified from freshly isolated lamina 
propria cells using multi-colour flow cytometry. Surface expression of activation markers, 
CD40, CD86, pattern recognition receptors, Toll-like receptor (TLR)-2 and TLR-4, and 
spontaneous intracellular  IL-10, IL-12p40, IL-6, and IL-13 production by DC were 
measured.  
Results: Ten of 14 patients on VSL#3 responded to treatment compared with 5 of 14 on 
placebo (p=0.064). In VSL#3-treated patients TLR-2 expression on DC decreased 
(p<0.05), IL-10+ colonic DC increased and IL-12p40+ DC decreased (p<0.005). In 
contrast, in patients on placebo TLR-2 expression, and IL-12p40 and IL-6 levels were 
increased (all p<0.05). Corticosteroid treatment was associated with significant increased 
IL-10 and reduced IL-12p40 production by colonic DC.  
Conclusions: In acute UC, treatment with the probiotic mix VSL#3 and corticosteroids  is 
associated with altered “favourable” intestinal DC function, inducing increased levels of 
regulatory cytokines and down-regulation of pro-inflammatory cytokines.    
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5.2 Introduction 
 
UC, a common chronic relapsing inflammatory disorder of large bowel, results from 
inappropriate mucosal immune response to indigenous microbiota and luminal antigens in 
genetically susceptible individuals. Intestinal microbiota in patients with active UC is 
altered compared with that of healthy individuals (Cummings et al., 2003; Swidsinski et 
al., 2002). Manipulating gut flora, using probiotics, may correct and/or prevent pro-
inflammatory signals in UC. VSL#3, which is a combination of eight different probiotic 
bacterial strains, is effective in maintaining remission and preventing development of 
pouchitis (Gionchetti et al., 2000; Gionchetti et al., 2003; Mimura et al., 2004). In an 
open-label study (Bibiloni et al., 2005), and a recent placebo-controlled trial published in 
abstract form (Makharia et al., 2008), VSL#3 is effective in the treatment of patients with 
mild to moderately active UC, with a response rate of 50 to 70 percent. Two components 
of VSL#3, S salivarius subspecies thermophilus and B. infantis, have been detected in 
biopsies, demonstrating that these bacteria reach the diseased bowel (Venturi et al., 1999). 
 
The ability of intestinal DC to sample and respond to gut bacteria, suggests that they may 
be targets for probiotic bacteria. The effects of probiotic bacteria on DC are likely to be 
central in immunomodulation by these bacteria (Ng et al., 2009). In vitro the VSL#3 
mixture, in particular its bifidobacterial components, is a potent inducer of IL-10 in DC 
from both blood and intestinal biopsies, and inhibits generation of Th1 cells. VSL#3 also 
diminishes proinflammatory effects of LPS by decreasing LPS induced production of IL-
12p40 in DC while maintaining IL-10 production (Hart et al., 2004c). It remains to be 
established whether the in vivo administration of probiotics, such as VSL#3, in the setting 
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of resident microbiota and active mucosal inflammation, results in the modulation of gut 
DC.  
 
It has been generally accepted that corticosteroids are highly effective and the most 
frequently used immunosuppressive agents to induce remission in patients with moderate 
to severely active UC, and in patients who have failed 5-ASA. The immunosuppressive 
effects of steroids have been ascribed mainly to the suppression of T cell activation 
(Liberman et al., 2009). Subsequent work has shown that steroids can regulate DC 
maturation and immune function in vitro and in vivo suggesting that these mechanisms 
may play a role in preventing overstimulation of the immune system (Moser et al., 1995). 
Whether corticosteroids modulate such DC functions, and thus contribute to its efficacy in 
patients with UC has not been studied. 
 
We studied the effects of therapeutic intervention with bacterial modification (probiotics) 
and standard immunosuppression (corticosteroids) on intestinal DC function in patients 
with UC. We included a control group of patients who have received placebo treatment. 
We correlated changes in DC function with therapeutic efficacy.  
 
 
5.3 Hypothesis  
 
Therapeutic manipulation with probiotic bacteria or conticosteroids induces 
immunoregulatory DC responses in patients with active UC. 
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5.4 Aims 
 
 
-           To investigate the effects of probiotics on DC function in vivo in patients with UC 
-  To assess the effects of corticosteroids on DC function in vivo in patients with 
 UC 
 
5.5 Patient Characteristics 
 
Patients with active UC were recruited at one specialist hospital, as part of a multi-centre, 
double blind, placebo-controlled therapeutic trial evaluating the effectiveness of the 
probiotic preparation, VSL#3, for the treatment of mild to moderately active UC.  Twenty-
eight patients with acute UC were included in this laboratory sub-study.  Twelve healthy 
controls with no history of bowel disease were studied as controls.  
 
Baseline characteristics of all patients, including concurrent medical therapy in the UC 
patients, are shown in Table 12. Diagnosis was made using clinical parameters, 
radiographic studies, endoscopic and histologic criteria.  
 
Disease activity was assessed using the UC disease activity index: UCDAI, range of 
scores 0 (no active disease) to 12 (maximum disease) (Singleton, 1987). Patients were 
eligible if they had an UCDAI of 3 to 8 and were symptomatic for less than four weeks. 
Tissue samples were from macroscopically inflamed rectal mucosa and inflammatory 
activity was confirmed by histological evaluation (Section 2.2.16).  
 
Patients were on stable doses of medication. Exclusion criteria included the use of steroids 
within the last 4 weeks; use of antibiotics within the last 2 weeks; change in dose of 5-
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aminosalicylate acid (ASA) within the last 4 weeks; change in dose of rectal 5-ASA or 
steroids within 7 days prior to study entry, or the use of probiotic preparations during 
study. Rectal therapy was not permitted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Baseline characteristic of patients with acute UC treated with VSL#3 or placebo  
 
 
 
5.6 Modulation of Intestinal DC by Probiotic bacteria VSL#3 in Vivo in Acute 
Ulcerative Colitis 
 
5.6.1 More Patients treated with VSL#3 had a Clinical Response Compared with 
Patients on Placebo 
 
Fourteen patients were randomized to VSL#3 and 14 to placebo. Ten of 14 patients on 
VSL#3 responded to treatment compared with five of 14 on placebo (p=0.064, Fisher’s 
Exact Test). Three and six patients from the VSL#3 and placebo group, respectively, 
VSL#3 Placebo
Male/female 4/10 7/7
Mean age, year (range) 45 (21-70) 42 (28-57)
Disease duration, years (range) 6 (1-16) 9 (1-27)
Disease extent
Distal 7 8
Extensive 2 1
Total 5 5
Mean UCDAI, range 7  (4-8) 6 (5-8)
Concomitant medications (%)
Mesalazine 7 (50) 11 (79)
AZA/6-MP 1 (7) 1 (14)
None 7 (50) 2 (14)
Mesalazine: Stable for at least 4 weeks
AZA/6MP: Stable for at least 12 weeks
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withdrew from the trial within one week due to lack of therapeutic efficacy or worsening 
disease and were treated with oral corticosteroids. In the VSL#3 group, intention to treat 
analysis, that is including those who withdrew within the first week of treatment, 
demonstrated that remission (UCDAI≤2) was achieved in 7 (50%) patients, clinical 
response in a further 3 (21%) patients, no response in 3 (21%) patients, and 1 (7%) patient 
did not have the final sigmoidoscopy assessment. In patients who had placebo, remission 
was seen in 5 (36%), response in 0 (0%) and no response in 9 (64%). Figure 5.1 shows the 
clinical response of treated patients by treatment arm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Clinical outcome of patients with UC treated with VSL#3, placebo and 
corticosteroids. In patients who were treated with VSL#3,  two of four patients did not have a 
response after one week and were treated with prednisolone 40mg daily (reducing by 5 mg each 
week) over a course of eight weeks. In patients who had placebo, six of nine patients did not have 
a response and were treated with prednisolone after one week. 
 
 
 
 
 
28 patients 
with UC 
14 placebo14 VSL#3
5 clinical response
2 withdrew within one 
week and were treated 
with corticosteroids *
4 no response 9  no response10 clinical response
6 withdrew within 1 
week and were treated 
with corticosteroids *
* Starting dose 40mg, reduce by 5mg each week
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5.6.2 VSL#3 Downregulates TLR-2 Expression on CD11c+ Colonic Dendritic Cells  
 
Expression of co-stimulatory molecules (CD40 and CD86) and TLRs (TLR-2 and TLR-4) 
was assessed on lamina propria CD11c+ DC before and after probiotic or placebo 
treatment. We assessed these markers as they have been shown to be activated in patients 
with IBD from our previous work (Hart et al., 2005). Two measures of expression were 
determined on these cells: the proportion of DC expressing a given marker and the 
intensity of staining or positive intensity ratio (PIR), which represents the amount a given 
marker is expressed on positive cells.  TLR-2 expression was significantly reduced in 
patients treated with VSL#3 (30±7% to 4±3%; p=0.04) (Figure 5.2A).  As there was no 
significant difference between TLR-2 expression on DC in the VSL#3 or placebo group 
before treatment, this suggested that reduction in TLR-2 post VSL#3 was unlikely to be an 
artifact due to higher TLR-2 expression in the VSL#3 group prior to therapy.  However, 
the median value for percentage TLR2-expressing DC in the pre-treated VSL#3 group was 
approximately twice that of the placebo group, hence there is a possibility that the 
significant reduction in TLR-2 expression post-VSL#3 treatment was an artefact. There 
were no significant differences in CD40, CD86 or TLR-4 expression after VSL#3 
treatment (Figure 5.2A).  
 
In patients on placebo, there were no significant changes in DC expression of CD40, 
CD86, TLR-2 and TLR-4 (Figure 5.2B).  
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Figure 5.2: Co-stimulatory molecule and Toll-like receptor expression by colonic CD11c+ DC 
after VSL#3 or placebo treatment. (A) The proportion of colonic CD11c+ DC expressing CD40, 
CD86, TLR-2 and TLR-4 in acute UC after VSL#3 treatment (n=10); (B) The proportion of 
colonic CD11c+ DC expressing CD40, CD86, TLR-2 and TLR-4 in acute UC after placebo (n=9). 
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5.6.3 VSL#3 Increases IL-10 and Inhibits IL-12p40 Production by CD11c+ Colonic 
 Dendritic Cells  
 
Cytokine production by DC extracted from the lamina propria of colonic tissue of patients 
with UC was assessed at two time points: (i) prior to the start of therapeutic intervention 
and, (ii) eight weeks post probiotic or placebo. The methods used for all cytokine data 
have been described in section 2.2.12. There was significantly greater IL-10 production 
(10 ±17% to 56 ±17%; p=0.005) and decreased IL-12p40 production (62±9% to -2±14%; 
p=0.005) by colonic DC following VSL#3 treatment (Figure 5.3). For patients who had 
placebo, there were no significant changes in the proportion of cytokine producing DC for 
IL-10, IL-12p40, IL-6 or IL-13 (Figure 5.4). 
 
The level of staining (PIR) of IL-12p40 was significantly lower after VSL#3 treatment 
(2.1±0.2 to 1.0±0.4; p<0.05), although the baseline IL-12p40 staining was higher in the 
VSL#3 group than placebo group. In contrast, there were no significant changes in 
percentage or level of staining in IL-6 or IL-13 production by DC after VSL#3. In patients 
treated with placebo, there was a significant increase in the level of staining for IL-12p40 
and IL-6 on CD11c+ DC (Figure 5.5). 
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     VSL#3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Cytokine production by colonic DC before and after treatment with VSL#3. 
Paired samples of colonic DC from patients with acute UC, obtained before and after VSL#3 
treatment were stained for the presence of intracellular IL-10, IL-12p40, IL-6 and IL-13. The 
proportion (%) of cytokine positive DC is shown in this figure (n=10). 
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    Placebo 
 
Figure 5.4. Cytokine production by colonic DC before and after treatment with placebo. 
Paired samples of colonic DC from patients with acute UC, obtained before and after placebo 
treatment, were stained for the presence of intracellular IL-10, IL-12p40, IL-6 and IL-13. The 
proportion (%) of cytokine positive DC is shown in this figure (n=7). 
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Figure 5.5: Positive intensity ratio of cytokine staining before and after VSL#3 or placebo. 
(A) Level of cytokine staining in patients who were treated with VSL#3 (n=10); (B) Level of 
cytokine staining in patients who received placebo (n=9).  
 
 
 
5.7 Modulation of Intestinal Dendritic Cells by Oral Corticosteroids in Vivo in 
Acute Ulcerative Colitis 
 
5.7.1 Corticosteroids did not Affect the Expression of Co-stimulatory Molecules and 
Toll-like Receptors on Colonic Dendritic Cells 
 
 
In a subgroup of patients who were treated with eight weeks of corticosteroids (starting 
dose oral prednisolone 40mg daily and reduced by 5 mg each week until zero; n=8) 
changes in colonic DC phenotype  and function after steroid therapy were assessed. As 
shown in figure 5.1, two and six patients from the VSL#3 and placebo group, respectively, 
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withdrew from the trial within one week due to lack of therapeutic efficacy or worsening 
disease and were treated with oral corticosteroids. 
 
There was no difference in the proportion and levels of staining of DC expressing co-
stimulatory molecules or TLRs before and after steroids. 
 
 
 
5.7.2 Corticosteroids Enhance IL-10 and Inhibit IL-12p40 Production by CD11c+ 
 Colonic Dendritic Cells 
 
There was a significant reduction in colonic CD11c+ DC production of IL-12p40 after 
treatment with corticosteroids (p=0.012). Conversely, IL-10 production by CD11c+ DC 
increased significantly after steroid therapy (p=0.032) (Figure 5.6).   In addition, mean 
PIR for IL-12p40 decreased from 1.7 to 1.0, whilst mean PIR for IL-10 increased from 1.3 
to 1.8 (p=0.04). There were no significant changes in CD11c+ DC IL-6 or IL-13 
production after corticosteroids. 
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Figure 5.6: Cytokine production by colonic dendritic cells before and after treatment with 
corticosteroids. Paired samples of colonic DC from patients with acute UC, obtained before and 
after steroid treatment, were stained for the presence of intracellular IL-10, IL-12p40, IL-6 and IL-
13. The proportion (%) of cytokine positive DC is shown in this figure. 
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5.8 Correlation of Disease and Histological Activities with Dendritic Cell 
Functions 
 
5.8.1 No Correlation between Ulcerative Colitis Disease Activity Index and 
 Changes in Dendritic Cell Phenotype or Functions 
 
There was no significant correlation between patients’ UCDAI score (median 6; range 4-
8) at baseline and the baseline measurement of percentage positive cells for surface 
phenotypic markers or intracellular cytokines.  
 
 
Table 13: Association between the UCDAI scores at baseline and the percentage of positive cells 
at baseline 
 
 
5.8.2 Lack of Change in Tissue Histologic Activity Index Post VSL#3 or 
 Corticosteroid Treatment 
 
Patient’s pre and post treatment tissue was scored for histological inflammatory activity. 
In all treated patients, there was no significant change in mean histologic activity index 
(VSL#3: 1.6 to 1.8; p=0.41; placebo 1.9 to 1.2; p=0.098; steroids 2.0 to 1.0; p=0.17). In 9 
of 10 patients, inflammatory infiltrate remained in tissue post VSL#3.  
 
214 
 
Eight patients were treated with prednisolone (two and six patients were initially 
randomised to VSL#3 or placebo, respectively, but withdrew due to lack of clinical 
response). In patients on steroids altered cytokine profile occurred irrespective of 
resolution of inflammatory cell infiltrate. In five patients who had steroids, an 
inflammatory cell infiltrate was still present on histology (score 1-3) but changes were 
detected in cytokine profiles. 
. 
5.8.3 Unchanged Inflammatory Cell Activities in Supernatants Measured by 
 Multiplex ELISA of Cytokines Post VSL#3 and Corticosteroid Treatment 
 
 In patients who were treated with oral VSL#3 or steroids, cytokines including IL-10, IL-8, 
IL-6, IL-4, IL-5, IL-1β, TNF-α, and IL-12p70 were detected in the supernatant measured 
in overnight tissue cultures. There was no significant difference in the amount of cytokines 
(in pg/ml/mg) in tissue before and after treatment (data not shown). The unchanged 
inflammatory cell activities in supernatants measured by ELISA, together with the lack of 
histological change post treatment, suggest that changes in DC cytokine production are 
unlikely to result from resolution of inflammatory cell infiltrates, and rather are likely to 
reflect altered cell function.  
 
 
5.9  Clinical Outcome and Dendritic Cell Function in VSL#3-treated Patients  
 
We explored whether there was any relationship between the change in percentage of 
cytokine produced by DC and clinical response in patients treated with VSL#3, but there 
was no association. Furthermore there were only two patients who did not achieve a 
clinical response and therefore numbers were too small to make any meaningful statistical 
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analysis. In Figure 5.7, open symbols represent patients with a clinical response or 
remission and red symbols and lines represent patients with no clinical response.  
 
We also compared cytokine changes in all patients (VSL#3 treated or placebo) who 
improved clinically post treatment (n=13) with cytokine changes in those who did not 
(n=6). There were no significant differences in any measured parameter between the two 
groups; observed changes in DC profile may therefore relate to effects of treatment rather 
than to disease resolution alone.  There were also no differences between patients in the 
placebo treated group who achieved remission and those who had no clinical response in 
DC changes for surface markers or cytokines. 
 
 
 
Figure 5.7: Clinical outcome and dendritic cell cytokine production in VSL#3-treated 
patients. This figure shows changes in DC production of IL-10 and IL-12p40 after VSL#3 
treatment in patients with a clinical response (defined by a reduction in >50% UCDAI) and in 
those without a clinical response. Open symbols represent patients with a clinical response or 
remission and red symbols and lines represent patients with no clinical response. 
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5.10 Discussion 
 
Patients with UC treated with oral VSL#3 had increased IL-10 and reduced IL-12p40 
production by colonic DC, these effects were not seen in placebo-treated patients. In this 
subset of trial patients, more patients on VSL#3 compared with placebo also had a clinical 
response to treatment and clinical response was associated with beneficial DC function in 
most patients. Despite limited numbers of DC isolated from human tissue, we have 
demonstrated that treatment with oral VSL#3 and corticosteroids, but not placebo, 
modulated human colonic DC towards a regulatory/anti-inflammatory profile, suggesting 
that probiotic and steroid effects on DC are likely to be central to their therapeutic effects 
in patients with UC.  
 
DC represent only around 0.2% of viable cells from human gut biopsies and numbers of 
DC are therefore limited; our development of techniques to identify, purify and study their 
functions were central to work in this chapter (Bell et al., 2001). DC are likely to be 
pivotal in mediating the balance between effector and regulatory lymphocyte responses 
with different outcomes influenced by exposure of DC to microbial products. Immature 
DC from non-intestinal sites expressed low levels of CD40 but this activation marker was 
up-regulated when DC underwent maturation or activation as occurred in inflamed mucosa 
of patients with IBD (Baumgart et al., 2004; Hart et al., 2005). We specifically measured 
TLR-2 and TLR-4 as previous work from our laboratory has shown that colonic myeloid 
DC have enhanced expression of TLR-2 and TLR-4 in IBD, especially in inflamed 
mucosa of patients with CD(Hart et al., 2005). 
 
DC respond differentially to different types of microbes via PRR (Bauer et al., 2001; 
Kadowaki et al., 2001; Takeuchi et al., 1999). Soluble factors such as cytokines or 
217 
 
bacterial products can modulate TLR expression. In UC, after probiotic treatment, 
downregulation of TLR-2 can be a direct or indirect effect. In murine models of colitis, the 
anti-inflammatory effect of probiotics may be mediated via TLR-9 (Rachmilewitz et al., 
2004), and possibly via TLR-2 as shown here. Downregulation of TLR-2 by DC after 
VSL#3 may reflect reduced inflammation after treatment, although this effect was not seen 
with resolution of inflammation after placebo; or it could be secondary to downstream 
local immune modulation or recruitment of un-activated cells from blood. The signalling 
of VSL#3 via TLR-2 on DC resulted in IL-10 production. TLR-2 knockout mice displayed 
defective production of IL-10 (Ferreira et al., 2007). In addition, Candida albicans 
induced immunosuppression through TLR2-derived signals that mediated increased IL-10 
production and survival of Treg cells (Netea et al., 2004). It has also been shown that DC 
expression on TLR resulted in a non-inflammatory response (Rescigno and Matteoli, 
2008). For instance, freshly isolated lamina propria murine DC showed little induction of 
IL-12 in response to TLR ligation, but was associated with constitutive IL-10. Thus, IL-10 
may maintain lamina propria DC in a partially non-responsive state to TLR ligation 
(Monteleone et al., 2008). 
 
Different probiotic bacteria act through multiple and contemporaneous pathways rather 
than by a single common mechanism. Current findings that in vivo treatment with VSL#3 
of patients with acute UC induced IL-10 and downregulated IL-12p40 production in 
colonic DC are in line with previously published in vitro data that VSL#3 is a potent 
inducer of IL-10 by blood and lamina propria DC (Hart et al., 2004c). These mechanistic 
studies were performed in a subgroup of patients who were part of a larger clinical trial; 
results of the larger trial assessing clinical effects of VSL#3 in acute UC will be presented 
separately at a future date.  
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IL-10 and IL-12p40 produced by DC exert largely opposite immunomodulatory effects. 
IL-12p40 is a Th1 polarising cytokine that induces IFN-γ production by T cells and NK 
cells (Heufler et al., 1996), whereas IL-10+ DC elicit a Th2 response to suppress IL-12 
production and consequently IFN-γ.   
 
In patients with pouchitis, VSL#3 increased pouch tissue IL-10, and reduced 
proinflammatory cytokines IL1-α, IFN-γ, and TNF-α to untreated levels(Ulisse et al., 
2001). These beneficial immune changes seen in vivo provide at least a partial explanation 
for efficacy of VSL#3 in pouchitis (Ulisse et al., 2001). IL-10 is likely to be important in 
the maintenance of immune homesotasis in the gut. The delivery of IL-10 to the intestine 
using bacterial or viral vectors appeared to ameliorate established inflammation in animal 
models of colitis. However, anti-IL-10 antibody has limited efficacy in the treatment of 
patients with CD (Schreiber et al., 1995), but have not been formally tested in patient with 
UC. 
 
As described in chapter 4, studies have identified IL-23 which shares the p40 subunit with 
IL-12, as a mediator of intestinal inflammation (Hue et al., 2006; Uhlig et al., 2006). Our 
assay for intracellular cytokine does not currently allow us to distinguish whether IL-
12p40 reflects biologically active IL-12 or IL-23 but effects of probiotic bacteria on DC 
IL-12p40 production may impact upon IL-23 production. IL-23 is produced by activated 
myeloid cells including DC following bacterial stimulation (Becker et al., 2003), or via 
CD40 signalling (Uhlig et al., 2006).  Becker et al. showed that DC from IL-23p19 
deficient mice produced elevated levels of IL-12, and that IL-23 downregulated IL-12 
expression upon TLR ligation. The in vivo blockade of IL-12p40 in IL-23p19 deficient 
219 
 
mice protected the mice from colitis. These data suggested a cross-regulation of IL-12 
expression by IL-23, at least, in T cell-dependent colitis (Neurath, 2007).  
 
Studies in human IBD showed increased IL-12 and IL-23 expression in the intestinal 
tissue of patients with CD (Fuss et al., 2006; Schmidt et al., 2005). Treatment with an 
anti-IL-12/23p40 antibody (directed against the p40 subunit of IL-12 and IL-23) revealed 
high remission and response rates in patients with active CD compared with placebo 
(Mannon et al., 2004). Ustekinumab, a similar antibody against IL-12/23p40 was effective 
in patients with active CD who had previously failed infliximab (Sandborn et al., 2008). 
Future trials assessing the efficacy of an anti-IL-23p19 antibody in human intestinal 
inflammation will help to clarify whether treatment success seen with IL-12/23p40 
antibody was specific to neutralising the Th17-specific IL-23 subunit. 
 
Several groups have demonstrated that therapies for IBD modulate DC functions (Hart et 
al., 2005; Mannon et al., 2009; Thomas et al., 2009). We have previously shown a 
precedent for therapy altering colonic DC in CD patients treated with anti-TNF- 
antibody, infliximab, which downregulated CD40 expression on colonic DC (Hart et al., 
2005). Probiotics may also have an indirect effect via APC in the gut; human monocyte-
derived DC matured in the presence of Lactobacillus rhamnosus resulted in both reduced 
T cell proliferation and IL-2, IL-4 and IL-10 production (Braat et al., 2004a). 
 
Saccharomyces bourladii, a probiotic yeast preparation, has demonstrated clinical efficacy 
in clinical trials; Thomas et al. showed that this probiotic yeast preparation may exhibit 
part of its anti-inflammatory activity through modulation of DC phenotype function and 
migration. In vitro culture of human monocyte-derived myeloid DC with S. Bourladii 
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supernatants led to reduced expression of CD40, CD80 and CCR7 on DC, increased IL-
10, and reduced IL-6 and TNF-α production (Thomas et al., 2009). In mice Lactobacillus 
acidophilus strain L-92 induced apoptosis of antigen-stimulated T cells by by modulating 
DC function in vitro and in vivo (Kanzato et al., 2008). Furthermore, Mannon et al. have 
recently demonstrated that the clinical benefit from granulocyte-colony stimulating factor 
(G-CSF) treatment in CD is accompanied by an increase in plasmacytoid DC (CD123+), a 
DC phenotype associated with regulatory responses, in the lamina propria of inflamed 
colonic mucosa; the increase in numbers of these cells were restricted only to patients who 
had a clinical response. Treated patients also had a significant increase in IL-10+ 
circulating memory T cells (Mannon et al., 2009).  
 
We have shown increased concentrations of both total faecal microbiota, and 
bifidobacteria associated with increased IL-10 by colonic DC, an observation consistent 
with effects of bifidobacteria on DC observed in vitro (Ng et al., 2008). Treatment of 
patients with CD with pre-biotic fructo-oligosaccharide increases total gut bacteria and 
bifidobacteria in patients with clinical improvement, together with a trend towards 
increase IL-10+ DC (Lindsay et al., 2006).   Altogether these data suggest that commensal 
microbiota, even without administered probiotics, may modulate intestinal DC function.  
 
Individual strains of within VSL#3 display distinct and diverse immunomodulatory 
effects, arguing against a common bacterial component such as peptidoglycan mediating 
their effects. In vitro, the most marked anti-inflammatory effect was shown by the 
bifidobacteria species which upregulated IL-10 production by DC and reduced expression 
of CD40 and CD80 (Hart et al., 2004c). Whether individual strains of bacteria may 
similarly exert immunomodulatory effects on ex vivo DC in IBD patients is currently 
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unknown.  Ibnou-Zekri et al. showed that two strains of Lactobacillus that exhibit similar 
in vitro growth, survival and adherence properties had different colonization patterns and 
resultant host immune responses at the mucosal and systemic levels (Ibnou-Zekri et al., 
2003). 
 
Corticosteroids, in the form of dexamethasone or prednisolone, have been known to affect 
DC function.  In vitro steroids inhibit DC production of IL-12p70 and TNF-α, and 
corticosteroid-exposed DC generate IL-10 producing regulatory T cells (Piemonti et al., 
1999b; Woltman et al., 2000).  In one study, dexamethasone selectively down-regulated 
expression of co-stimulatory molecules on viable DC in vitro, and reduced their 
immunostimulatory properties, whereas in vivo, a single injection of dexamethasone 
results in impaired antigen presenting function; this finding correlated with reduced 
numbers of splenic DC (Moser et al., 1995). 
 
Human monocyte-derived DC cultured with dexamethasone showed a higher endocytic 
activity, a lower APC function, and a lower capacity to secrete cytokines than untreated 
cells. Dexamethasone cultured-DC also has the ability to partially block terminal 
maturation of already differentiated DC (Piemonti et al., 1999b; Piemonti et al., 1999a). In 
patients with myasthesnia gravis, an autoimmune neuromuscular disease, oral 
prednisolone treatment prevented LPS-induced maturation of monocyte-derived DC by 
inhibiting the up-regulation of costimulatory molecules, limiting production of IL-12 and 
IL-23, and enhancing IL-10. CD4+ T cells cultured in the presence of tolerogenic DC were 
hyporesponsive and can suppress autologous CD4+ T cell proliferation(Luther et al., 
2009). Here, we have demonstrated for the first time in a defined group of patients with 
acute UC, the beneficial effects of oral steroid therapy on ex vivo colonic DC suggesting 
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that one mechanism by which corticosteroids ameliorated intestinal inflammation was via 
modulation of DC. Corticosteroids appeared to share similar effects to those of VSL#3 on 
DC function in vivo. 
 
Changes in DC with therapy may be from sampling of bacteria by DC or via bacterial 
interactions with other cells. It is unlikely to be secondary to resolution of inflammation as 
beneficial cytokine changes were seen even when post-treatment tissue still contained 
inflammatory cells (by histological criteria). Inflammatory cell infiltrates are slow to 
resolve after treatment of acute colitis, despite symptomatic and macroscopic mucosal 
improvement, reinforcing the potential for longer term effects on overt inflammation of 
changes in DC.  It is unlikely that other existing medications played a significant role in 
cytokine changes observed in our experiments as these patients have remained on stable 
medication before and throughout the study.  
 
In conclusion, we have shown effects of medical therapy on DC function in acute UC, 
providing evidence that exogenously administered bacteria influence gut inflammatory 
activity via effects on gut DC. Clinical improvement in patients treated with VSL#3 but 
not placebo was associated with significant increase in ongoing production of IL-10 and 
decrease in IL-12p40 and TLR-2 expression in gut DC. Corticosteroids had similar effects. 
Accumulating data suggest that properties of DC may be fundamental to modulation of 
inflammation in IBD. 
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Chapter 6 
 
Expression of Gut Homing Markers on T Cells and 
Human Colonic Dendritic Cells 
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6.1 Abstract 
 
Introduction: Recruitment of lymphocytes to sites of intestinal inflammation is central to 
the inflammatory process in IBD, and appears to be heavily influenced by specialized gut 
DC. Intestinal DC imprint homing molecules on T cells that they activate. In the mouse, 
the ability to imprint gut homing is confined to CD103+ DC. In vitro colonic DC from UC 
induce higher levels of β7 integrin on T cells than do DC from healthy tissue. To test 
whether DC imprinting is dysregulated in human IBD, the expression of CD103 on 
colonic DC, and the expression of tissue-specific homing receptors on dividing T-cells, 
were examined in patients with UC.  
Methods: Multi-colour flow cytometry was used to measure the (1) expression, including 
the proportion and level of staining, of CD103 on colonic DC in patients with UC, and  (2) 
expression of homing markers on CD4+ naive T-cells following activation by lamina 
propria mononuclear cells (LPMC). 
Results: In UC, the proportion and level of staining of CD103+ colonic DC were 
significantly lower in UC compared with equivalent cells from controls, due to a genuine 
loss of CD103+ cells rather than an increase in CD103- cells. Compared with myeloid DC 
population, CD103+ cells were infrequent among CD11c- and lymphocyte populations. 
There was no difference in the proportion of CD103+ DC in paired samples of tissue from 
ileum and colon of UC.  Whole LPMC from UC tissue were highly stimulatory, and 
subsets of responding T-cells expressed high levels of β7 and CCR4, but little CLA and 
CCR9.  
Conclusions: In UC, colonic DC expressing CD103 were significantly reduced possibly 
as a result of increased migration from the tissues. A substantial proportion of T cells 
activated by colonic LPMC expressed the homing molecules, β7 and CCR4, but not CLA 
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and CCR9. Alterations in the number and phenotype of CD103+ DCsuggest dysregulation 
of the homing process in UC; this process may serve as a valuable therapeutic target. 
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6.2 Introduction 
 
Mucosal immune responses are compartmentalised. T cells that are activated in lymphoid 
tissue draining intestinal sites home selectively back to the gut by upregulating homing 
markers including α4β7 (Berlin et al., 1993; Butcher and Picker, 1996). This process is 
tightly controlled by multiple signals (Mora et al., 2003; Stagg et al., 2002). In mice, 
homing of T cells is imprinted by the activating DC; only T cells activated by intestinal 
DC become α4β7hi and CCR9+  (Hart et al., 2004b). Altered DC recruitment or local DC 
modulation in inflammatory disease may lead to dysregulated imprinting of lymphocytes. 
In IBD, there are changes in numbers and functions of gut homing β7 and CCR9+ 
populations (Hart et al., 2004b; Papadakis et al., 2001). Furthermore, levels of β7 are 
higher on T cells activated by colonic DC from UC patients compared with controls 
(Rigby et al., 2006). β7 pairs with the integrins, αE (CD103) and α4. In mice, αE is 
expressed by mucosal DC and lymphocytes, and the ability to imprint CCR9 and α4β7 
resides in a population of MLN and intestinal lamina propria DC that express the integrin 
CD103 (Johansson-Lindbom et al., 2005); this integrin may indicate a population of DC 
that has received local conditioning signals (Jaensson et al., 2008).  However, the ability 
to induce CCR9 on T cells is not a property of all CD103+ DC found in many mucosal 
tissues and LN, but a selective property of MLN and small intestinal lamina propria 
CD103+ DC (Benson et al., 2007; Coombes et al., 2007; Mucida et al., 2007; Sun et al., 
2007). CD103+ DC are found in lymphoid tissue which drains non-intestinal epithelial 
surfaces but the imprinting properties of these cells remain to be defined.  
 
A population of intestinal DC characterised by CD103 has the ability to induce the de 
novo differentiation of naive T cells into CD4+ CD25+ Foxp3+ Treg via a TGF-β- and RA-
227 
 
dependent mechanism (Coombes et al., 2007). This population is presumed to be recruited 
from the lamina propria (Johansson-Lindbom and Agace, 2007; Sun et al., 2007). Thus, in 
the steady state intestinal RA-producing CD103+ DC, possibly conditioned by local 
environmental signals, may favour the generation of gut trophic Treg that limit the 
development of chronic intestinal inflammation. The impact of inflammation upon these 
DC imprinting pathways is currently unknown.  
 
DC populations in tissue in steady state are likely to be functionally distinct from those 
present in inflammation (Brenan and Puklavec, 1992; Kilshaw and Karecla, 1997), but 
currently little is known about how these ‘inflammatory DC’ imprint homing or how 
dysregulated imprinting may contribute to human IBD. In addition, in man, the role of 
CD103 expression on DC in the control of lymphocyte homing and the effects of 
inflammation have not been explored.  
 
6.3 Hypothesis 
Imprinting of lymphocyte homing by lamina propria mononuclear cells and DC is altered 
in inflammatory bowel disease. 
 
 
6.4 Aims 
- To investigate the expression of CD103 on colonic DC from UC and healthy 
 controls. 
-  To assess expression of tissue-specific homing receptors on T-cells activated 
 by whole LPMC in UC patients.  
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6.5 Human Intestinal Lamina Propria Dendritic Cells Express CD103 
 
The integrin CD103 (αEβ7) is expressed by a proportion of DC isolated from the MLN and 
colonic lamina propria of normal mice (Johansson-Lindbom et al., 2005). In a murine 
model, CD103 is expressed by the majority (64 to 80%) of the CD11c+ MHC class II+ 
lamina propria DC (Annacker et al., 2005; Johansson-Lindbom et al., 2005).  To assess 
CD103 expression by colonic DC in human, LPMC were obtained from biopsy tissue and 
CD11c+ HLA-DR+ lineage-/dim myeloid DC were identified by multi-colour flow 
cytometry.  
 
In healthy controls, CD103 expression was detectable within the lamina propria CD11c+ 
HLA-DR+ lineage-/dim population (37±3%), and to a much lesser extent within the CD11c- 
HLA-DR+ lineage-/dim population (6±3%; p<0.05). As expected, a small population of 
lymphocytes also expressed CD103 in controls (8±1%).  
 
The level of expression of CD103 by CD11c+ DC (7.3±1.2) was not significantly different 
from the level of expression by lymphocytes (6.7±2%), but was significantly higher than 
those of CD11c- cells (3.5±0.7; p<0.05). 
 
 
 
6.6 CD103 is Expressed on Dendritic Cells from Ileal and Colonic Tissue 
 
We next compare expression of CD103 in ileal and colonic tissue. In three healthy 
controls with endoscopically and hisologically normal mucosa, paired samples were taken 
from the ileum and colon and CD103 expression was assessed. There was no significant 
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difference in the proportion of DC expressing CD103 in the ileum compared with the 
colon (Figure 6.1). 
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Figure 6.1 CD103 expression on DC and lymphocytes in ileal and colonic tissue of controls. 
The proportion of CD103+ CD11c+ DC, CD103+ CD11c- DC and CD103+ lymphocytes is shown in 
ileal and colonic tissue of healthy controls. Paired samples (from ileum and colon) were taken 
from 3 healthy controls. Lines link samples taken from the same individual. 
 
 
6.7 Fewer Colonic Dendritic Cells from Ulcerative Colitis Express CD103 
 
The proportion of lamina propria CD11c+ DC and CD11c- cells expressing CD103  was 
significantly lower in cells from UC patients (22±5% versus 37±3% for CD11c+ DC, 
p<0.05; 0% versus 6±3% for CD11c- cells, p<0.05; Figure 6.2) than controls.  
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Figure 6.2: Proportion of CD103 expression on lamina propria DC and lymphocytes in 
controls and UC. The figure shows the proportion of CD103+ CD11c+ DC, CD103+ CD11c- cells 
and CD103+ lymphocytes in healthy controls (n=15) and patients with UC (n=11). All samples 
were taken from colonic tissue. Horizontal line represents mean value. 
 
 
This difference was due to a genuine loss of CD103+ cells rather than an increase in the 
CD103- population because the absolute number of CD103+ CD11c+ DC isolated from 
colonic tissue was lower for UC patients than controls. (UC 22±9 per mg tissue versus 
control 47±9 per mg tissue; p<0.05; Figure 6.3). In contrast, the numbers of CD103- cells 
did not differ significantly between UC patients and controls. The number and proportion 
of CD103+ CD11- cells and CD103+ lymphocytes did not differ between UC patients and 
controls. 
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Figure 6.3: Absolute number of CD103+ CD11c+ DC and CD103- CD11c+ DC in controls and 
UC. The number of CD103+ and CD103- CD11c+ DC per milligram tissue from inflamed UC 
tissue and normal control tissue are shown (UC=15, controls=11). 
 
 
Examples of expression of CD103 on lamina propria CD11c+ DC, CD11c- cells and lamina 
propria lymphocytes in controls and UC are shown in Figure 6.4. In addition, CD11c+ DC 
and CD11c- cells from UC tissue both expressed lower levels of CD103 than equivalent 
cells from control tissue (Positive intensity Ratio; PIR= 4±0.8 versus 7±1.3 for CD11c+ 
DC, p<0.05; PIR=1±0.2 versus 3.0±0.7 for CD11c- cells, p<0.05;  Figure 6.5). CD103 
levels on lymphocytes were not significant between UC and controls.  
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Figure 6.4: Examples of expression of CD103 on lamina propria DC and lamina propria 
lymphocytes in controls and UC. Flow cytometric representative examples showing CD103 
expression on LP CD11c+ DC, CD11c- cells and lymphocytes from inflamed mucosa of a patient 
with active UC and normal tissue of a control subject. For each cell type, the top panel (A) shows 
the proportion positive cells. All events falling within the box region exceed isotype control 
staining intensity and are regarded as positively labeled cells. In the bottom panel (B), the shaded 
part of the histogram (PIR) indicates the level of staining of CD103 after subtraction of staining 
with the isotype control. We analysed a total minimum of 2000 events for each cell subset. 
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Figure 6.5: Level of CD103 expression (PIR) on DC and lymphocytes in controls and UC. 
The level of CD103 staining observed on CD11c+ DC, CD11c- cells and lymphocytes was 
measured relative to the aurofluorescent properties of an unlabelled bead population (n=10 each 
patient group). 
 
 
6.8 In Ulcerative Colitis, Whole Lamina Propria Mononuclear Cells Stimulate 
Naive T Cells to Express B7 
 
The influence of LPMC upon T cell expression of homing and migration molecules was 
assessed in a series of stimulation experiments. We used whole LPMC instead of sorted  
DC as it was practically difficult to extract DC for stimulation  experiments  due  to  the  
small numbers present in the human lamina propria. Whole LPMC were extracted from  
inflamed  UC  tissue  as  described  in  methods (Section 2.2.2 ).  CFSE-labelled  T-cells    
(4x105/well)  were incubated for 5 days in round-bottom  96-well microtitre plates  with  
LPMC  (8x104/ well or graded concentrations).   Similar  concentrations  of  LDC  from  
peripheral blood of a healthy control were also cultured stimutaneously with naive T cells.  
235 
 
Cells were recovered and CFSElo proliferating cells were identified and quantified by flow  
cytometry.  The  expression  of  gut  homing  (β7, CCR9)  and  skin homing (CCR4, CLA)  
markers  was  measured  on  proliferating  T  cells. The proportion of dividing T cells were  
greatest  when  stimulated  by  the  highest   concentration of LPMC (LPMC concentration  
8X104;    proportion   dividing   T  cells   =  50%)   compared   with  stimulation  by  lower  
concentrations of LPMC (LPMC concentration 4X104; proportion dividing T cells =15%)  
(Figure 6.6). 
 
β7  was  consistently  expressed  on  T  cells  activated  by  whole LPMC from UC. LPMC  
induction  of  β7  was  comparable to  that  achieved  when  using  peripheral  blood  LDC 
as the stimulus (mean proportion of  β7+ CD4+ T cells:  LMPC-stimulated, 61±4%; LDC- 
stimulated, 58±6%).  Approximately 25 percent of dividing T cells  stimulated  by  LPMC  
and LDC expressed CCR4  (mean proportion of  CCR4+CD4+  T cells:  LMPC-stimulated,  
25±2%;  LDC-stimulated,  25±2%; n=2).   Examples of expression of homing markers on  
dividing cells are shown in Figure 6.7.  There was a dose dependent expression of β7 and  
CCR4  on  proliferating  T  cells  stimulated  by  LPMC. Conversely, proportion of T cells  
expressing of β7 and CCR4 reduced as the concentration of LDC increased (Figure 6.8). 
 
Approximately  15  percent  of  proliferating T  cells  expressed  CLA  when stimulated by  
LDC  but  CLA  expression  was  almost  undetectable  on  T  cells  stimulated by  LPMC.  
Overall there was little expression of CCR9 on T cells stimulated by both LDC and LPMC  
(Figure 6.8). 
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Figure 6.6: Stimulation of naive CD4+ T cells by LPMC from UC patient  
LPMC extracted for UC tissue were cultured for 5 days in round bottom well plates  
with CFSE-labelled naive T cells. Responder cells were cultured with medium alone; (A)  
and with LPMC; (B) % represents proportion of dividing cells and figure in bold represents 
absolute number of dividing cells. Figure (C) indicates the cumulative percentage of T cells  
plotted that are dividing when stimulated by LPMC and LDC  (enriched DC from peripheral  
blood of healthy control) of different concentrations. Results were pooled data from two  
experiments. 
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Figure 6.7: Examples of expression of homing markers on proliferating T cells  
stimulated by LPMC from UC; (A) β7 (B) CCR4 (C) CCR9 and, (D) CLA. 
Numbers in bold indicate absolute number of dividing cells per well. Relative to an isotype  
control, % figure indicate the proportion of dividng T cells expressing the given marker. 
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Figure 6.8: Cumulative percentage of expression of β7, CCR4 , CCR9 and CLA on  
CD4+ T cells activated by LPMC from UC patients and LDC from healthy controls.  
Three different concentrations ofLPMC (8X104, 4X104 , 2X104) obtained from UC tissue and  
LDC (8X104, 4X104 ,2X104) from peripheral blood of healthy controls were cultured for 5 days  
in round-bottom well plates with CFSE-labelled naive T cells.  Dividing cells were labelled for  
homing markers. This figure shows the proportion of dividing T cells that express β7, CCR4,  
CCR9 and CLA (results were pooled data from 2 experiments).  
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6.9 Discussion 
 
In the first part of this chapter, CD103 is expressed on human colonic DC and there is 
reduced CD103+ myeloid DC in the colon of UC patients compared with control tissue. In 
mice, the ability to imprint a gut homing phenotype resides in a CD103+ DC population 
found in the lamina propria of the small intestine and in gut-associated lymphoid tissue 
(Jaensson et al., 2008).  This specialised DC population has been shown to enhance Foxp3 
T cell differentiation, upregulate RA receptor and induce α4β7 and CCR9 on responding T 
cells (Jaensson et al., 2008). CD103+ lamina propria DC appeared to be derived from 
circulating DC precursors but were less likely to be from lamina propria CD103 
intermediate DC. Importantly, CD103+ DC with similar phenotype and functional 
properties have been identified in human MLN (Eksteen et al., 2008; Eksteen et al., 2009; 
Jaensson et al., 2008).  The ability of these cells to selectively induce CCR9 seems to be 
maintained by CD103+ MLN DC isolated from small bowel Crohn's patients. These data 
suggest that human intestinal lamina propria DC may represent a novel target for 
regulating human intestinal inflammatory diseases.  
 
In humans CD103 was expressed by almost 40 percent of colonic lamina propria CD11c+ 
DC from healthy donors but only on approximately 20 percent of DC from patients with 
UC. There was indeed a true loss of CD103+ DC from the UC colon rather than a 
dilutional effect due to the recruitment of additional CD103- DC based on absolute number 
analysis. Together with the enhanced T-cell expression of β7 integrin in the presence of 
migratory ‘walk-out’ DC from UC patients (Rigby et al., 2006), we speculated that the 
loss of CD103+ DC from the colon in UC may be secondary to increased migration of 
CD103+ DC out of the tissues.  Murine studies suggest that CD103+ DC were indeed 
migratory (Bedoui et al., 2009; Siddiqui and Powrie, 2008). Bedoui et al. showed that 
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dermal CD103+ DC were the migratory subset most efficient at processing viral antigens 
into the MHC class I pathway, potentially through cross-presentation of skin-derived self 
antigens (Bedoui et al., 2009). It will be valuable to confirm this theory by assessing 
CD103 expression on “walk out” DC cultures. Nonetheless this possibility has been 
supported by a recent study showing an increase in CD103+ DC in the lymph nodes of 
IBD patients (Jaensson et al., 2008). 
 
Intestinal CD103+ DC, but not DC at other anatomical sites express key enzymes involved 
in the oxidative metabolism of retinol.  In mice MLN and small intestinal lamina propria 
CD103+ DC efficiently induced enhanced Foxp3 T cell differentiation, RA receptor 
signaled and generated CCR9+ α4β7+ gut tropic T cells in vitro (Jaensson et al., 2008; 
Johansson-Lindbom et al., 2005). Additionally, CD103+ intestinal DC, but not their 
CD103- counterparts, expressed RALDHs and were able to generate RA from retinal 
(Lampen et al., 2000). In CCR7- deficient mice, total DC numbers were reduced in the 
MLN but there was a greater reduction in the CD103+ DC population than other DC 
populations (Jang et al., 2006; Johansson-Lindbom et al., 2005; Worbs et al., 2006). 
 
Recent data showed that human intestinal epithelial cells promoted the differentiation of 
tolerogenic DC to drive the development of adaptive Foxp3+ Treg cells. This process was 
not seen in patients with CD. Human MLN CD103+ DC that expressed CCR7 were able to 
drive Treg differentiation, and were likely to represent a lamina propria-derived migratory 
population (Iliev et al., 2009b). 
 
CD103+ DC have emerged as a functionally specialised DC in various tissues. In the skin, 
only the CD103+ subset, but not langerhan cells and classical dermal cells, can efficiently 
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present antigens of herpes simplex virus type 1 to naive CD8+ T cells, suggesting that 
CD103+ DC were the main migratory subtype that have the ability to cross-present viral 
and self antigens (Bedoui et al., 2009). 
 
In small bowel CD, CD103+ DC were present in the MLN and these DC induced CCR9 on 
responding T cells (Jaensson et al., 2008). αEβ7 is thought to be important for 
intraepithelial lymphocyte (IEL) localization or function.  In α E-/- mice, intestinal and 
vaginal IEL numbers were reduced, consistent with the known binding of αEβ7 to E-
cadherin expressed on epithelial cells. Lamina propria T lymphocyte numbers also 
diminished, and αEβ7 was involved in the expansion/recruitment of TCR αβ+ CD8+ IEL 
following microbial colonization (Hart et al., 2004b; Papadakis et al., 2001). 
 
In the second part of the experiments, we used freshly isolated LPMC from UC patients to 
stimulate naive T cells and assessed the expression of homing molecules on proliferating T 
cells. β7 integrin expression on responder T cells was observed when stimulated by 
LPMC, and the proportion of β7 expression was comparable to that achieved when using 
peripheral blood LDC as the stimulus. Furthermore, CCR4, a receptor implicated in 
homing to the skin, but not CLA, was also up-regulated on T cells stimulated by LPMC 
from UC tissue. We have yet examined the expression of these markers on control tissue 
in parallel and the direct comparison of T cell expression of homing molecules cultured 
with LPMC from UC tissue and control tissue requires further investigation. The enriched 
blood DC were obtained from donors different from donors of LPMC cells. Future 
experiments will concentrate on comparison of stimulation by both LPMC and LDC from 
UC patients to avoid patient variability.  
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Nonetheless, previous experiments using colonic DC or “walk-out” cells from tissue 
enriched for DC from UC patients have shown that these cells stimulated a strong, dose-
dependent, proliferative response in allogeneic, naïve CD4+ T-cells, and they expressed a 
higher proportion of β7+ than blood DC. In addition the levels of B7+ were significantly 
higher on T-cells activated by colonic DC from UC tissue than control colonic tissue, or 
on T-cells activated in parallel by blood DC (Rigby et al., 2006). 
 
We have shown that both blood and LPMC stimulated naïve T cells to express high levels 
of β7. However only T cells stimulated by blood expressed CLA; this observation may be 
secondary to the failure of LPMC to upregulate skin homing molecule.  
 
The observation that LPMC induced dividing T cells to express a skin homing marker 
CCR4 is plausible. A complex pattern of marker co-expression irrespective of the tissue 
source of the DC added to the culture has been previously observed. Our group has 
previously shown that dividing T cells expressing B7, CLA, CCR4 and low levels of 
CCR9 have been detected irrespective of whether stimulating DC were derived from the 
gut, skin or sputum (Rigby et al., 2006). In that study, the majority β7+ population 
stimulated by colonic DC in UC patients could be subdivided into CCR4+ and CCR4- 
cells, as well as CLA+ and CLA- subset. CLA and CCR4 also appeared to be 
predominately reciprocally expressed.  
 
In the mouse, the chemokine CCL25 and its receptor CCR9 plays a selective role in 
effector T-cell homing only to the small intestinal mucosa. In this regard, it contrasts to 
α4β7/MAdCAM-1 that facilitate recruitment of effector T cells into the small and large 
intestine (Svensson et al., 2002).  CCR9 is expressed by a subset of α4β7+  T cells in the 
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human peripheral blood, by most of human and murine small intestinal T cells, and by the 
minority of colonic cells (Zabel et al., 1999). Its ligand CCL25 is constitutively expressed 
by small intestinal epithelial cells but not colonic cells (Wurbel et al., 2000).  
 
In summary, these data show dysregulated DC imprinting of lymphocyte homing in 
patients with UC, and it is likely that a better understanding of the regulation of these 
processes may help facilitate targeting of these pathways for future therapy. 
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Chapter 7 
General Discussion and Future Research 
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7.1 General Discussion 
 
In the first part of the thesis, intestinal DC populations from patients with IBD were 
altered compared with that from healthy controls suggesting that they may play a role in 
the inflammatory process. This is a follow-up from previous work assessing the 
characteristics of DC in the intestine of patients with IBD. Our group has previously 
characterised the CD11c+ DC and showed that they were activated in IBD.  In this study 
we characterised the CD11c- cells in the human intestine in both IBD and healthy controls. 
The proportion of these cells was increased in UC compared with controls. CD11c- cells 
were unlikely to be macrophages or activated lymphocytes as under the electron 
microscope they had morphology of DC and phenotypically they expressed putative DC 
markers but not CD14 or CD16.  Consistent with their low expression of costimulatory 
molecules, CD11c- HLA-DR+ lin-/dim cells were probably weak stimulators of T cell 
proliferation.  CD11c- cells also appeared to be poor producers of IL-12p40 and IL-6 and 
weak activators of T cells. Based on these functional properties, we speculate that this 
population may function in immune regulation and tissue repair, although this functional 
relevance needs further investigations (discussed under future work).  DC have been 
reported to have repair or angiogenic properties (Fields et al., 2003). For instance, the 
production of serine proteases by damaged cells promotes DC maturation and tissue repair 
(Riboldi et al., 2005). Myeloid DC activated in the presence of LPS, IL-10 and calcitriol 
produce vascular endothelial growth factor (VEGF) which leads to production of potent 
angiogenic cytokines (Riboldi et al., 2005). 
 
CD11c- cells showed morphological and functional features of immature DC.  Abundant 
numbers of langerin+ immature DC have been identified in the subepithelial space of IBD 
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tissue (Kaser et al., 2004). Langerin is a marker for immature DC involved in antigen 
presentation. Immature DC can mount non-responsiveness to specific antigens. This may 
be important in the resolution of intestinal inflammation. In some autoimmune disorders 
DC non-responsiveness to antigen that cross-react with self antigen (auto-antigen) play a 
critical role (Knight et al., 2002) in immune homeostasis. For example in patients with 
type-1 diabetes mellitus there was failure of DC “proper” maturation which resulted in 
insufficient stimulatory effects on the proliferation of suppressor T cells (Jansen et al., 
1995).  
 
An “immature DC” milieu is likely to favour a Th2 response with the induction of anti-
inflammatory cytokines and the downregulation of pro-inflammatory cytokines during the 
resolution phase of inflammation, and therefore promoting tissue remodelling and repair 
(Gratchev et al., 2001; Takahashi et al., 2004). These data emphasize that DC may also 
have a secondary role in reinforcing and maintaining tissue repair, in addition to the 
controlling the passage of antigens and/or pathogens via the tissues. 
 
CD11c- cells expressed high levels of CD56 but did not exhibit phenotypic markers of 
plasmacytoid DC. The acquisition of CD56, a distinct adhesion molecule on CD11c- cells, 
suggest that this population might have been recruited to sites of inflammation; we found 
both CD56bright and CD56dim CD11c- cells in the UC tissue, but increased numbers of the 
former;  it is possible that CD56bright cells differentiate into CD56dim  cells with resolution 
of inflammation. The physiologic site of CD56+ CD11c- cells in the inflamed human 
mucosa provides a framework for the pursuit of further studies on this novel population. 
Human NK cells with antigen presenting cell-like features  regulated T cell activation 
(Hanna et al., 2004), expressed MHC class II and T cell receptor co-stimulatory molecules 
248 
 
in vivo.,  as well as “fine-tuned” T cell activation, when there was direct insult to the 
peripheral organs (Hanna et al., 2003).  
 
The increased of CD11c- cells in quiescent or inactive UC may be a marker of subclinical 
inflammation. Both macroscopic and histological intestinal inflammation in IBD is a risk 
factor for the development of dysplasia and colorectal carcinoma (Rutter et al., 2004). 
Further exploration of the potential of CD11c- cells as a biomarker for microscopic 
inflammation in patients with a long- standing UC will be of interest. Here we used 
patients with CD as our positive controls. The increase of these cells in both UC and CD 
suggest that they are likely to be associated with inflammation instead of disease-specific.  
Although CD11c- CD56+ cells may not be unique to UC, specific modulation of this 
population may lead to new therapeutic approaches. Further clarification of the role of 
these cells in mucosal immunity will better our understanding of pathological intestinal 
inflammation and could identify new targets for gut specific-intervention.  
 
The methods established in our laboratory have allowed us to identify and phenotype 
freshly isolated lamina propria DC from small numbers of intestinal biopsies obtained at 
endoscopy with minimal manipulation (Bell et al., 2001). These experiments were 
technically challenging due to the limited numbers of DC extracted from each biopsy. 
Intestinal DC derived from human colonic tissue were sorted on flow cytometry; small 
numbers of DC were then assessed by immunofluorescence and used in stimulation 
experiments.  In all experiments, epithelial DC were removed using EDTA and the lamina 
propria DC were studied. Recently, there has been growing evidence of the importance of 
epithelial cells in barrier function in inflammatory disorders, therefore these cells may be 
targets for future work. Intestinal immune homeostasis is likely to be regulated by the 
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interaction between epithelial cells and DC (Rimoldi et al., 2005); several investigators 
have shown that commensal bacteria can interact with epithelial cells to induce inhibitory 
signals (Artis, 2008; Kelly et al., 2004; Neish et al., 2000). PRR, like TLR-9, has been 
shown to be expressed on the cell surface of epithelial cells to induce partial activation of 
inflammatory response (Lee et al., 2006). The local environment, in particularly, intestinal 
epithelial cells may also play a role in shaping DC function (Rimoldi et al., 2005). Thus it 
would be of interest to extract human intestinal epithelial cells during steady state and 
intestinal inflammation, and study their interplay with DC in maintaining immune 
homeostasis.  
 
In the second part of the thesis, we studied spontaneous production of cytokines in IBD. 
DC have the ability to produce cytokines without stimulation, and that these data reflect 
more accurately their functions than when stimulated with LPS. There was an increased in 
ongoing IL-10 production by DC in acute UC. Although the initial events leading to IL-10 
production may be a response to inflammation aimed at down-regulating the acute 
inflammatory response, IL-10 may also function to exacerbate the disease in this milieu 
(Furukawa et al., 1999; Santin et al., 2000). The observation of elevated IL-10+ DC in 
acute UC is likely to have therapeutic implications. Recent genome wide association 
scanning has demonstrated a susceptibility gene specific for UC related to IL-10 (Franke 
et al., 2008; Silverberg et al., 2009; Zhang et al., 2008). Although two large earlier clinical 
trials with IL-10 treatment in CD patients have shown limited therapeutic effects and bell-
shaped dose–response curves (Fedorak et al., 2000; Schreiber et al., 2000), IL-10 may be a 
potential therapeutic target for UC although this idea has not been formally tested.  
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The traditional concept of UC as a strict Th2-mediated disease (Berrebi et al., 2003), has 
been recently challenged. The infiltrate in UC evolves during the course of disease; early 
in the disease there was an increase in both Th1 (TNF-α) and Th2 (IL-4) cytokines 
produced by intestinal homing B7+ homing memory cells, whereas disease progression 
was characterised by increased activated NKT cells that produced IL-13 and IL-5 (Fuss et 
al., 2004). We have shown that colonic DC produced increased amount of both Th1 and 
Th2-related cytokines, IL-12p40 and IL-10 in UC. In contrast, CD was characterised by 
increased IL-6 production by DC which correlated with the severity of disease activity and 
CRP levels; IL-6 secreted by DC in CD may render pathogen-specific T cells refractory to 
the suppressive activity of T regulatory cells (Pasare and Medzhitov, 2003). “Walk out” 
cells from UC tissue also demonstrated secretion of both Th1 and Th2-related cytokines .  
 
In the third part of the thesis, we studied, for the first time, the in vivo immunological 
effects of a clinically active probiotic mixture, VSL#3. The intestinal bacteria flora 
contributes significantly to the pathogenesis of IBD, along with genetic susceptibility and 
mucosal immune dysregulation. Probiotics are likely to become an integral component of 
the therapeutic armamentarium of IBD in combination with traditional anti-inflammatory 
and immunosuppressive agents. Clinical results of the randomised placebo-controlled trial 
of VSL#3 are currently being analysed and will be presented separately.  
 
Almost all data in the literature of probiotics were derived from in vitro studies and animal 
models. Studies in animal models of colitis and experimental studies with probiotics are 
characterized by a high level of heterogeneity, and in most currently available animal 
models, disease largely occurs as a result of experimental manipulation. In patients with 
UC, the probiotic mixture VSL#3 induced IL-10 production by intestinal DC. Such effects 
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were not seen in placebo-treated patients.  It is increasingly apparent that different 
probiotic bacteria act through multiple and contemporaneous pathways rather than by a 
single common mechanism. Ibnou-Zekri et al. have highlighted that the activity of 
probiotic strains in vitro may not parallel similar in vivo behaviour. In their study, two 
strains of Lactobacillus that exhibited very similar in vitro growth, survival and adherence 
properties showed distinct differences in colonization patterns and resultant host immune 
responses at both the mucosal and systemic levels (Ibnou-Zekri et al., 2003). In contrast 
we have demonstrated consistent in vitro and in vivo mechanistic data of the effects of 
probiotics on human DC, suggesting an important mechanism by which these bacteria 
appear to mediate resolution of inflammation. In vitro probiotics increased IL-10 
production and inhibited IL-12p40 secretion by DC (Hart et al., 2004c). Even such 
consistent in vitro and in vivo mechanistic data, however, only correlate with the clinical 
outcome in some patients. Some of our IBD patients were on immunomodulators. These 
drugs change DC function.  However due to the stringent criteria of patient recruitment in 
the trial, existing medication were used at stable doses for at least three months, 
suggesting that changes in DC were likely to be the true effects of probiotics and less 
likely to be contributed by effects of other concurrent medication.   
 
The positive effects of VSL#3 on intestinal inflammation have been tested in animal 
models and humans. In DSS-induced colitis, mice fed with VSL#3 showed decreased tight 
junction protein expression, and increased apoptotic ratio, hence providing protection to 
epithelial barrier (Mennigen et al., 2009). VSL#3 also upregulated mucosal alkaline 
sphingomyelinase activity in the intestine of IL10-knock out mice with colitis and in 
humans with UC (Soo et al., 2008). 
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Up to now, much of the information on DC subsets at this time is derived from cells 
isolated ex vivo. Most studies of DC function to date have relied either on purification of 
cells from tissues, which detach them from thir complex microenvironment, or on studies 
of cells produced in culture, which is far from physiological. It will therefore be valuable 
to manipulate these DC subsets in vivo as well as to determine their consequences for 
tolerance and immunity, in both health and inflammation. One way of doing so is to 
selectively deliver antigen to a DC subset, as can now be done with dying cells that 
selectively target the CD8+ subset of mouse DC (Liu et al., 2002; Schulz and Reis e Sousa, 
2002). The next leap in this front will involve techniques which allow one to label and 
track subpopulations of DC, for instance by using two-photon microscopy. Future 
advances that allow for the studies of the genome and proteome of small numbers of DC 
will provide us with a more precise analysis of the states of DC differentiation and 
functions in animal models. 
 
One key element in the pathogenesis of intestinal inflammation in IBD is increased 
leukocyte recruitment from the circulation to target intestinal tissue. This is a highly 
regulated process that depends on sequential interactions with a series of adhesion 
molecules (Butcher and Picker, 1996). In patients with UC, DC imprinting of T-cells with 
a colonic homing phenotype is altered; colonic DC stimulate more CD4+ T cells to express 
the gut homing integrin β7, and induce higher levels of β7, than do equivalent cells from 
the healthy colon (Rigby et al., 2006). Enhanced β7 expression may result in increased T-
cell migration to the colon contributing to the local inflammatory process, and this may 
relate to disease pathogenesis. T cells activated in the absence of DC but with exposure to 
stimulating antibodies in the presence of RA can also upregulate β7 expression (personal 
communication N Gellatly). 
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In the mouse MLN, CD103 expression defined a subset of functionally specialised and 
lamina propria-derived DC (Annacker et al., 2005; Coombes et al., 2007). In CCR7 
deficient mice, CD103+ DC were reduced in MLN but not in the lamina propria. This 
observation would suggest that CD103+ MLN DC were derived from the lamina propria 
and that these cells were responsible for the generation of gut-trophic T cells in the MLN. 
Although earlier work has suggested a role of MLN environment in DC imprinting, DC 
were imprinted with the ability to generate gut-trophic T cells prior to entry into MLN. For 
example, small intestinal lamina propria DC can generate α4β7+ CCR9+ T cells while 
CD103- MLN DC cannot (Annacker et al., 2005). This observation indicates that the MLN 
environment is not essential for imprinting DC with the ability to generate gut-trophic T 
cells (Johansson-Lindbom et al., 2005). This discrepancy may relate to the production of 
RA, presumely by CD103+ DC, which within the MLN are sufficient to act in trans to 
generate α4β7+ T cells by CD103- DC (Agace, 2006). We have shown that less CD103+ 
DC were identified in the lamina propria of UC patients, compared with control tissue. 
Whether this relates to increased migration to MLN requires further investigation. To take 
this observation further, one would explore whether “walk-out” cells express CD103, and 
secondly, separate CD103 populations and their assess their stimulatory capacity. 
 
RA is required for the development of gut homing phenotype. It also acts as a co-factor for 
TGF-β dependent FoxP3+ regulatory T-cell development (Coombes et al., 2007; Sun et 
al., 2007) Thus, RA-producing gut DC may contribute to the generation of regulatory T 
cells targeted to intestinal tissue. In light of these data it will be important to examine the 
production and the activation of TGF-β by colonic DC from UC patients and healthy 
subjects and to determine the functional properties of the gut-targeted T-cells generated. 
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Our data showed that LPMC from inflamed UC tissue stimulated naive T cells to express 
β7 and CCR4. In contrast, CCR9 was not detectable on dividing T cells activated by 
colonic LPMC in UC. The role of CCR9 and CCL25 in mediating homing to the colon is 
ill-defined. Kunkel et al. showed that a proportion of CD4+ CD8+ T cells isolated from the 
human colon expressed CCR9. However, CCL25 expression was not expressed on colonic 
tissue in patients with CD (Papadakis et al., 2001). Moreover entry of T cells into the 
murine colon during “steady state” or tissue inflammation was not dependent on CCR9 or 
CCL25 (Hosoe et al., 2004).  
 
In IBD gut inflammation can trigger inflammation at extraintestinal sites. Up to 40 percent 
of patients with IBD develop skin and liver manifestations of their disease. Most of these 
extraintestinal manifestations such as pyoderma gangrenosum, erythema nodosum, non-
erosive arthropathy and uveitis have been linked to disease relapses and improve on 
disease resolution (Orchard et al., 1998; Orchard et al., 2002). It will be of interest to 
compare the imprinting of a skin homing phenotype by intestinal DC or LPMC from 
patients with UC and CD, with and without extra-intestinal skin manifestations, to explore 
whether inappropriate targeting of T-cells to the skin might contribute to disease at these 
distant sites.  
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7.2 General Conclusions 
 
In the first part of the thesis, the phenotypic and functional properties of human intestinal 
lamina propria DC have been described. In healthy controls, lamina propria cells were 
predominantly myeloid DC. In patients with IBD, we identified an increase in an 
inflammation-associated population of CD11c- cells that expressed MHC class II, had 
morphological features of DC on electron microscopy, and proportionally expressed 
increased NK cell marker, CD56, but did not belong to the plasmacytoid DC lineage.   
These cells reduced in number after inflammation resolved. We speculated that they may 
play a role in immune regulation or tissue repair (Chapter 3). 
In the second part of the thesis, we assessed the functional activities of myeloid DC during 
different stages of inflammatory bowel disease, and explored their relationship with 
intestinal microbiota in patients with IBD. In patients with acute UC, more colonic 
myeloid DC produced both the regulatory cytokine IL-10 and the pro-inflammatory 
cytokine IL-12p40 than DC from healthy controls, whereas in patients with chronically 
active CD, there were increased colonic IL-12p40+ DC, and elevated IL-6 and IL-12p40, 
compared with controls. In CD, level of IL-6 on DC correlated with the severity of disease 
acitivity and serum CRP. The ratio of bacteroides:bifidobacteria in faecal samples also 
correlated positively with pro-inflammatory IL-12p40+ DC staining. The proportion of 
bifidobacteria correlated positively with IL-10+DC staining.  IL-6+ DC also correlated 
negatively with the proportion of F. prausnitzii. These data support the concept that 
intestinal DC function is influenced by the composition of the commensal microbiota and 
that in patients withactive CD, the balance of proinflammatory and regulatory bacteria was 
associated with altered DC function (Chapter 4). 
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We next hypothesise that probiotic bacteria with clinically evident benefits in IBD 
modulate the immune system, at least in part, via effects on DC in vivo. In patients with 
acute UC treated with the probiotic mixture VSL#3, TLR-2 expression on DC 
significantly decreased, DC production of IL-10 was enhanced and IL-12p40 was reduced. 
These effects were not seen in patients treated with placebo. Oral corticosteroid treatment 
was associated with increased IL-10 and reduced IL-12p40 production by colonic DC 
(Chapter 5). Thus therapeutic effects in IBD may, in part, relate to modulation of DC 
function.   
In the last part of the thesis, we showed that in patients with active UC, colonic DC 
expressing the integrin, CD103, were significantly reduced compared with controls. 
LPMC from inflamed UC tissue stimulated naive T cells to express β7 and CCR4 but not 
CLA or CCR9. Altogether the data suggest dysregulation of the gut homing process in 
patients with UC (Chapter 6). 
 
 
7.3 Future Work  
 
Data presented in the first part of the thesis highlighted a striking increase in a unique 
population of inflammation-associated cells in the tissue of IBD patients that share 
features of both DC and NK cells. Studies in the future will involve the investigation of 
the role of these cells in the inflammatory response in IBD. Indeed NKT cells have been 
implicated in chronic mucosal inflammation in animal models of colitis (Fuss et al., 2004). 
Distinct subsets of NKDC in mucosal inflammation have also been described in vitro. 
There is a possibility that in vitro CD11c- cells may become CD11c+ DC (or vice versa) 
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following stimulation with inflammatory cytokines and or bacterial products/components. 
It will be of interest to determine whether CD11c+ and CD11c- cells are distinct lineage or 
whether they have been derived from the same precursors. The examination of the 
functional response of CD11c- cells to TLR ligands may provide further insight into their 
role in bacterial recognition and intestinal inflammation. Human CD56+ NKp44+ cells 
present in the Peyer’s patches and lamina propria have been shown to secrete IL-22 and 
IL-17. These cells expressed CCR6 which promoted leukocyte homing to the intestinal 
mucosa, as well as CCL20, the ligand for CCR6, suggesting that they can also promote 
their accumulation in the intestine (Colonna, 2009). Unlike typical NK cells, they did not 
release perforin and IFN-γ. Future experiments to delineate the functions of our described 
cells would involve assessing their expression for CCR6 and their ability to produce IL-
22. 
 
The observation that CD11c- cells expressed CD56 raised the possibility that they may 
function in the killing of target cells (eg. MHC-class 1 targets). Lastly, IFN-γ and TGF-β 
are known to be produced by DC and it will be important to assess whether this unique 
population of cells are major sources of these regulatory cytokines. Other cytokine to be 
tested include TNF-α. The techniques employed here to assess the effects of CD11c- cell 
stimulation on conventional T cell populations could also be extended to examine cytokine 
production and killing activities by this population. Experiments as such are however 
challenged by the small numbers of human intestinal DC.  
 
More clinically relevant would be to investigate the role of these cells in IBD-associated 
dysplasia. These cells were present during macroscopic inflammation but may also 
represent early markers of microscopic inflammation, given that they were also increased 
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in non-inflamed inactive UC tissue. It will be useful to assess whether this is a truly 
recruited mucosal subset or a local DC population, as such, examining the expression of 
α4β7 or CD103 on freshly isolated cells. Ex vivo stmulation by TFG-β for the induction of 
mucosal homing markers would help further characterise the functions of these cells. 
Stimulation with TLR ligands of CD56+ CD11c- cells would allow us to understand the 
“low responsiveness”. Lastly, whether CD11c- cells are influenced by other anti-
inflammatory therapies which target PPAR-γ receptor such as mesalazine warrants further 
investigations.  
 
In patients with UC, we observed two distinct groups of patients in terms of IL-10 
production by DC, a group with IL-10+ DC and a second group with no detectable IL-10+ 
DC. We speculated that this difference may relate to differences in the genetic profile of 
these patients. Hence further characterisation of phenotype and genotype of patients with 
IBD will be important. For instance, the assessment of cytokine production by DC in UC 
and CD in patients with either IL-10 genetic susceptibility or NOD2/CARD 15 mutation 
and those without these genetic variants will be important. 
 
There has been growing interest in other members of the IL-12 family, and their role in 
IBD. IL-23 is produced by activated myeloid cells including DC following bacterial 
stimulation (Becker et al., 2003), or via CD40 signalling (Uhlig et al., 2006). IL-27 is a 
heterodimeric cytokine composed of p28 and Epstein-Barr virus-induced gene 3 (EBI3). 
In vitro IL-27 is produced by activated monocytes and DC. Apart from inducing 
proliferation of naive CD4+ T cells, it synergises with IL-12 for IFN-γ production. Our 
assay for intracellular cytokine did not currently allow us to distinguish whether IL-12p40 
reflects biologically active IL-12 or IL-23. Effects of probiotic bacteria on DC IL-12p40 
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production may impact upon IL-23 production. Future work should clarify whether IL-
12p40 in DC reflects IL-12, IL-23 and/or IL-27.  
 
Altered microbial composition and function in IBD result in increased immune 
stimulation, epithelial dysfunction, or enhanced mucosal permeability. DC function was 
influenced by the resident intestinal microbiota. Investigating the signals from pro or anti-
inflammatory bacteria that dictate functions of DC in vivo would be important. In addition, 
host genetic polymorphisms most likely interact with functional bacterial changes to 
stimulat immune responses that result in chronic tissue injury. Identification of these 
susceptibility genes and microbial alterations in individual patients could lead to selective 
targeted interventions. 
 
The most clinically significant area of research described in this thesis is the in vivo 
immunoregulatory effects of VSL#3 on DC function in patients with UC. Understanding 
probiotic action may permit modulation of the immune system, both locally and 
systemically, and to offer novel and useful means to modulate host immunity for 
protection from, or treatment of IBD. In vitro not all lactobacillus and bifidobacterium 
species are equally beneficial; each may have individual mechanisms of action that is 
dependent on host characteristics. Different bacteria may have dominant effects in 
different genetic backgrounds and in diseases which vary in their pathogenesis. Thus 
optimal use of various probiotics may depend on identifying patient subsets by genetic, 
phenotypic, stool microbiologic or serologic criteria. Apart from live organisms, DNA 
derived from probiotic bacteria has now been shown to enhance IL-10 production by DC, 
possibly via a TLR-9 dependent manner. These data suggest that probiotic bacterial DNA 
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alone may represent a means of modulating DC function; this hypothesis requires further 
testing in patients with IBD.   
 
In the healthy intestine, commensal bacteria in the form of probiotic bacteria have the 
ability to induce regulatory cytokines by intestinal DC thus contributing to a regulatory 
environment. Similar observations have been described in the inflamed intestine in IBD. 
Future experiments aimed at measuring cytokine production including IL-10, IL-12p40, 
TGF-β and IL-4, by naive T cells following stimulation by intestinal DC in both health 
and inflammation will provide insight into whether intestinal DC stimulate regulatory or 
inflammatory responses under different conditions. 
 
An extension to our data should involve experiments looking at the effects of standard 
immmunosuppressants (AZA/6MP), and 5-ASA, on ex vivo DC function. 5-ASA mediates 
its an-inflammatory effects via PPAR-γ. It will be interesting to explore DC as therapeutic 
targets in such a scenario. Such data will provide novel mechanisms into the effects of 
drugs on ex vivo DC phenotype and function, so that treatments can be more targeted in 
such patients.  
 
The homing process in IBD has gained immense interest in exploring disease 
pathogenesis. Apart from studying lamina propria DC, future experiments should involve 
the isolation of epithelial cells for their expression of CD103. In mice, CD103 appeared to 
be expressed predominantly by intraepithelial cell. CD8+ effector T cells acquired CD103 
subsequent to the entry into epithelial tissues, a process that was dependent on TGF-β (El-
Asady et al., 2005; Ericsson et al., 2004; Lefrancois et al., 1999). Human intraepithelial 
cells promoted the differentiation of tolerogenic DC to drive the development of adaptive 
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Foxp3+ Treg cells. It is possible that CD103 is induced following interaction between 
lamina propria DC and epithelial cells. We have shown for the first time that CD103 is 
expressed on human lamina propria DC and numbers of these cells are reduced in UC. The 
ability of CD103+ DC to generate small intestinal-trophic T cells suggests that DC 
imprinting may occur simultaneously to their acquisition of CD103. This process is 
potentially modulated by factors released by epithelial cells or their local surrounding 
environment(Iliev et al., 2009a; Rescigno et al., 2008). In this regard, the putative role of 
epithelial cells in the generation of α4β7 gut-trophic T cells merits further studies. For 
example, DC can be conditioned with intraepithelial cells isolated from healthy or IBD 
donors and analyzed for their ability to induce α4β7+ T cells and Treg cell differentiation. 
Separated CD103+ and CD103- DC from human MLN can also be used to stimulate Treg 
development, with and without RA or TGF-β. DC can also be assessed for their expression 
of chemokine receptors such as CCR7 to assess for migratory properties.  
 
We have performed some preliminary experiments but failed to identify sufficient 
epithelial DC for phenotypic analysis although epithelial lymphocytes were detectable; the 
latter demonstrated consistent expression of CD103. Future studies should focus on 
optimisation and refinement of methods used to extract epithelial DC from human 
intestinal tissue, and thus study on their expression of CD103. In the mouse, intestinal 
CD103+ DC expressed ALDH1a2, a key enzyme which is responsible for β7 expression 
on T cells. In human, it is unclear whether colonic CD103+ DC function in similar ways, 
and whether CD103+ DC induce β7+ T cells similarly between colonic DC from inflamed 
and non-inflamed IBD tissues. 
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We have cited evidence throughout this thesis describing the importance of the interaction 
between the intestine as an immune priviledged site and its interaction with the intestinal 
microbiota. Recent work has focused on the bacteria-host interaction showing that the 
host, a component of its microbiota, and probiotic bacteria can adapt their substrate 
utilization in response to one another. A better understanding of the host bacteria-to-
immune cell interactions in the GI tract will provide potential mechanisms of disease 
pathogenesis and how we could manipulate the GI microenvironment. A picture is also 
emerging of the various roles of DC in immune homeostasis and bacteria recognition in 
the healthy intestine and inflammatory state. As our knowledge of these specialized cells 
expand, manipulating and targeting them for the treatment of intestinal inflammatory 
diseases will become possible. 
 
 
7.4 Ongoing Work 
 
The ingestion of the prebiotic, fructo-oligosaccharide increases luminal bifidobacteria and 
improve clinical response in patients with CD (Lindsay et al., 2006).  A multi-centre 
placebo-controlled trial of fructo-oligosaccharide in the treatment of CD is in progress and 
is close to completion. It has provided us with the opportunity to assess ex vivo functional 
properties of DC before and after ingestion of prebiotics. The immunological data will be 
available when the study is completed and unblinded. We have analysed the pre-treatment 
data on DC functions in patients with CD (Chapter 4) and the post-intervention data will 
be analysed once patients recruitment has completed. 
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